University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
Fall 2011

Computer-Aided, Multi-Modal, and Compression Diffuse Optical
Studies of Breast Tissue
David R. Busch Jr
University of Pennsylvania, drbusch@physics.upenn.edu

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Bioimaging and Biomedical Optics Commons, Biological Engineering Commons, Optics
Commons, and the Radiology Commons

Recommended Citation
Busch, David R. Jr, "Computer-Aided, Multi-Modal, and Compression Diffuse Optical Studies of Breast
Tissue" (2011). Publicly Accessible Penn Dissertations. 438.
https://repository.upenn.edu/edissertations/438

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/438
For more information, please contact repository@pobox.upenn.edu.

Computer-Aided, Multi-Modal, and Compression Diffuse Optical Studies of Breast
Tissue
Abstract
Diffuse Optical Tomography and Spectroscopy permit measurement of important physiological
parameters non-invasively through ~10 cm of tissue. I have applied these techniques in measurements of
human breast and breast cancer. My thesis integrates three loosely connected themes in this context:
multi-modal breast cancer imaging, automated data analysis of breast cancer images, and microvascular
hemodynamics of breast under compression. As per the first theme, I describe construction, testing, and
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compression, e.g., mammography.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Physics & Astronomy

First Advisor
Arjun G. Yodh

Keywords
diffuse optics, DOT, MRI, CAD, multi-modal imaging, compression, blood flow

Subject Categories
Bioimaging and Biomedical Optics | Biological Engineering | Optics | Radiology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/438

COMPUTER-AIDED, MULTI-MODAL, AND
COMPRESSION DIFFUSE OPTICAL STUDIES OF
BREAST TISSUE
David Richard Busch Jr.
A Dissertation
in

Physics and Astronomy
Presented to the Faculties of the University of Pennsylvania in Partial
Fulfillment of the Requirements for the Degree of Doctor of Philosophy
2011
Supervisor of Dissertation

Arjun G. Yodh
James M. Skinner Professor of Science, Department of Physics and Astronomy

Graduate Group Chairperson

Alan T. Johnson
Professor, Department of Physics and Astronomy
Dissertation Committee
Mark Goulian, Associate Professor, Department of Physics and Astronomy
Edmund J. and Louise W. Kahn Endowed Term Associate Professor of Biology
Philip Nelson, Professor, Department of Physics and Astronomy
Burt A. Ovrut, Professor, Department of Physics and Astronomy
Ravinder Reddy, Professor, Department of Radiology

c Copyright 2011
David Richard Busch Jr.

Acknowledgements
The simultaneous optical and MR breast imaging project discussed in Chapter 4-6 were the results
of a long standing collaboration between Prof. Arjun Yodh and Prof. Britton Chance. The late Prof.
Chance, in whose lab I was based for several years, consistently provided unique and simplified solutions
to scientific problem, often tying in a wide range of historical precedents. Dr. Xavier Intes and Jiangsheng
Yu constructed opto-electronics of the second generation (GenII, Chapter 4-5) University of Pennsylvania
Optical/MR Imaging system used in much of my work; Dr. Intes also patiently taught me the concepts and
realities of time-domain instrumentation and analysis. Dr. Thomas Connick designed and constructed the
(GenII and GenIII Chapter 4-6) electronics for MR Imaging. I thank Jun Zhang and Zhongyao Zhao, who
assisted in the GenII and GenIIm optical/MR clinical data collection, along with the research MR technical
team, Tanya Kurtz, and Doris Cain. Norman Butler patiently taught me how to run the MR scanners and
answered a huge number of naive questions on clinical procedures. Dr. Saurav Pathak spent a great deal
of time and effort in adapting and improving reconstruction software for diffuse optical tomography with
the GenIII optical-MR imaging system; the reconstructions in Chapter 6 are due to his work. Design,
construction, modification, and repair of theses multi-modal instruments were heavily dependent on the
skills of the instrumentation specialists in the Department of Physics and School of Medicine, especially
Mike Carman, William Pennie, and Harold (‘Buddy’) Borders. Barry Chen, David L. Minkoff, and Daniel
Friedman assisted in various opto-electronic instrumentation used in the work described in Chapter 4-6; Han
Y. Ban’s assistance in construction and debugging were especially helpful.
Moving novel instrumentation into clinical settings is fraught with difficulty; Dr. Mark A. Rosen and
Dr. Mitchell D. Schnall were instrumental in providing the opportunity to apply our instrumentation during
their clinical research MRI studies. They also greatly assisted in clinical data collection and introduced me
to clinical breast imaging. The ABI clinical coordinator team of Kathleen Thomas, Tamara April, Deborah
Arnold, and Stephanie Damia, was extremely helpful in recruiting subjects for our study.
Dr. Mary Putt and Dr. Wensheng Guo provided guidance among statistical pitfalls as I put together the
work in Chapter 7; Dr. Regine Choe was unstinting generous in her assistance, interpretation, and data sets.
Data used in this chapter was derived from work by Dr. Joseph P. Culver, Dr. Soren D. Konecky, Dr. Alper
Corlu, Dr. Kijoon Lee, Dr. Turgut Durduran, Dr. Regine Choe, Han Y. Ban, and Dr. Saurav Pathak. Our
clinical collaborators include Dr. Mark A. Rosen, Dr. Mitchell D. Schnall, Dr. Brian J. Czerniecki, Dr. Julia
Tchou, Dr. Douglas L. Fraker, and Dr. Angela DeMichele.
The compression study in Chapter 8 grew out of a series of conversations I had with Dr. Mark A.
Rosen; Dr. Turgut Durduran and Dr. Regine Choe helped guide it to practical application. Alpha Kamara,
Lauren Chaby, Avinash Rajput, and David L. Minkoff assisted in construction of various portions of the
iii

opto-electronics; Jiaming Liang and Dr. Turgut Durduran in writing software; and Wesley Baker and Dr.
Turgut Durduran in data analysis. Dr. Daniel Chen significantly eased my interpretation of the response of
breast tissue to external loading. Our clinical coordinators Dalton Hance, Tiffany Alverna, Monika Koptyra,
and Ellen Foster made human testing possible.
I thank the other members of Dr. Yodh’s lab during my time at University of Pennsylvania not directly
involved in the projects above, especially Dr. Rickson C. Mesquita, Dr. Ulas Sunar, Dr. Soren D. Konecky,
Dr. Jonathan Fisher, and Aninidita Basu. Dr. Erin M. Buckley is a generous and helpful colleague, in whose
company I deciphered University of Pennsylvania’s regulations on graduation. My classmates at University
of Pennsylvania, especially Dr. Daniel Swetz, Dr. Charles Ratliff, Dr. Jesse Kinder, and Dr. Michelle Caler,
were of indubitable help in my graduate school career. Dr. Gregory Faris and Dr. George Alexandrakis
introduced me to diffuse optical theory and experiment.
Dr. Turgut Durduran and Dr. Regine Choe became my mentors during the second half of my PhD work;
their patience, insightful comments, and support were essential to its completion.
My parents, aunts, uncles, and, especially, siblings and cousins have supported, encouraged, and prompted
me throughout my education, as well as being a reservoir of esoteric facts and contacts; I particularly thank
Andrew, Megan, and Shannon. My first introduction to working science came from my uncle and godfather,
the late Prof. James J. O’Leary M.D., Ph.D., who introduced me to scientific inquiry, chess, and the use of
lasers to answer biological questions.
The clarity, readability, and science of Prof. Yodh’s papers drew me into University of Pennsylvania and
his lab. Prof. Yodh’s weekly lab meetings focused not only on extracting the important kernels amidst the
chaff of complicated data sets, but also on how to efficiently communicate results. His high standards and
patience defined my graduate career.
Lastly, I would like to thank the volunteers who participated in these studies.

iv

ABSTRACT
Computer-Aided, Multi-Modal, and Compression Diffuse Optical Studies
of Breast Tissue
David Richard Busch Jr.
Arjun G. Yodh
Diffuse Optical Tomography and Spectroscopy permit measurement of important physiological parameters non-invasively through ∼10 cm of tissue. I have applied these techniques in measurements of human
breast and breast cancer. My thesis integrates three loosely connected themes in this context: multi-modal
breast cancer imaging, automated data analysis of breast cancer images, and microvascular hemodynamics
of breast under compression.
As per the first theme, I describe construction, testing, and the initial clinical usage of two generations
of imaging systems for simultaneous diffuse optical and magnetic resonance imaging. The second project
develops a statistical analysis of optical breast data from many spatial locations in a population of cancers
to derive a novel optical signature of malignancy; I then apply this data-derived signature for localization
of cancer in additional subjects. Finally, I construct and deploy diffuse optical instrumentation to measure
blood content and blood flow during breast compression; besides optics, this research has implications for
any method employing breast compression, e.g., mammography.
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Chapter 1

Introduction and Organization
Diffuse Optical Spectroscopy (DOS) utilizes light in the low absorption near-infra red (NIR) window, between 650 and 950 nm, to measure chromophore concentrations and scattering in thick tissues, e.g., through
∼10 cm of human breast tissue. Information about tissue concentrations of water, lipid, oxy- (HbO2 ), deoxy(Hb), and total-hemoglobin (Hbt ), as well as blood oxygen saturation (StO2 ), and tissue scattering (i.e., the
reduced scattering coefficient, µ0s ) are readily derived using diffuse optics. These non-invasive, low-risk
diagnostics are emerging as useful clinical tools for detection, diagnosis, and monitoring of breast cancer1
and other pathologies2–4 . Indeed, various studies have successfully compared Diffuse Optical Tomography
(DOT) and DOS against more established clinical modalities5–11 and have correlated pathologic findings
with optically measured chromophores12–15 .
Diffuse Optical Tomography (DOT) utilizes many DOS measurements at different locations on a tissue
surface to reconstruct spatially heterogeneous concentrations of chromophores and scattering parameters
within the tissue interior. Images are obtained by inverting the heterogeneous diffusion equation16–25 . The
resulting tomograms are 3D maps of optical properties and chromophore concentrations, which are correlated with physiological signatures of tumors. For example, optically measured total hemoglobin concentration (Hbt ) has been correlated with micro-vessel density measured by histopathology15 ; similarly, the
reduced scattering coefficient (µ0s ) has been correlated with cellular and organelle volume fraction and mean
size14 . The diffuse optics community is still in the process of discovering which optically measured parameters are the most important indicators of malignancy; recent work, for example, on H2 O26 and collagen27
has opened up new possibilities along these lines. Furthermore, researchers at University of Pennsylvania
and elsewhere have expanded the optical portfolio to measure tissue physiology via Diffuse Correlation
Spectroscopy (DCS), which permits direct measurement of microvasculature blood flow with NIR light.
1

In a different vein, the combination of diffuse optics with other modalities has a rich history at the University of Pennsylvania. Pioneering clinical research combining diffuse optical measurements with ultrasound28
and magnetic resonance imaging (MRI)5, 6 , as well as sequential optical imaging and co-registration with
positron emission tomography (PET)29 and MRI,30, 31 have provided road maps for the development of
multi-modal clinical diffuse optical measurements.
The work described herein focuses on applications of diffuse optics to breast cancer under three loosely
connected themes: multi-modal imaging, statistical image analysis, and hemodynamic changes under compressive perturbation.
Chapter 1 provides a brief introduction to the subject and organization of this thesis. The mathematical
formalism underlying diffuse optical analysis and measurable data types is presented in Chapter 2, and is
followed by a description of some applications of diffuse optics to clinical problems in Chapter 3.
Some of the research described in this thesis expands upon previous multi-modality work in our group.
Specifically, I have constructed new instrumentation combining optical and MR imaging, and I have begun
to test these systems in the clinic (Chapter 4-6). The basic construction and application of the University
of Pennsylvania 2nd Generation multi-modality MR-optical imaging system is described in Chapter 4 and
Chapter 5, respectively. Then, in Chapter 6, I describe my development of a new, 3rd Generation, modular
bilateral diffuse optical system for simultaneous imaging of breast cancer with 3 Tesla MRI.
DOT provides 3D maps of multi-parameter data about breast cancer; a major contribution of my thesis
research shows how to use all of these optical parameters simultaneously to derive a probability of malignancy. In Chapter 7, I describe development and application of a novel Computer Aided Detection (CAD)
schema for breast cancer in tomographic optical images. The new approach enables improved identification
and localization of tumors. I also describe results from a pilot studies applying this technique to distinguish
benign from malignant lesions and for tracking changes in breast cancer during chemotherapy.
In Chapter 8, I describe my work under the third theme: a set of pilot studies measuring microvascular
blood flow with DCS during ‘simulated’ mammography. These data provide the first direct measurements
of changes in microvascular blood flow during external compression, and the experiments provide proofof-principle data for tomographic optical imaging of blood flow in breast. Finally, conclusions and future
directions are summarized in Chapter 9.

2

Chapter 2

Introduction to Diffuse Optics
2.1

Introduction to Diffuse Optics

In this chapter, we introduce diffuse optical spectroscopy and tomography in the context of breast cancer,
with some focus on multi-modal and contrast enhanced imaging. Diffuse optics is introduced in Section 2.1
and the mathematics required to interpret data are developed in Section 2.2. Experimental data types, geometries, and applications are described in Section 2.3.
Optical imaging of breast cancer traces its roots back to Cutler’s 1929 observations32, 33 in tissue using
broadband transillumination and ocular detection. Jobsis34 later noted that near-infrared light (∼650-950
nm) passed through tissue with very little absorption. Part of this phenomena can be observed when one
holds a flashlight against one’s hand in a dark room; in this case, one can observe red light passing through
the tissue. Traditional imaging methods, however, do not reveal internal tissue morphology, because of the
high degree of tissue scattering. Of course, multiple light scattering by suspended particles is frequently
observed in everyday life (e.g., milk or fog). Diffuse optics applies to highly scattering media, where the
directionality of input light is quickly lost and wherein the absorption is low enough so that photons travel
long distances in the media. This effect is demonstrated in Figure 2.1.

3

Schematic

No Scattering

Low Scattering

High Scattering

Figure 2.1: Images of laser light propagation through samples with increasing amounts of scattering agent
(Intralipid, an emulsion of soy oil). Note how the input light loses direction very quickly in the rightmost
figure; in this case, the input pencil beam is approximately converted into an isotropic point source just
inside the scattering liquid interface. (Figure courtesy of R. Mesquita and H. Ban.)

2.2

Mathematical Basis of Diffuse Optical Specroscopy &
Tomography

The diffusion equation for light fluence rate in an absorbing and highly scattering media can be rigorously
derived via approximations to the radiative transport equation (RTE). See, for example, the P1 approximation
in Case35 applied to the problem of neutron transport. Durduran et al.25 recently added to the many useful
reviews on the topic available in the literature22, 24, 36 , providing a detailed derivation of the diffusion equation
from the RTE. In tissue, these limits of high scattering and low absorption are often satisfied by light with
wavelengths in the range of 650-950 nm, i.e., in the near-infrared (NIR) region of the spectrum. If the
diffusion approximation is not valid, then the full RTE, or other approximations of the RTE, are required
to properly model light transport. These alternate approaches are especially superior for modeling light
transport within a few photon scattering lengths of the source position. Klose and Hielscher37 have provided
an overview of optical tomography in these latter contexts.
Photon transport of NIR light in tissue is microscopically described as a random walk characterized by
two length scales, la and ls , the photon absorption and scattering lengths, respectively. The photon absorption length is a strongly wavelength-dependent function of chromophore concentration; in most tissues, oxyand deoxy-hemoglobin dominate light absorption in the NIR. The photon scattering length depends on the
number and size of scattering particles. In soft tissue, organelles, collagen matrices, and other cellular and
sub-cellular structures with sizes on the order of the wavelength contribute to scattering. In many tissues,
the scatterer size distribution produces a ‘Mie-like’ wavelength dependence of the photon scattering length,
and a typical scattering event tends to send photons mostly in the forward direction. The mean of the cosine
of the scattering angle associated with a typical photon scattering event (i.e., the anisotropy, g =< cos[θ] >,
explained further in Equation 2.7), ranges38, 39 in tissue from ∼ 0.7−0.99. Thus many forward-biased single
4

scattering events are typically required in tissue for a photon to loose memory of its initial direction. The
net scattering effect of these ‘composite events’ is to isotropically scatter the “incident” photon; the distance
traveled on average, by photons to become isotropic is called the photon random walk step-length or the
‘reduced’ photon scattering length ls0 = ls (1 − g)−1 . Typically, ls ∼ 100 µm and ls0 ∼ 1 mm in tissues.
This situation is depicted schematically in Figure 2.2.
The diffusion approach generally assumes that la  ls0 , that is, photons are scattered much more often

than they are absorbed. Jacques and Pogue22 showed that light transport in media with ls0 /la > 20 is very

well approximated with the photon diffusion equation. These limits apply to measurements of many tissues
with light in the NIR. For example, human breast tissue ( la ∼ 20 cm, ls0 ∼ 0.1 cm) has la /ls0 ∼ 200 at
∼800 nm (other tissues are shown in Table 2.1).
The next few sub-sections will provide a mathematical underpinning for the analysis presented throughout this thesis. Section 2.2.1 introduces notation. Section 2.2.2 briefly describes the derivation of the photon
diffusion equation from the radiative transport equation. Section 2.2.3 describes the diffusion equation for
photon fluence; Section 2.2.4 describes the accompanying boundary conditions. Several analytic solutions to
the diffusion equation for photon fluence in the Time (Section 2.2.5) and Frequency (Section 2.2.6) domains

Figure 2.2: Schematic of light scattering in tissue. Most individual scattering events (black) are strongly
forward biased with scattering path length ls ∼ 10 µm. However, many (∼100) of these forward scattering
events can be lumped together into a single, isotropic, event (red) with reduced scattering path length ls0 ∼ 1
mm (blue). The absorption path length (not shown) in the diffusion regime is many times ls0 .
Tissue
Muscle
Brain
Breast
Liver

la [ cm]
5
10
20
0.1

ls0 [ cm]
0.2
0.1
0.1
0.7

la /ls0
25
100
200
7

Table 2.1: Approximate Optical Properties in the NIR for various tissues near 800nm. Note that liver is not
in the diffusion regime due to high hemoglobin content (and therefore high absorption).
5

are then described; these solutions are used in the analysis of Diffuse Optical Spectroscopy (DOS) measurements. We then introduce Diffuse Correlation Spectroscopy (DCS; Section 2.2.7) and Diffuse Optical
Tomography (DOT; Section 2.2.8).

2.2.1

Diffuse Optical Notation

Diffusion models of photon transport are parameterized by la and ls0 , the mean free paths for absorption
and isotropic scattering. However, in the Biomedical Optics Community, these models of photon transport
are typically written in terms of the inverses of the photon scattering lengths (i.e., the scattering coefficient,
µs = 1/ls , the reduced scattering, µ0s = 1/ls0 coefficient, and the absorption coefficient, µa = 1/la ).
If tissue had a single absorbing species, then µa = C ·[λ]. Here [λ] is the species wavelength dependent
extinction coefficient, and C is the species concentration. Scattering and absorbing cross-sections vary with
wavelength, and therefore both µ0s and µa are wavelength dependent. This notation is summarized in Table
2.2.

D
g
la
ls
ls0
µa
J [r,t]
L[r, Ω̂, t]
µs
µ0s
Ψ[r]
Ref f
S[r]
v

Photon Diffusion Coefficient; D = 3(µ0 v+µa ) , see Equation 2.11 [cm2 s−1 ].
s
Anisotropy, mean cosine of scattering angle, see Equation 2.7.
Photon absorption length [cm].
Photon scattering length [cm].
Isotropic photon scattering length ls = (1 − g)ls0 [cm].
Absorption coefficient, inverse of the absorption length, µa = 1/la [cm−1 ].
Photon flux, vector sum of radiance emanating from an infinitesimal volume centered at r, see
Equation 2.4 [W cm−2 ].
Light radiance at r and t in direction Ω̂, see Equation 2.1 and Equation 2.2 [W cm−2 Sr−1 ].
Scattering coefficient, inverse of the scattering length, µs = 1/ls [cm−1 ].
Reduced scattering coefficient, inverse of the isotropic scattering length, µ0s = µs (1−g) [cm−1 ].
Photon fluence rate; angular integral of the radiance at position r [W cm−2 ].
Effective Fourier reflection coefficient from a diffuse non-diffuse boundary (e.g. tissue-air).
Isotropic source term; photons emitted per volume per time at position r [W cm−3 ].
Speed of light in the medium [cm s−1 ].

Table 2.2: Important quantities and symbols in diffuse optics, to simplify discussion. Further context and
definition is provided in Eqn. 2.13.
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2.2.2

Approximation to the Radiative Transport Equation

Transport theory may be used to describe the propagation of light in tissues and other multiply scattering
media. The Radiative Transport Equation (RTE) is a conservation equation for radiance, i.e., L[r, Ω̂, t], the
power per area traveling in direction Ω̂, [W cm−2 Sr−1 ] in an infinitesimal volume centered at r. (This
description follows that in Durduran et al.25 .) The RTE is given below.
1 ∂L[r, Ω̂, t]
+ Ω̂ · ∇L[r, Ω̂, t] = −µt L[r, Ω̂, t] + Q[r, Ω̂, t] + µs
v
∂t

Z

L[r, Ω̂0 , t]f [Ω̂, Ω̂0 ]dΩ̂0

(2.1)

4π

Here, f [Ω̂, Ω̂0 ] is the normalized differential scattering cross section associated with a tissue scattering
(single-scattering) event (i.e., the probability of a photon traveling in Ω̂ to scatter into Ω̂0 ); Q[r, Ω̂, t] is
the power per volume emitted by sources at position r in direction Ω̂ at time t, and v is the speed of light in
the medium. The loss of radiance in an infinitesimal volume is dependent on the total attenuation coefficient
µt = µs + µa . The RTE describes photon transport under a wide range of conditions, but must be solved
numerically for most cases of interest. However, if L[r, Ω̂, t] is nearly isotropic (e.g., in a scattering medium
far from the source), an expansion of the RTE in spherical harmonics truncated after the first term turns out
to be useful. This so-called P1 approximation (e.g., as in Case35 ) simplifies the radiance to
L[r, Ω̂, t] =

3
1
Ψ[r, t] +
J[r, t] · Ω̂.
4π
4π

(2.2)

Equation 2.2 introduces two terms describing photons emerging from an infinitesimal volume at r and time
t:
Ψ[r, t] ≡

Z
L[r, Ω̂, t]dΩ,

(2.3)

4π

the photon fluence rate (W cm−2 , total power per area), and
Z
J[r, t] ≡
L[r, Ω̂, t]Ω̂dΩ,

(2.4)

4π

the photon flux (W cm−2 , vector sum of emitted radiance). Note that J[r, t] · Ω̂ gives a power per area
traveling in direction Ω̂.
Integrating Equation 2.1 over all solid angle results in an equation relating Ψ and J:
1 ∂Ψ
+ ∇ · J[r, t] + µa Ψ[r, t] = S[r, t].
(2.5)
v ∂t
R
Here we have introduced an ‘isotropic’ source term S[r, t] = Q[r, Ω̂, t]dΩ (the total power per volume
emitted at position r and time t; W cm−3 ). Multiplying Equation 2.1 by Ω̂ and substituting in Equation 2.2
we arrive at
∇Ψ[r, t] = −

3 ∂J[r, t]
− 3µt J[r, t] + 3
v ∂t

Z

Z
Q[r, Ω̂, t]Ω̂dΩ + 3µs J[r, t]
4π

7

f [Ω̂, Ω̂0 ]Ω̂ · Ω̂0 dΩ̂0 .

(2.6)

The rightmost integral in Equation 2.6 is an ensemble average of the cosine of the scattering angle θ
Z
g ≡ hcos[θ]i =
f [Ω̂, Ω̂0 ]Ω̂ · Ω̂0 dΩ̂0

(2.7)

4π

and defines the anisotropy g. As scattering in tissue becomes more forward scattering, g becomes closer to
1; g ∼ 0.7 − 0.99 for most soft tissues38, 39 .
We next assume that we have isotropic sources, i.e.,
Z
Q[r, Ω̂, t]Ω̂dΩ = 0,

(2.8)

and slow temporal changes in J, i.e.,
1 ∂J
 (µt − µs g)J.
v ∂t

(2.9)

In this case, Equation 2.6 reduces to Fick’s law of diffusion:
∇Ψ[r, t] = −3 (µa + µs ) J[r, t] + 3gµs J[r, t],
= −3 (µa + µs (1 − g)) J[r, t],
= −3 (µa + µ0s ) J[r, t],
v
∇Ψ[r, t] = − J[r, t],
D

(2.10)

where we have utilized the reduced scattering coefficient µ0s ≡ (1 − g)µs and defined the photon diffusion
coefficient
D≡

v
v
vl0
'
= s,
3(µs + µa )
3µs
3

(2.11)

since µa << µ0s .
With Equation 2.10, Equation 2.5 becomes


∂
− ∇ · (D[r]∇) + vµa [r] Ψ[r, t] = vS[r, t].
∂t

(2.12)

Equation (2.12) is the time dependent photon diffusion equation for light in a medium with heterogeneous
optical properties under the assumptions noted above.

2.2.3

Time and Frequency Domain Diffusion Equation for Photon Fluence

For time-domain experiments, it is useful to consider the time domain diffusion equation with losses. The
diffusion equation for photon fluence rate (Equation 2.12, Ψ[r, t], [W cm−2 ]) at a point r and time t due to
an infinitely short, pulsed, isotropic point source at the origin (S[r, t] = S0 δ[t]δ[r]) is:



∂
− ∇ · D[r]∇ + vµa [r] Ψ[r, t] = vS0 δ[t]δ[r]
∂t
8

(2.13)

where δ[x] denotes the Kroneker Delta Function for x.
For frequency domain analysis, it is convenient to separate the point source term into oscillating (ac)

and constant (dc) components: S[r, t] = Sdc + Sac e−ı̇ωt δ[r]. Solutions to the diffusion equation (Equation 2.13) which oscillate at the same frequency will have the form
Ψ[r, t] = U [r]e−ı̇ωt .

(2.14)

By substituting Equation 2.14 into Equation 2.13, we arrive at


∇ · D[r]∇ − (vµa [r] − ı̇ω) U [r] = −vSac δ[r]

(2.15)

In a homogeneous medium, this reduces to

v
∇2 − k 2 U [r] = − Sac δ[r]
D

(2.16)

with
k2 =

(vµa − ı̇ω)
.
D

(2.17)

Note that the frequency domain diffusion equation has a general solution in the form of an over-damped
‘diffusive’ wave.
Boundary conditions are discussed in Section 2.2.4; solutions in the time (Section 2.2.5) and frequency
(Section 2.2.6) domains are then presented in several important experimental geometries.

2.2.4

Boundary Conditions

The spatial boundary condition for an infinite medium is simple: Ψ → 0 as r → ∞. However, this geometry
has limited practical utility; various geometries used in practical experiments are discussed in Section 2.3.2.
Here we will discuss the boundary conditions for ‘semi-infinite’ geometry (planar boundary between
clear and turbid half spaces). In the case of biomedical optics, tissue in air will typically be reasonably
well modeled as such a system; the resulting index of refraction mismatch will cause some photons to be
reflected from the boundary. The semi-infinite boundary conditions lead naturally into those for the ‘infinite
slab’ (two parallel planar boundaries) geometries; solutions using these conditions are utilized for the data
analysis presented in subsequent chapters.
In setting out the planar boundary conditions for the semi-infinite and slab solutions to the diffusion
equation, we will use a number of derived quantities to simplify notation; these quantities are summarized
in Table 2.3.
Consider a turbid medium occupying an infinite half space. It is convenient to shift to cylindrical coordinates; +ẑ is directed into the slab and ρ is the transverse distance, as shown schematically in Figure 2.3.
9

z0 =

1
µ0s

zb = 2(ls0 + la )

1 + Ref f
3(1 − Ref f )

z+,m = 2m(d + 2zb ) + z0

z−,m = 2m(d + 2zb ) − 2zb − z0
2
r+,m
= ρ2 + (z − z+,m )2

2
r−,m
= ρ2 + (z − z−,m )2

z1,m = d(1 − 2m) − 4mzb − z0 = d − z+,m

z2,m = d(1 − 2m) − (4m − 2)zb + z0 = d − z−,m
2
2
2
r1,m
= r+,m
[ρ, z = d] = ρ2 + z1,m

2
2
2
r2,m
= r−,m
[ρ, z = d] = ρ2 + z2,m
vµa
2
kdos
=
D
vµa − ı̇ω
2
k =
D

Table 2.3: Notation used in describing semi-infinite and slab solutions to the diffusion equation in both time
and frequency domain, where m is the index of an infinite sum of dipoles used in the method of images, d is
the thickness of the slab, zb is the extrapolated boundary condition (Equation 2.30), and z0 is the effective
source position. r{1,2},m and z{1,2},m simplify notation when one is discussing transverse measurements
through a slab (i.e., z = d).

Air

Tissue
Figure 2.3: Schematic of reflection of radiance (L[Ω̂]) off tissue-air boundary. The fraction of light reflected
is the Fresnel coefficient (RF [Ω̂]); both quantities dependent on the input angle. n̂ is the surface normal;
nin and nout the indices of refraction in and outside the medium, respectively.
Assume input light impinges on the boundary in a narrow beam (e.g. from an optical fiber) at the origin.
This input light is generally well modeled as a point source at position z0 = 1/µ0s into the medium.
Photons which exit the turbid medium are permanently lost. To determine the quantity of light which
reflects off the boundary, we return to the discussion in Section 2.2.2 and note that the photon flux into
the tissue at the boundary is equal the angular integral of the radiance in the positive ẑ (as in Figure 2.3)
10

direction:
Z
Jin =
Ω̂·n̂<0

L[Ω̂]Ω̂ · (−n̂)dΩ.

(2.18)

Thus, at the boundary, all of the inward diffuse radiance is due to outward radiance reflected from the index
of refraction mismatch at the air-tissue boundary, i.e.,
Z
Jin =
RF [Ω̂]L[Ω̂]Ω̂ · (n̂)dΩ,

(2.19)

Ω̂·n̂>0

where RF [Ω̂] is the angularly dependent Fresnel reflection coefficient. By setting Equation 2.18 equal to
Equation 2.19
Z
Ω̂·n̂<0

L[Ω̂]Ω̂ · (−n̂)dΩ =

Z
Ω̂·n̂>0

RF [Ω̂]L[Ω̂]Ω̂ · (n̂)dΩ.

Substituting in Equation 2.2 we arrive at:




Z
Z
1
1
3
3
RF [Ω̂]
Ψ[r, t] +
J[r, t] · Ω̂ Ω̂ · (−n̂)dΩ =
Ψ[r, t] +
J[r, t] · Ω̂ Ω̂ · (n̂)dΩ.
4π
4π
4π
4π
Ω̂·n̂>0
Ω̂·n̂<0
(2.20)
The azimuthal angular dependence integrates out, leaving only the component in the ẑ direction:
Z π/2
1
(Ψ[r, t] + 3Jz [r, t]cos[θ]) cos[θ] sin[θ]dθ,
4π 0
Z π/2
1
=
RF [θ] (Ψ[r, t] + 3Jz [r, t]cos[θ]) cos[θ] sin[θ]dθ.
4π 0

(2.21)

We define
Z

π/2

RΨ = 2

RF [θ] cos[θ] sin[θ]dθ,

(2.22)

RF [θ] cos2 [θ] sin[θ]dθ,

(2.23)

0

Z
RJ = 3

π/2

0

and perform the angular integrals on the left side of Equation 2.21, which can then be rewritten as
Ψ[r, t]
Jz [r, t]
Ψ[r, t] Jz [r, t]
+
= RΨ
+ RJ
,
4
2
4
2
Ψ[r, t](RΨ − 1) = 2Jz (1 − RJ ).
Thus, we can write the fluence rate as a constant times the flux at the boundary:
Ψ[r, t] =

1 − RJ
2JZ .
RΨ − 1

(2.24)

From Equation 2.10,
Jz = −

D ∂Ψ
,
v ∂z
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(2.25)

and therefore, at the boundary,
Ψ[r, t] =

RJ − 1 2D ∂Ψ
.
RΨ − 1 v ∂z

(2.26)

We then define an effective reflection coefficient for Ψ
RΨ + RJ
,
2 − RΨ + RJ

(2.27)

1 + Ref f 2D ∂Ψ
1 − Ref f v ∂z

(2.28)

1 + Ref f 2D
n̂ · ∇Ψ.
1 − Ref f v

(2.29)

Ref f =
and arrive at
Ψ[r, t] =
or more generally
Ψ[r, t] =

Where n̂ is the surface normal as shown in Figure 2.3. We then define an extrapolated boundary position:
zb =

1 + Ref f 2D
1 − Ref f v

(2.30)

and arrive at the typical formulation of the so-called partial flux or Robin boundary condition (which includes
boundary Fresnel reflection effects):
Ψ[r, t] = zb n̂ · ∇Ψ[r, t].

(2.31)

While exact, the partial flux boundary condition is relatively difficult use in obtaining analytical solutions
to Equation 2.13. However, if we perform a Taylor expansion on Equation 2.31 and truncate after the first
derivative term, we obtain a condition for which the fluence rate equals zero, i.e.,
Ψ[ρ, z = −zb , t] = 0.

(2.32)

This is the so-called extrapolated zero boundary condition40, 41 ; in this approximation, the fluence rate goes
to zero in the plane parallel to the interface, but at a distance zb into the ‘air’ side of the interface. A
schematic of this extrapolated boundary is shown in Figure 2.4.
Ref f , and therefore zb , is somewhat cumbersome to calculate, but can be well approximated by a polynomial in the ratio of the indices of refraction. Contini42 writes zb as
2D
A
v
1 + Ref f
A=
1 − Ref f

zb =

12

(2.33)
(2.34)

Figure 2.4: Schematic of geometry for extrapolated zero boundary condition between air and tissue. The
z-axis points into the medium. A narrow beam of light (red) impinges on the surface of the tissue. This
light is modeled as a point source z0 = 1/µ0s below the surface (red). An extrapolated boundary is placed at
−zb and an image source at −(2zb + z0 ) (black dot); superposition of solutions from these sources produces
Ψ[zb ] = 0.

and approximates A as

A '504.332889 − 2641.00214n + 5923.699064n2
− 7376.355814n3 + 5507.53041n4
− 2463.357945n5 + 610.956547n6
− 64.8047n7 + . . .
for n =

nin
nout

(2.35)

> 1 (nin is inside the turbid medium and nout outside) and

A '3.084635 − 6.531194n + 8.357854n2
− 5.082751n3 + 1.171382n4 + . . .
for n =

nin
nout

(2.36)

< 1.

With this effective zero fluence rate interface, analytic solutions to the diffusion equation (Equation 2.13
and Equation 2.15) for the semi-infinite and slab geometries can be obtained using the solutions in the
infinite medium along with the method of images43, 44 ; the negative image source required for modeling a
semi-infinite boundary is shown in Figure 2.4. A similar analysis for two interfaces can be applied to an
infinite slab. These solutions will be discussed in 2.2.5 and 2.2.6. For these simple geometries, the Green’s
functions and solutions are just superpositions of the infinite-media solutions (with different coefficients).
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Collected
Light
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Light
Time

Time

Figure 2.5: A schematic of a time domain measurement in an infinite homogeneous medium (i.e., µa and
µ0s are constants). A narrow input pulse is introduced into the medium (black dot, e.g. with an optical fiber).
Photons scatter off the scattering centers (blue) and are absorbed by the absorbing centers (green). Most
photons travel considerable distance from the input site; a few of these will arrive at a detector (gray dot,
e.g., an collection optical fiber). As photons will travel many different paths to arrive at the detector, the
input pulse is broadened by the time it reaches the detector.

2.2.5

Time Domain Solution to the Diffusion Equation

2.2.5.1

Solution to the Diffusion Equation in an Infinite Medium (Time-Domain)

The Green’s function for Eqn. 2.13 in an infinite homogeneous turbid medium (µa [r] = µa , D[r] = D) is:
G∞ [r; rs , t] =

|r−rs |2
v
e− 4Dt −µa vt
3/2
(4πDt)

(2.37)

where r = |r|, and the source is positioned at rs . Note G∞ → 0 as r → ∞ and t → ∞. Figure 2.5 provides
a schematic of this process for a source positioned at the origin. Real physical sources will have finite
spatial size and temporal width, and the fluence rate in these cases will be derived from a convolution of the
Green’s function with some spatial and temporal form characteristic of the source. In typical experiments,
the temporal form is measured; this measured signal is often called the ‘Instrument Response Function’
(IRF; discussed in detail in Section 2.3.3) and included in the analysis by convolution with the solution for
an infinitely-short pulsed source.
Note that this analysis permits calculation of the average photon dwell time in tissue: G[r, t] describes
a distribution function of photon arrival times due to a source at the origin and a detector at r. The time
integral of this function is the CW photon transmission probability; higher order moments can also be used
14

directly for calculation of optical properties45 . Arridge46, 47 has calculated these mean transit times (first
temporal moments) for several geometries; Eqn. 2.38, below, is the mean time for an infinite homogeneous
medium, where r is the displacement between the source and detector.
hti =

1
|r|2
√
2 D + |r| µa · v · D

(2.38)

This mean transit time is sometimes converted into a Differential Path Length Factor (DPF) or Differential
Path length (DP) where DP F =
2.2.5.2

vhti
|r|

and DP = v hti (see also Sassaroli48 ).

Solution to the Diffusion Equation in a Semi-Infinite Medium (Time Domain)

In the semi-infinite geometry (Figure 2.6), we apply the method of images to account for the boundary:
Gsemi−∞ [r; rs , t] = G∞ [r; rs , t] − G∞ [r; rs0 , t]

(2.39)

where rs0 is the position of the so-called image source.
Light is generally introduced into tissue using an optical fiber or a thin ‘pencil’ beam; for simplicity of
notation, we choose to place our input position at the origin (e.g., at ρ = 0, z = 0 or r = 0). This situation
is well modeled by a point source displaced one reduced scattering path length into the medium (ρ = 0,
z = z0 = ls0 or rs = [0, 0, z0 ]); i.e.,
S[ρ = 0, z, t] = S0 δ[t]δ[ρ]δ[z − zb ].

(2.40)

This geometry is shown schematically in Figure 2.6.
Utilizing this model for the source and the extrapolated zero boundary condition described in Section 2.2.4, we obtain
Gsemi−∞ [r; rs , t] = G∞ [r; rs , t] − G∞ [r; rs0 , t]


(z+z0 +2zb )2 +ρ2
(z−z0 )2 +ρ2
v
−µa vt
−
−
4Dt
4Dt
Gsemi−∞ [ρ, z; ρs = 0, zs = z0 , t] =
e
e
−
e
(4πDt)3/2

(2.41)
(2.42)

where rs0 = [0, 0, −(2zb + z0 )] (see Figure 2.4).
Note, the analytical solution for the fluence rate Ψ from a source at rs of the form S = S0 δ[t]δ[rs ] is
simply
Ψ[r, t] = S0 G[r; rs , t].

(2.43)

Combining the source term described in Equation 2.40 with the Green’s function solution to the diffusion
equation in Equation 2.42, we can express the photon fluence rate in a semi-infinite medium Ψsemi−∞ as


(z+z0 +2zb )2 +ρ2
(z−z0 )2 +ρ2
v
−µa vt
−
−
4Dt
4Dt
Ψsemi−∞ [ρ, z, t] = S0
e
e
−e
;
(2.44)
(4πDt)3/2
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Figure 2.6: Schematic of semi-infinite (remission) geometry DOS, for a measurement on the input plane.
see Kienle 49 for additional details.
Evaluating this expression on the clear-turbid (air-tissue, z = 0) interface results in
Ψsemi−∞ [ρ, z = 0, t] = S0



z 2 +ρ2
(z +2zb )2 +ρ2
v
−µa vt
− 04Dt
− 0 4Dt
e
e
−
e
(4πDt)3/2

(2.45)

and measurable signal (power crossing the boundary or the integration over all possible photon angles exiting
the turbid medium a distance ρ from the source)42 is
D ∂
Ψsemi−∞ [ρ, z = 0, t]
v ∂z


z 2 −ρ2
(z +2zb )2 −ρ2
S0
−µa vt
− 04Dt
− 0 4Dt
=
e
z0 e
+ (z0 + 2zb ) e
2(4πD)3/2 t5/2

R[ρ, t] =

2.2.5.3

(2.46)
(2.47)

Solution to the Diffusion Equation in an Infinite Slab (Time Domain)

Similarly, we can apply the extrapolated boundary conditions to a pair of parallel planar interfaces making
up an infinite slab (Figure 2.7). Various derived quantities which permit simplification of the equations are
shown in Table 2.3. The source is positioned at [ρ = 0, z = z0 ] for notational convenience. This geometry
is shown schematically in Figure 2.8.
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Collected Light
Input Light
Time
Time

Figure 2.7: Schematic of infinite slab geometry DOS. A thin ‘pencil’ beam of light introduced to the tissue
at ρ = 0, z = 0 is well modeled as a point source at ρ = 0, z = z0 ∼ ls0 .
The Green’s function in such a slab with extrapolated boundary conditions, solved with the method of
images is42 :
ρ2

ve−µa vt e− 4πDt
Gslab [ρ, z; ρs = 0, ρz = 0, t] =
2(4πDt)3/2


!
+∞ 
+∞ 
X
X
(z−z+,m )2
(z−z−,m )2
−
−
4Dt
4Dt
e
−
e
.

m=−∞

m=−∞

(2.48)
However, this solution does not yet describe the detected light (i.e., the radiance integrated over the
collection solid angle). Integrating over all possible photon angles existing the slab at a distance ρ from the
source, the detectable light transmission can be shown to be
T [ρ, t] = −

D ∂
Ψ[ρ, z = d, t].
v ∂z
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(2.49)

Extrapolated
Boundary
Source

Detector

Figure 2.8: Compressed breast geometry (‘slab’). r distance between source and detector, ρ lateral (in plane)
separation between source and detector, d plate separation, z0 = (µ0s )−1 extrapolated source position, and
zb is the location of the extrapolated boundary.
Combining Equation 2.43 and Equation 2.49, the transmitted light is described by
ρ2

T [ρ, t] =

S0 e−µa vt e− 4πDt
2(4πD)3/2 t5/2

+∞ 
X
m=−∞

z1,m e−

2
z1,m
4Dt

− z2,m e−

2
z2,m
4Dt


.

(2.50)

This expression usually is truncated after sufficient terms have been included to fit experimental data to the
required accuracy. Note that we have not yet included the finite temporal width of a physical source in this
expression; as mentioned above, this is accounted for by convoluting the solution for an infinitely short pulse
with the measured Instrument Response Function for a particular instrument.
Equation 2.50 can be integrated over time to provide the CW transmission as a function the transverse
distance ρ:
T [ρ] =

∞
S0 X z1,m
(1 + kdos r1,m ) e−kdos r1,m
3
4π m=−∞ r1,m

−

z2,m
(1 + kdos r2,m ) e−kdos r2,m .
3
r2,m
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(2.51)
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Figure 2.9: Graphs of Equation 2.50 for a slab with d=6 cm, ρ = 0 cm, µ0s = 10 cm−1 , and µa as noted
in the legend. The amplitude for all the curves is normalized to show how longer photon paths (i.e., longer
times) are suppressed as the absorption is increased.
This is the probability per unit area of a photon exiting the medium at ρ on the output plane. Examples of
Equation 2.50 with various combinations of parameters are shown in Figures 2.9 through 2.11.
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Figure 2.10: Graphs of Equation 2.50 for a slab with d=6 cm, ρ = 0 cm, µa = 0.05 cm−1 , and µ0s as
noted in the legend. The amplitude is normalized for all curves. Note that the primary effect of increasing
scattering is to delay the time-to-peak of the curve; the terminal slopes of all of the scattering values are
approximately equal.
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Figure 2.11: Graphs of Equation 2.50 for a slab with d=6 cm, µa =0.05 cm−1 , µ0s = 10 cm−1 , and ρ as
noted in the legend. Note, as the transverse distance between the source and detector increases, the entire
curve is shifted to later times.
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2.2.6

Frequency Domain Solution to the Diffusion Equation

This section summarizes some important results solving the photon diffusion equation in the frequency
domain (Equation 2.15). The geometries used are identical to those shown schematically in Section 2.2.5.

2.2.6.1

Solution to the Diffusion Equation in an Infinite Medium (Frequency Domain)

In an infinite homogeneous medium, Equation 2.16 has a well known Green’s function:
G∞ [r; rs , ω] =
Where rs is the location of the source k 2 =

1
e−k|r−rs | .
4π|r − rs |

µa v−ı̇ω
D

(2.52)

(note that this reduces to the kdos defined in Table 2.3

for ω = 0).

2.2.6.2

Solution to the Diffusion Equation in a Semi-Infinite Medium (Frequency Domain)

Again applying the method of images and the boundary conditions described in Section 2.2.4, the Green’s
function solution for a semi-infinite medium can be written as
Gsemi−∞ [ρ, z; ρs = 0, zs = z0 , ω] =

1
4π



e−k|ra |
e−k|rb |
−
ra
rb


(2.53)

for a source positioned at [ρ = 0, z = z0 ], ra2 = (z − z0 )2 + ρ2 , and rb2 = (z + 2zb + z0 )2 + ρ2 .
2.2.6.3

Solution to the Diffusion Equation in an Infinite Slab (Frequency Domain)
 −k|r+,m |

∞
1 X
e
e−k|r−,m |
Gslab [ρ, z; ρs = 0, zs = z0 , ω] =
−
4π m=−∞
r+,m
r−,m

for a source positioned at [ρ = 0, z = z0 ]. For the ω = 0 CW case, k → kdos =

vµa
D ,

(2.54)
and the Green’s

function is
 −kdos |r+,m |

∞
1 X
e
e−kdos |r−,m |
Gslab [ρ, z; ρs = 0, zs = z0 , ω = 0] =
−
4π m=−∞
r+,m
r−,m

(2.55)

evaluating this in transmission (i.e., z = d as in Table 2.3), r±,m → r{1,2},m
Gslab [ρ, z = d; ρs = 0, zs = z0 , ω = 0] =

 −kdos |r1,m |

∞
1 X
e
e−kdos |r2,m |
−
.
4π m=−∞
r1,m
r2,m

(2.56)

As with Equation 2.50, these Green’s function solutions can be used to compute the photon current at
the surface of the boundary50 ; examples are shown in Figure 2.12.
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Figure 2.12: Graphs of Equation 2.56 for a slab with d=6 cm, µa =0.05 cm−1 , µ0s = 1 mm−1 , and ρ as noted
in the legend. Note, these graphs are plotted vs. |r|, not ρ, to linearize the change in phase and amplitude.

2.2.7

Diffuse Correlation Spectroscopy (DCS)

Diffusing light can also probe the dynamics of scatterers in tissue. It is well known that coherent light
reflected off a surface or passed through a sample of dilute scatterers (single scattering limit) will form an
interference (‘speckle’) pattern. Similarly, in the multiple scattering limit, an interference pattern is formed
on tissue surfaces after illumination with a coherent source. At any one point, the speckle intensity is due to
the summation of the electric fields over all arriving photons, each with a different path. If one monitors a
speckle as a function of time, the temporal fluctuations of intensity or field can be used to derive information
about the scatterer motions in the sample.
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Diffuse Correlation Spectroscopy (DCS) is a technique wherein light from a long-coherence-length (narrow bandwidth) laser illuminates tissue. Diffuse (multiply scattered) light from the tissue is then detected
one photon at a time and then the intensity temporal auto-correlation function of the diffuse light is calculated. As scatterers move, the superimposed contributions of the scattered light from different photon paths
are detected as an intensity fluctuation. The temporal autocorrelation of this intensity as a function of delay
time τ is dependent on the mean-squared displacement, < ∆r2 [τ ] >, of the scattering particles (e.g. Figure 2.13). It turns out that the transport of the associated field auto-correlation function through the medium
can also be modeled using a diffusion equation of a slightly different form than for fluence rate. (Note, DOS
does not measure these dynamics; it measures only the average intensity.)
The key concept behind the use of DCS in tissues is that an increase in blood flow leads to an increased
rate of fluctuations of the phase of the diffuse light field. A schematic of this technique is shown in Figure 2.13. Essentially, light from a long coherence length laser is introduced into tissue and a single mode
fiber collects scattered light, and the light is thus routed into a photon-counting APD operating in Geiger
mode. A multi-delay auto-correlator then computes the temporal intensity auto-correlation function and
transmits it to a computer for storage. An example experimental apparatus is shown in Figure 2.13.
In the remainder of this section, we will sketch out key assumptions and results for DCS, including solutions for the correlation diffusion equation in several geometries. A recent review by Durduran25 provides
a more complete explanation and many detailed references.
Dynamic light scattering (sometimes called quasi-elastic light scattering) is a well known technique to
measure the motion of dilute suspensions of scatterers (e.g. in the single scattering limit)52–54 . Light from
an illumination beam induces a dipole in each of the scatterers; these oscillating dipoles emit scattered light
fields in all directions. A detector measures the superposition of the radiating dipole electric fields as a
function of time. When the scattering particles move, the relative phases of the scattered light fields at the
detector change; thus, the detected intensity fluctuates with time.
In the single scattering limit for independent particles with isotropic dynamics, the detected normalized
electric field temporal auto-correlation function is
g1 [τ ] ≡

2
2
< E∗ [t] · E[t + τ ] >
= eı̇2πf τ e−q <∆r [τ ]>/6
2
< |E[t]| >

(2.57)

where f is the light frequency, q = kout − kin is the scattered wave vector, < ∆r2 [τ ] > is the mean-square
displacement of the typical scatterer in time τ , E is the total electric field at the detector, and brackets <>
denote time or ensemble averages. In practice, it is much easier to measure intensity (I[t] = |E[t]|2 ), than
the field auto-correlation function:
g2 [τ ] ≡

< I[t] · I[t + τ ] >
.
< |I[t]|2 >
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(2.58)

Figure 2.13: Conceptual Diffuse Correlation Spectroscopy (DCS) schematic. A long coherence length
(∼50m) laser is coupled to tissue. If we consider a single optical path at time t, the total phase change
between the inputPand output fiber will be the sum of the magnitude of the wave vectors between each
scattering event ( j kkj k). At a later time, t + τ , the scatters will have shifted slightly (∆rj [τ ]), and thus
change the phase of the detected light. The interference pattern due to all such paths produces a speckle
pattern; we utilize a single mode fiber to couple light from a single speckle output light to a photon-counting
APD. An autocorrelator produces an intensity autocorrelation curve. Increased blood flow changes the path
length of light in tissue more rapidly, leading to faster fluctuations in intensity and therefore faster decay of
the correlation curve51 .
25

The Siegert relation relates the electric field and intensity auto-correlation functions55 :
g2 [τ ] = 1 + β|g1 [τ ]|2

(2.59)

where β is a constant dependent on the experimental optics. This relationship is valid when E[t] is a
Gaussian variable with zero mean. The input light E[t] does not satisfy this condition, but this condition
is satisfied after many statistically independent scattering events, provided the input light is sufficiently
coherent and there is not a static contribution to E[t]. An ideal apparatus collecting a single mode of
polarized light would produce β = 1; for unpolarized light, β =

1
2

.

Boas56 showed how to construct a diffusion equation that describes the transport of electric field temporal autocorrelation functions in turbid media, and thence access blood flow in microvasculature. A full
description of this technique is beyond the scope of this work; various authors57–61 have studied biomedical applications and validations of this technique against other modalities. Note that a different (original)
integral formulation of this technique is also referred to as ‘Diffusing Wave Spectroscopy’62 (DWS) in the
condensed matter community.
The unnormalized light electric field autocorrelation function is
GT1 [r, Ω̂, τ ] =< E∗ [r, Ω̂, t] · E[r, Ω̂, t + τ ] > .

(2.60)

Integrating over all angles, we define a ‘correlation fluence rate’57, 63 :
Z
G1 [r, τ ] =
GT1 [r, Ω̂, τ ]dΩ
4π

=< E ∗ [r, t] · E[r, t + τ ] > .

(2.61)

where E[r, t] is the total electric field at r and t.
As shown for photon fluence rate in Section 2.2.2, the P1 approximation to the correlation transport
equation64, 65 produces a diffusion equation for G1 in turbid media:


α
∇ · (D[r]∇) − vµa [r] − vµ0s κ20 < ∆r2 [τ ] > G1 [r, τ ] = −vS[r].
3

(2.62)

Here S[r] is an isotropic source term, κ0 = 2π/λ is the wave number for the light source, α is the fraction
of scattering events from moving particles, and the remaining variables are as defined for DOS. This formulation has the same requirements as the photon diffusion equation (e.g., µa << µ0s , measurement distant
from source, etc.) and also requires isotropic scatterer dynamics and a CW source. Note that in a typical
measurement of biological tissue, the moving scatterers are primarily red blood cells, which make up a small
percentage of the total body mass (blood as a whole makes up ∼7%66–68 ); thus α will be quite small (e.g.,
∼0.05-0.1).
The correlation diffusion equation (Equation 2.61) has the same form as the photon diffusion equation
(2.13). Thus, an analogous set of boundary conditions arise for the correlation diffusion equation as those
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described for the photon diffusion equation in Section 2.2.4. We can therefore utilize the solutions worked
out for the photon diffusion equation (i.e. Equation 2.53) with the correlation rate taking the place of
the photon fluence rate and kdcs taking the place of kdos . Again using the extrapolated zero condition
(G1 [z = −zb , τ ] = 0, in the semi-infinite geometry the solution to Equation 2.62 is
2
2
2
2
e−kdcs [τ ]((z+2zb +z0 ) +ρ )
e−kdcs [τ ]((z−z0 ) +ρ )
−
(z − z0 )2 + ρ2
(z + 2zb + z0 )2 + ρ2
 −kdcs [τ ]ra

v
e
e−kdcs [τ ]rb
=
−
4πD
ra
rb

v
G1 [ρ, z, τ ] =
4πD

!
(2.63)
(2.64)

where
v
kdcs [τ ] =
D
2



αµ0s κ20 < ∆r2 [τ ] >
µa +
3

(2.65)

for a source positioned at [ρ = 0, z = z0 ], and the remaining parameters are as defined in Equation 2.53.
Note that kdcs [τ ] contains the dynamical information about the tissue sample.
As mentioned above, measuring intensities is much more practical than electric fields; we again rely
upon the Siegert relation (Equation 2.59) to convert the intensity autocorrelation function, G2 , into that for
the field, G1 :
G2 [r, τ ] =< I[r, t]I[r, t + τ ] >

(2.66)

where I[r, t] = |E[r, t]|2 |.

The mean square particle displacement < ∆r2 [τ ] > is dependent on the type of particle motion (e.g.

diffusion or random flow). Various researchers have found that < ∆r2 [τ ] > in biological tissue is best
described with a Brownian model51, 61, 69–73 :
< ∆r2 [τ ] >= 6DB τ

(2.67)

where DB is an effective diffusion coefficient that is several orders of magnitude larger than the thermal
(Einstein) coefficient for particles the size of red blood cells; see Durduran et. al25 for a discussion of DB .
In this case of ‘effective’ Brownian motion, the diffuse correlation wave number is
2
kdcs
[τ ] =

v
2 02
(µa + 2kD
µs αDB τ ).
D

(2.68)

Note that for τ = 0
2
kdcs
[τ = 0] =

vµa
2
= kdos
D

(2.69)

as defined in Table 2.3.
All of the data presented in the remainder of this thesis is collected in transmission geometry. Solutions
to the photon diffusion equation for the infinite slab are well known (e.g. Contini42 ) and were presented in
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Section 2.2.5. Chapter 8 presents data taken with Diffuse Correlation Spectroscopy (DCS); as with DOS,
the analysis is performed using a solution to the DCS diffusion equation for an infinite slab.
Recall from Table 2.3:
2
2
r1,m
= ρ2 + z1,m
2
2
r2,m
= ρ2 + z2,m
.

In analogy to Equation 2.56, we write the DCS solution for every decay time τ at transverse distance ρ as
 −kdcs |r1,m |

∞
1 X
e
e−kdcs |r2,m |
dcs
−
(2.70)
Gslab [ρ, z = d] =
4π m=−∞
r1,m
r2,m
with the diffuse correlation wave number kdcs as defined in Equation 2.69.
To summarize, we collect an intensity auto-correlation function, we convert it to a field auto-correlation
function using the Siegert relation, and then we fit this to a solution of the diffusion equation for correlation fluence rate. Experimental applications will be discussed in Section 2.3.5 and my applications of this
technique to measurement of hemodynamics during simulated mammograms will be discussed in Chapter 8.

2.2.8

Diffuse Optical Tomographic (DOT) Reconstruction

The simplest diffuse optical spatial information comes from making a series of measurements on a surface
and projecting the results onto a 2-D map74, 75 . This approach is sometimes used for functional brain studies
and with hand-held probes76 . More sophisticated volume imaging strategies rely on tomography wherein
we seek to answer the question:
What is the distribution of absorbers and scatterers inside a medium which would produce the
measured outputs, given the known inputs?
Diffuse Optical Tomography (DOT) localizes and quantifies heterogeneities in a volume based on measurements of photon fluence rate on the surface of the volume. Calculation of a simulated set of measurements (the ‘calculated measurement vector’) from known inputs, i.e., from known µa [λ, r] and µ0s [λ, r],
is termed ‘the forward problem’. The inverse problem aims to derive the distribution of optical properties
within the tissue volume from the measurement vector; it is generally ill-posed and is much more computationally complex than the forward problem. In contrast to X-Ray CT, which uses a columnated thin beam
of incident photons which will reach the far side of the medium at approximately the same beam size as it
had on the input side, in diffuse optics, the volumes probed by photons arriving at adjacent detectors overlap
significantly. The DOT reconstruction problem is therefore more complex than X-Ray CT. In the following
sections, we will introduce the ‘forward problem’ and formulate it for a medium with heterogeneous optical
properties. We will then explain the ‘inverse problem’, which enables us to extract the spatial absorption
maps from optical measurements on the surface of a medium.
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2.2.8.1

Formulation of the DOT Problem

For small variations in optical properties, the heterogeneous forward problem can be treated within perturbation theory: small heterogeneities will slightly perturb the measurement vector from the homogeneous
tissue case, to which solutions are known or can be calculated (e.g. the Green’s functions for homogeneous
(0)

media in Section 2.2.5 and Section 2.2.6). The background or bulk optical properties (µa , D(0) ) can be
measured using DOS and we can write these perturbations as
µa [r] = µ(0)
a + δµa [r]
D[r] = D(0) + δD[r].

(2.71)

The tomographic problem is now to find the spatially varying values of δµa [r] and δD[r], given some
distribution of fluence rates on the tissue surface and the bulk optical properties. Recall Equation 2.13, the
time dependent diffusion equation for spatially varying optical properties:



∂
− ∇ · D[r]∇ + vµa [r] Ψ[r, t] = vS0 δ[t]δ[r]
∂t
can be written in the frequency domain as Equation 2.15
∇ · (D[r]∇U [r]) − (vµa [r] − ı̇ω)U [r] = −vSδ[r],

(2.72)

where we have dropped the subscript ‘ac’ off the source term for clarity. Equation 2.13 and Equation 2.72
are used for the ‘forward problem’ calculation, i.e., determining the fluence rate at a detector position due
to light input at a source position for a given spatial distribution of optical properties.
If we assume that heterogeneities in the tissue are slowly varying in space, we may apply the Rytov
approximation77 to describe the scattered fluence. (See Kak78 and Arridge17 for overviews and perspectives
of linear approximations.) Here, we write the total fluence rate (Ut ) in terms of the ‘unperturbed’ input wave
(U0 ) and a spatially dependent exponential factor eφs [r] , i.e.,
Ut [r] = U0 [r]eφs [r] .

(2.73)

Then, plugging Equation 2.73 and Equation 2.71 into Equation 2.72, collecting leading order terms, and (for
simplicity) assuming δD = 0, it is straightforward to show for a source positioned at rs and a detector at rd
that



Z
Ut [rs , rd ]
1
vδµa [r]
ln
= φs [rs , rd ] =
U0 [rs , r]
G[r, rd ]d3 r.
U0 [rs , rd ]
U0 [rs , rd ] V
D(0)

(2.74)

Here, G[rs , rd ] is the Green’s function solution for the heterogeneous diffusion equation and r is integrated
over the entire tissue volume.
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The fluence rate in a homogeneous medium, U0 , due to a point source is the homogeneous Green’s
function multiplied by a source term, i.e. U0 = S · G0 . The Green’s functions for homogeneous media
in simple geometries are well known (e.g., as in Section 2.2.4). Furthermore, since we are working in the
small perturbation regime, the heterogeneous Green’s function is approximately equal to the homogeneous
Green’s function (i.e., G ' G0 ), allowing us to rewrite Equation 2.74 as:


Z
Ut [rs , rd ]
1
vδµa [r]
ln
G0 [r, rd ]d3 r.
= φs [rs , rd ] =
G0 [rs , r]
U0 [rs , rd ]
G0 [rs , rd ] V
D(0)

(2.75)

In diffuse optical tomography, we consider measurements made by Nd detectors during serial illumination by Ns sources, all located on the surface of the tissue. We then reconstruct Nv volume elements
(voxels) in the interior of the tissue. One can formulate this problem in matrix or operator form based on
Equation 2.75. Specifically, we discretize Equation 2.75 as
N

v
X
1
v
G0 [rs , rj ]δµa [rj ]G0 [rj , rd ]h3
φs [rs , rd ] = (0)
D G0 [rs , rd ] j=1

(2.76)

where h3 is the voxel volume, s and d index the sources and detectors, and j indexes the voxels. Equation 2.76 describes a series of coupled linear equations, shown in matrix form below.
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(2.77)

where
(i)

Wi,j =

(i)

v G0 [rs , rj ]G0 [rj , rd ]
.
(i)
(i)
D(0)
G0 [rs , rd ]

(2.78)

and the index i runs over all source-detector pairs. Wi,j are the ‘weights’18 or ‘hitting density’79 which give
the importance of the absorption in any particular voxel in a measurement from a given source-detector pair.
Note that the elements of the weight matrix are proportional to the three-point Green’s function between rs ,
rj , and rd , that gives the probability that a photon entering the turbid medium at rs will pass through the
voxel at rj and then be detected at rd .
The desired output of a DOT measurement is a spatial map of absorption and scattering over all the
volume elements in the medium (i.e., δµa [r] in Equation 2.77). However, we measure light at points on the
surface of the tissue (i.e., the left hand size of Equation 2.77). W is therefore a forward operator, converting
a distribution of absorption within the sample into a detected light output for a given light input. In DOT, we
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seek to find an inverse operator, which will use surface measurements to find the distribution of absorption
within the sample. This is known as the ‘inverse problem’. This problem is sometimes complicated by the
fact that in many experiments Nv > Ns × Nd . In this case, the problem is under-determined (i.e., more
unknowns then measurements/equations).
2.2.8.2

Example Solution to the Inverse Problem in Diffuse Optical Tomography: Singular Value
Decomposition

The most intuitive approach to obtaining the inverse solution to Equation 2.77 is to simply invert the weight
matrix W to obtain δµa [r]. For example,
If Wδµa [r] = φs ,
then δµa [r] = W−1 φs .
However, an analytic inverse of W does not generally exist as W = WNs ×Nd ,Nv . The number of measurements, Ns × Nd , will often be less than the number of voxels, Nv , i.e., W is not square. The Moore-Penrose
pseudo-inverse80 is defined for rectangular matrices, but is not unique. We therefore approach this problem
by first pre-multiplying by the transpose of W, i.e., WT to form a symmetric square matrix:
WT Wδµa [r] = WT φs .

(2.79)

The matrix M = WT W is now square and symmetric, but can be poorly conditioned (i.e., the range of
eigenvalues is large).
We calculate the Moore-Penrose pseudo-inverse (M+ ) by decomposing M:
M = UΛUT
+
M+ = UΛUT
+
+
= UT Λ+ (U)
= UΛ+ UT

(2.80)
(2.81)
(2.82)
(2.83)

where Λ is a diagonal matrix of the ordered eigenvalues of M and the columns of U are the corresponding
orthonormal eigenvectors of M. Note that (UT )+ = U, and U+ = UT , because U is orthogonal. The
smaller eigenvalues of M+ correspond to high spatial frequency modulations in the image. We therefore
choose to use ‘Truncated Singular Value Decomposition’ (tSVD), in which we set all eigenvalues smaller
than a regularization parameter (γr ) to zero thus reducing the effect of high frequency noise81 . The components of Λ+ are
λ+
i =



λ−1

if λi > γr ,


0

if λi ≤ 0.

i
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(2.84)
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Figure 2.14: Example of regularization parameter (γr ) selection using an ‘L-Curve’, in which the image
norm (kδµa [r][r]k) is plotted against the residual (∆ ≡ kWδµa [r] − φs k). The optimal regularization
parameter is at the corner of the ‘L’, here, 0.05.

As there is no abrupt change in the magnitude of the singular values, we choose the value of γr using the so-called ‘L-curve’, which plots the norm of the solution (kδµa [r][r]k) against the residual(∆ ≡
kWδµa [r] − φs k)82, 83 for various values of γr . We choose to use value of γr for the point of maximal curvature (closest to the ‘corner’ of the L) is then used for the remaining analysis. An example of this process
is shown in Figure 2.14.
Therefore we have the solution for the spatial distribution of absorption,

δµa [r] ' UΛ+ UT WT φs .

(2.85)

This truncated SVD approach usually works at some level, and it was employed often in the early
days of DOT. This and other linear ‘subspace’ techniques are superior to linear algebraic reconstruction
techniques84 , but non-linear iterative techniques (e.g. TOAST, as in Section 2.2.8.3) are currently the standard in the field. However, the single computationally expensive step in the tSVD reconstruction allows
images at many time points to be reconstructed quickly, in near real time.
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2.2.8.3

DOT with Nonlinear Iterative Techniques and Spatial Regularization

As will be described in Chapter 6, our GenIII system enables acquisition of many more spatial data points
than the GenII or GenIIm systems (Chapter 4). We therefore adopted a more sophisticated image reconstruction scheme to take advantage of this additional data. Building upon a long term collaboration with
Dr. Simon Arridge and Dr. Martin Schweiger at University College London, we have applied the TOAST
(Time-resolved Optical Absorption and Scattering Tomography)85, 86 software package to the reconstruction
problem.
TOAST utilizes an iterative approach to the DOT inverse problem, adjusting a proposed map of chromophores until a computed measurement vector matches the experimental measurement vector, within an
error. A sketch of the general iterative process is given below, which applies to many numerically-based
iterative inverse problem schemes.
1) Define an objective function (χ2 ), which characterizes the difference between predicted and experimental measurements.
2) Make an ‘initial guess’ chromophore map for the reconstructed volume (µ0 [r], here D[r] = D(0) for
simplicity).
3) Compute measurement vectors (forward problem) based on the chromophore map (µ[r]).
4) Compare ‘calculated’ values to actual measurements; compute the objective function (χ2i ) for this
iteration.
5) Check objective function value against stopping criterion (e.g. χ2i < ).
6) If stopping criteria is realized, terminate procedure, otherwise, adjust the chromophore map and repeat.
Specifics of how this approach is applied to our experimental data are included in Section 2.3.6.
2.2.8.4

Other DOT Techniques

A number of mathematical techniques can be used to solve the integro-differential equations arising from
inverting the diffusion equation in heterogeneous media; such algorithms are an area of current research. A
complete discussion of the merits in accuracy and computational cost of these techniques is beyond the scope
of this thesis; Arridge and Schotland have recently reviewed new developments in optical tomography24 .
Several academic groups have assembled diffuse optical tomography software packages: Arridge’s
TOAST85, 86 (University College London)i , Dehghani’s NIRFASTii (University of Exeter), Ripoll’s ART/SIRT
i http://web4.cs.ucl.ac.uk/research/vis/toast/
ii http://newton.ex.ac.uk/research/biomedical/hd/NIRFAST.html
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codesiii (FORTH), the Oregon Medical Laser Center’s Radiative Transport Softwareiv , and Boas’s HomER
and PMI Toolboxv (MGH). Several of these packages are freely available to the academic community.
Recently, the trend in image reconstruction has been towards large numbers of source detector pairs
(> 106 )31 frequently using CCD detectors. Deliolanis87 and colleagues have applied this to small animal
fluorescence imaging. Culver88 and Choe31 et al.applied CCD detection to 3D tomography of absorption
properties in the breast; Corlu et al.89 extended this work to perform 3D reconstruction of ICG fluorescence in breast cancer. The resulting data sets, especially when scaled up to the human brain or breast,
require significant computational resources to reconstruct tomographically with Finite Element Modeling or
Finite Difference methods. Konecky et al.90 applied much more efficient inversion algorithms developed by
Schotland, Markel, and Mital91–93 to ultra large (107 source-detector pairs) data sets from phantoms and, in
unpublished data, to healthy human breasts.

2.3

Experimental Realizations of Diffuse Optics

Several different types of diffuse optical instrumentation have been developed for use in both laboratory and
clinical settings. The various data types are described in Section 2.3.1 and experimental geometries in Section 2.3.2. Section 2.3.3 describes Time Domain Diffuse Optical Spectroscopy (TD-DOS) and Section 2.2.7
describes blood flow measurements with Diffuse Correlation Spectroscopy (DCS). The research presented
in this thesis was accomplished using several instrument and data types: the GenII Optical/MRI system described in Chapter 4 utilizes DOT and DOS; the GenIII Optical/MRI system described in Chapter 6 utilizes
DOT, and DOS (future plans include DCS); and the compression study described in Chapter 8 utilizes DOS
and DCS.

2.3.1

Experimental Data Types

Diffuse optical data is collected from pulsed (time domain, TD), modulated (frequency domain, FD), or
steady state (continuous wave, CW), light sources. The relative information content per source-detector
pair of these DOS systems is TD>FD>CW. Detectors include photo-multiplier tubes (PMT’s), avalanche
photo-diodes (APD’s), photo-diodes (PD’s), streak cameras, and CCDs. Some of the attributes of these data
types are summarized in Table 2.4.
Time Domain (TD) or Time Resolved Spectroscopic (TRS) techniques introduce a brief pulse of light
into a medium and measure the broadening of this pulse due to the different trajectories taken by photons
transversing the medium. Together with the tissue index of refraction, the mean of this transit time gives
iii http://esperia.iesl.forth.gr/

˜jripoll/
forward problem, but includes adding-doubling inverse code http://omlc.ogi.edu/software/
v http://www.nmr.mgh.harvard.edu/PMI/resources.htm

iv Mostly
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Time
Domain

TD
or
TRS
Frequency FD
Domain
Continuous
Wave

CW

Absolute optical properties with a single
source and detector.

Expensive components.

Absolute optical properties require many
frequencies or source-detector combinations
Only relative optical properties

Relatively inexpensive components

Very inexpensive (∼$20)
components.

Table 2.4: Diffuse optical data types; note that spatially modulated data can be collected using any of the
temporally modulated techniques.

the average photon path length, which is related to the absorption and scattering of the tissue44, 46, 94 (see
also Section 3.1.1). Most modern techniques use a streak camera95, 96 or Time-Correlated Single Photon
Counting (TCSPC)5, 97 devices to measure transmitted pulse profiles. The TCSPC technique relies on detectors (APDs or PMTs) operating in Geiger mode and a low photon flux: on average, each channel receives
less than one photon per laser pulse (∼2-70 MHz). The time of each photon arrival is recorded and a histogram of arrival times is built up over an integration period; the results are fit to solutions of Eqn. 2.13
appropriate for the geometry and boundary conditions to obtain absolute values for µa [λ ] and µ0s [λ ].
In practice, TD measurements are limited by the TCSPC electronics maximum count rate (∼1-10 MHz)
to fairly low detected signal intensities, and thus longer integration times are required per source-detector
position compared to similar FD measurements.
TD systems permit rejection of unwanted photons (e.g., those due to reflections in the system) through
time-gating. For example, the length of optical fibers can be adjusted such that a reflection off the face of
the fibers is separated in time from the data pulse; in an FD system, such a reflection could be a source of
phase noise. Torricelli and colleagues98 extended this concept by placing their source and detector directly
adjacent to one another and enabling their short rise-time detector only after photons experiencing specular
reflection from the surface or only a few scattering events had arrived.
TD systems permit use of time-resolved data directly by fitting to time-dependent solutions to the diffusion equation. Information can also be codified by decomposition into temporal moments or by application
of the methods of FD analysis (discussed below) to Fourier transformed TD data. These data types are
addressed in detail by E. M. C. Hillman in her thesis99 and by Liebert et al.45 .
The phase of an amplitude modulated measurement (first suggested by Gratton100 ) encodes information
similar to the mean tissue transit time; current instrumentation typically utilizes frequencies from 30-200
MHz76, 88, 101–107 with a few groups using up to ∼800 MHz108 . These frequency domain (FD) measurements
are the Fourier analogues of the time domain measurements, but for practical reasons, most researchers
measure one or a few frequencies instead of sweeping the frequency through a range (e.g. 300 kHz to
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800 MHz as in Madsen et al.108 ). This frequency restriction reduces the information content of the FD
measurements: those researchers (e.g. Bevilacqua et al.109 ) who use swept frequency devices have much
more information per measurement than single frequency FD instrumentation. Swept frequency domain
systems are currently limited to less than ∼1 GHz by the practical speed of modulation of source laser
diodes and detector response time, while the frequency component of the TD signal extends to several
GHz. However, single frequency lock-in electronics are relatively inexpensive and these single frequency
instruments can be more economical than the TD or swept FD instruments, especially for systems with many
detectors (e.g. Sevick-Muraca et al.110 ). FD systems also have the advantage of a significantly higher duty
cycle than TD: the ‘signal’ is detected continuously, instead of a single photon per laser pulse, permitting
very short (e.g. 10-100 ms) integration times for each source-detector pair.
Calculation of absolute optical properties is possible for homogeneous media with single frequency FD
devices, but the measurement is markedly improved through use of multiple source-detector separations.
Simple measurements of attenuation with continuous wave (CW) light cannot discriminate absolute absorption and scattering except under special circumstances99, 111–113 .
Intes and Chance114 addressed analysis of multi-frequency data, noting that 7-12 frequencies spanning
0-500 MHz provided optimal results. FD systems with more then one non-zero frequency have been implemented for DOS109 and Tromberg’s group at the Beckmann Laser Institute has applied this system in many
clinical studies74, 115, 116 . However, the Beckmann system relies upon a sophisticated network analyzer. Multiple frequency data for DOT are generally derived from TD measurements (e.g., by Fourier transformation)
as discussed in Section 2.2.5 and Section 2.3.3.
In the ω = 0 (steady state or continuous wave) case, it is difficult to separate changes in absorption
and scattering, except in a few special cases117 . However, especially in situations where scattering remains
roughly constant, CW techniques have proven particularly useful to measure changes in the absorption both
in space (e.g. hematomas118 ) and time (e.g. exercising muscle119 ); these techniques can be very inexpensive
(e.g. ∼$20 in opto-electronic parts for a 1 wavelength, 1 source-detector system).
To summarize, CW data simply records intensity, typically referenced to a baseline value I0 as

I
I0 .

FD data at a single frequency ω =ω1 provides amplitude and phase; many FD systems can collect data at
both a finite frequency (ω1 ) and ω =0. The pulse broadening in the time domain of a brief pulse of light
passing through a scattering medium is perhaps more intuitively obvious than the phase shift one observes
in the more commonly used frequency domain measurements; the time domain is the natural formulation
convenient for Monte Carlo simulations of photon transport. Most importantly, TD measurements permit
absolute quantification of scattering and absorption coefficients in a homogeneous medium with a single
measurement. Technically, FD measurements of phase, amplitude (AC), and average intensity (DC) are
sufficient to calculate absolute optical properties, but this approach is more susceptible to systematic errors.
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Thus most researchers using FD techniques rely upon either multiple source-detector separations or multiple
frequencies. CW measurements lack sufficient information to separate attenuation due to scattering and
absorption, unless spectral models are employed.

2.3.2

Experimental Geometries

In addition to the type of source modulation, a variety of data collection geometries are used. Hand-held
probes with one or a few source-detector pairs offer simplicity and easy placement wherever measurements
are desired. Probes for the muscle and brain are generally taped or otherwise fastened to the body, i.e., these
probes are not hand-held, but the probes are similar in concept, since both function in the remission geometry (sometimes termed the reflection geometry). Hand-held probes have been used for cancer detection75, 109 ,
and therapy monitoring11, 72 . The most basic of these hand-held measurements measure differential changes
in absorption using an estimate of the diffuse path length (DPF, see Eqn. 2.38); a slightly more sophisticated
analysis uses homogeneous, semi-infinite analytic solutions to the diffusion equation. The most sophisticated hand-held instruments permit limited imaging (e.g., distinct layers); multi-modal instruments can also
use structural information from one modality (e.g., ultrasound) to image tissue (see Sec. 3.2.2). Li120 has
recently implemented a layered model and applied the technique to phantom studies. Layered techniques improve the quantification of optical properties deeper into a medium, which is important to those researchers
using naturally layered (e.g., scalp/skull/brain) organs.
Spatial information for hand-held devices is mostly derived by moving the probe. Thus, hand-held
devices produce a map of local optical properties, with practical resolution determined by the number of different positions used; given a sufficiently large number of positions, this scheme could be used for limited
tomography or a surface map74, 75 . Note the average penetration depths for most surface remission measurements are dependent on the source-detector separation; this is part of the reason authors cite widely varying
depth sensitivity75, 121 . Similarly, the most probable photon penetration depth for a remission geometry device in the frequency domain depends (weakly) on the modulation frequency of the source. In a phantom
study of quantification possible with CW remission DOT, Kepshire et al.122 found quantification of concentration to fall off significantly with a depth of only 5 mm. In the time domain, Liebert et al.45 have used the
difference in depth sensitivity of the 0th , 1st , and 2nd temporal moments to separate signals originating in
the scalp and brain of adult humans. Full tomographic measurements (i.e. 3D reconstructions) are generally
made with many fixed or a few scanning sources and detectors, although Ge and colleagues have recently
developed a two part hand-held breast FD tomographic probe123 .
In the breast, cylindrical or cone geometries have been used by several research124–126 groups and
commercially with the Phillips ‘Optical Mammoscope’127, 128 and the breast version of the NIRx DYNOT
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Figure 2.15: A schematic of clinical coordinate system terminology. Figure adapted from Choe138 ; courtesy
of R. Choe and Y. K. Choe.
system129 . Slab geometry (mild compression of the breast between two flat plates) is currently used by several groups for breast imaging, primarily with axial compression (see Figure 2.15). Scanning slab geometry,
in which a few sources and detectors are raster scanned in tandem across the compression plates, has been
used by academic groups130–132 and in the ART ‘SoftScan’ R 96 . However, these measurements are all on
or about an axis through the slab (paraxial, i.e., the source and detector are almost directly across from one
another), with very few oblique measurements. Therefore, it is difficult to ascertain the depth into the slab
of any lesion detected (the transverse resolution is much greater than the through-slab resolution). These
measurements are sometimes known as ‘transillumination’, but are distinct from the planar transillumination pioneered by Culter32, 33 in 1929 as he illuminated with a planar source. Fixed position slab geometry,
in which an array of optical fibers delivers light to the breast has been used primarily by Culver, Choe, and
colleagues31, 88 and commercially in the DOBI ‘ComfortScan’ R 133, 134 . Detection can be either by an array
of optical fibers leading to detectors, detectors placed directly against the tissue surface, or lens-coupled
CCD cameras. Leff1 has recently reviewed DOS/DOT breast cancer contrast, adding to previous reviews by
Nioka135 , Hebden136 , and Ntziachristos137 and their colleagues.
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2.3.3

Time Domain Diffuse Optical Spectroscopy (TD-DOS)

Time Domain Diffuse Optical Spectroscopy (TD-DOS) or Time resolved spectroscopic (TRS) techniques
rely on introducing a brief pulse of light into a turbid medium and measuring the transit times of a distribution of many photons. Together with the index of refraction of tissue, the mean of this transit time gives the
average photon path length, which is related to the absorption and scattering of the tissue46 . This average
path length can be utilized directly to derive chromophore concentrations (see Equation 3.3). Alternately,
one can fit a diffusion model (e.g. Equation 2.50) to the data.
A TD-DOS measurement consists of the following steps:
1) Introduce a very short (∼300) pulse of light into tissue.
2) Collect diffuse output light using a high-speed photon counting PMT or APD.
3) Collect output pulses from detector to create a very high (∼10 ps) temporal resolution histogram.
4) Measure the Instrument Response Function (IRF) and convolute with a theoretical model (e.g. Eqn.
2.37).
5) Fit the data to the above convolution to extract µa [λ ] and µ0s [λ ]; iterate parameters of theoretical
model.
Alternatively, one could deconvolute the IRF from the measured data and fit the result to the theoretical
curve, but this is computationally more expensive; the IRF will be discussed in detail below. Roughly
speaking, scattering determines the peak of the photon arrival time histogram and absorption determines the
terminal log-slope. The latter is obvious by rewriting Eqn. 2.37 as
Ψ[r, t] =

r2
vS0
− 4Dt
e
e−µa vt .
(4πDt)3/2

(2.86)

The last term dominates at long times (i.e. as t → ∞, Ψ → e−µa vt ). An example histogram is shown
in Figure 2.16; Figure 2.17 shows the effect of titrating an absorbing dye into a liquid phantom on the TD
histograms.
Measurements using short source-detector separations (e.g. < 10l∗ ) generally require a more careful
treatment of light propagation in scattering media, including realistic modeling of sources and detectors. In
the context of DOS and DOT of the breast, sources and detectors are generally well separated (> 2.5 cm for
hand-held systems, > 6 cm for parallel plate tomographic systems) and point approximations of the source
and detector are reasonably accurate.
The output of a TD measurement is a histogram of photon arrival times, as shown in Figure 2.16. If
the light source and detector have an infinitely fast response, this histogram can be directly fit to a solution
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Figure 2.16: Example of IRF, fitted theoretical curve, and data for subject 61003 (8.3 cm compression, BMI
41.5, bra size 44 DDD) at 798 nm. Fitted parameters: µa = 0.034 cm−1 , µ0s = 13.3 cm−1 , t0 = 0.029 ns,
and amplitude = 0.73. These correspond to a very fatty breast with fairly low signal (max 746) because of
the thickness. Note, the IRF is clipped at 10% on the up slope and 5% on the down slope and t0 is measured
relative to a reference channel.
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Figure 2.17: An example of the effect of increasing absorption on TD data histograms. Black is the IRF;
as the colors change from blue to red, the absorption goes up from 0.02 cm−1 to 0.2 cm−1 in steps of 0.024
cm−1 .
of the time domain diffusion equation in the appropriate geometry (e.g. Eqn. 2.37). As with FD and CW
measurements, a TD source is generally modeled as a point source located z0 =

1
µ0s

into the medium, where

µ0s is the average reduced scattering44, 46 . This extrapolated source position z0 is shown schematically in
Figure 2.8 and a schematic of a basic TD system is shown in Figure 2.18.
Dealing with the assumption of an infinitely narrow input pulse of light is somewhat more complicated.
As a practical matter, one must consider the convolution of the laser output pulse, the pulse broadening
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Figure 2.18: Conceptual schematic of TD-DOS measurements. A narrow pulse of light is introduced to
the tissue from a laser diode, driven by an oscillator. Several possible photon paths through the scattering
and absorbing centers of the media are shown. Light is detected using a PMT in Geiger mode; counting
electronics determine the transit time of the detected photon compared to the input pulse.

(dispersion) in any optical elements (fibers, etc.), the transit time spread (TTS) of the detector, and any
delays in recording electronics. The convolution of these elements is referred to as the ‘Instrument Response
Function’ (IRF). For DOT in the breast, an IRF with full-width-at-half-max (FWHM) of ∼400 is sufficient
for recovery of optical properties139 . An example of the convolution and fit is shown in Figure 2.16.
Note: in order to properly replicate the detector fiber collecting light from a diffuse media, the IRF
must be collected in such a manner that all of the fiber modes are excited. In practice, this consists of
separating the source and detector fiber by ∼1 cm and inserting a plano-convex lens to quasi-collimate the
beam from the source fiber. Additionally, one can insert a thin diffuser (e.g. a layer of tissue paper) after the
plano-convex lens to further homogenize the input beam.
An offset t0 accounts for time delays not originating in the diffuse media and would be included in
Equation 2.86 as an offset (i.e., t → (t − t0 )). This offset t0 can change with time, for example, as a result
of temperature changes in the opto-electronics139 .
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2.3.4

TD-DOS Data Fitting

‘Fitting’ in this context is the process of minimizing an error function between measured data and a theoretical model characterized by some parameter set; different values of these parameters are used to produce
a model which is then compared to data, until some stopping criterion (number of iterations, value of difference between fit and data, etc.) is reached. We define a background level (B) as the average photon
count away from the data pulse (D[t]) (e.g. between 1 and 2 ns in Figure 2.17). We calculate an error as
σ[t]2 = D[t]+StdDev[B]; in other words, assuming Poisson noise at every point in the data plus a constant
defined by the standard deviation of the background. We then calculate a theoretical temporal response using Eqn. 2.50 for a set of optical parameters and convolve it with the measured IRF to produce a fit function
F [t]. We then compared the fit function to the measured data with an error function defined by
χ2 =

X  D[t] − F [t] 
σ[t]

t,λ

.

(2.87)

The χ2r function is minimized using fminsearchbnd, a bounded version of the Matlab c (Mathworks,
Inc.) function fminsearchvi . Parameters were scaled such that the numerical values passed to the fit were
between ∼0.1 and ∼20 and the data and fit were normalized to a smoothed peak value: the resulting fits
are therefore less sensitive to skin-optode coupling (i.e. pulse amplitude is ignored). Note that this overall
amplitude is not important for calculation of µ0s or µa . Parameter bounds were placed outside of physically
expected values (typical bound values values: 10−4 < µa < 1, 1 < µ0s < 50, normalized peak amplitude
1 ± 0.2; t0 varies with the particular optical components). See Figure 2.16 for an example of a convolution
and fitted curve.
After obtaining µa of each the measured wavelengths (λ), one can find chromophore concentrations by
solving the system of equations
µa [λi ] =

Nc
X
i=1

i [λ] · Cc

(2.88)

for each wavelength i and major tissue chromophore C. Note, all major chromophores must be included if
one is fitting absolute absorption. Alternately, one can fit data directly for all λ simultaneously, as introduced
by Corlu117 .
µa [λi ]

=

µ0s [λi ]

=

Nc
X

i
i=1
−b

Aλ

· Cc

(2.89)
(2.90)

Here, µ0s [λ] is modeled by simplified Mie approximation140 .
vi By John D’Errico; available at http://www.mathworks.com/matlabcentral/fileexchange/loadFile.do?objectId=8277; downloaded
November 2006.
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2.3.5

Applications of Diffuse Correlation Specroscopy

DCS measurements are typically conducted in the photon counting regime. A single mode fiber is used
to collect light from tissue. Indeed, the correlator in common use at Penn (Digital Correlator, Flex05-8ch,
Correlator.com, Bridgewater, NJ) requires the detected photon rate to be below ∼1 MHz (roughly the inverse
of the smallest bin size); in typical experiments, the rate is ∼100-200 kHz in remission from tissue with a
source-detector separation of 2.5 cm, ∼5 kHz at ∼6 cm separation in transmission. Most tissue work has
been carried out in the remission geometry with source-detector separations of ∼2.5 cm in breast73 , brain141 ,
and muscle142 tissue. Signal derived from adjacent DCS single mode fiber detectors can be summed to
improve SNR.
In Chapter 8, I utilize DCS to measure blood flow in the human breast during mammogram-like compression. To our knowledge, this study provided the first reports of DCS blood flow measurements from
light transmitted all the way through the human breast143–145 . Our pilot results provided proof-of-principle
information for transmission Diffuse Correlation Tomography (DCT) in breast. In Chapter 6, I describe
instrumentation which may permit us to utilize a priori structural information from MRI to produce the first
in vivo transmission DCT.

2.3.6

Applications of Diffuse Optical Tomography

Section 2.2.8, introduces the mathematics behind DOT in terms of the fluence rate. However, the measured
signal is an intensity proportional to the fluence rate. This proportionality constant involves the integral
over the numerical aperture of the detection optics, optical coupling constants, and is, in general, difficult
to calculate. If one can normalize the measured signal to that from a phantom, the proportionality constant
cancels out, e.g.:
Um [λw , rs , rd ]
I[λw , rs , rd ]
= R
R [λ , r , r ]
Um
I
[λw , rs , rd ]
w s d

(2.91)

R
for data (Um , I) and reference (Um
, I R ) measured fluence rates and intensities. This cancellation relies

on consistency in the proportionality constant between measurements. Such a normalization of DOT data
generally requires detailed information on the reference phantom optical properties, but greatly simplifies
the reconstruction task. In the data presented in this thesis, I normalize data using measurements from
homogeneous liquid or gelatin phantoms (Chapter 6 and Chapter 7) and by pre-contrast agent injection
data (Chapter 4). The latter depends utilizes an optically heterogeneous reference measurement (i.e., due to
endogenous chromophores) to reconstruct the larger changes in optical properties due to an injected contrast
agent (e.g., ICG), as shown by Ntziachristos146 .
The DOT reconstructions for the GenIII system (Chapter 6) were performed in TOAST85, 86 with an
iterative conjugate gradient technique147 . We also included the spatially dependent regularization scheme
43

I
Li
µ
µ0 [rk ]
Nλ
Ns
Nd
Nt
rs
rd
Q
γ[rk ]
χ2

Measured Intensity
Size of the reconstructed volume in the ith direction
Solution vector (i.e. µa and D)
Initial guess of solution vector
Number of wavelengths
Number of sources
Number of detectors
Total number of voxels
Source position
Detector position
Image Norm
Spatial regularization term
Objective function
Table 2.5: Notation for DOT reconstruction.

described by Choe et al.31 in our algorithm; DOT is especially vulnerable to such artifacts at the source and
detector positions, and so we vary the regularization parameter to be larger near the boundaries of the image.
This spatially-dependent regularization reduces image artifacts. The specific reconstruction work-flow our
work is based on were developed by Drs. Regine Choe, Kijoon Lee, Soren Konecky, and Alper Corlu31 ;
DOT reconstructions using this work-flow was used to develop our statistical tumor localization technique
(Chapter 7).
Iterative techniques require some measure of the reconstruction quality to determine if additional iterations should be performed. We define a common objective function χ2 . This quantity is a metric of the
difference between the measured and calculated values of the fluence rate for each wavelength, source, and
detector (Um [λw , rs , rd ] and Um [λw , rs , rd ], respectively), summed over all measurements. In practice, we
normalize these values by the measured and calculated values of a homogeneous phantom (i.e. a reference
R
[λw , rs , rd ] and UcR [λw , rs , rd ]). This normalization reduces the impact of differences
measurement; Um

between light detected at each fiber, since each will have a different skin coupling coefficient and a slightly
different transmission. Table 2.5 summarizes the notation used to write out these functions. We define an
objective function


2
Nλ X
Nd  
Ns X
1 X
Um [λw , rs , rd ]
Uc [λw , rs , rd ]
χ =
ln
− ln
+Q
R [λ , r , r ]
2 w=1 s=1
Um
UcR [λw , rs , rd ]
w s d
d=1
2
Nλ X
Nd  
Ns X
1 X
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d=1

The image norm, Q,
Q=

Nt
X
k=1

γ[rk ] µ[rk ] − µ0 [rk ]

2

(2.93)

computes the difference between the chromophore maps for the initial guess and the current iteration. Note
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that Q includes a spatially dependent regularization factor
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which weights the relative importance of differences in µ as a function of spatial position. Work is ongoing
to determine the optimal reconstruction parameters for the GenIII DOT-MR Imaging system (Chapter 6).
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Chapter 3

Clinical Applications of Diffuse Optics
in Biological Tissue
Diffuse optics can be used to measure concentrations of intrinsic and extrinsic chromophores in living tissue using the mathematical techniques discussed in Chapter 2. A wide range of interesting biomedical
problems can be addressed with this information. For example, blood oxygenation levels provide information on aerobic exercise in muscle119 , total hemoglobin content appears to distinguish breast cancer from
normal tissue1 , and an injected molecular tracers can show different blood transit times when an artery is
blocked148 . Measurements of endogenous contrasts permit frequent non-invasive measurements; exogenous
contrasts, through more invasive, can potentially provide higher signal-to-background and more dynamic
(e.g. pharmacokinetic) information compared to their endogenous cousins.
DOT and DOS utilize Near Infra-Red (NIR) wavelengths (∼650-950 nm). These wavelengths are safe
for frequent and long-term measurements. NIR photons are non-ionizing, unlike X-Rays. Tissue damage
mechanisms by radiation at these wavelengths are considered to be exclusively thermal by both ANSI149
(American National Standards Institute) and the FDA150 (United States Food and Drug Administration).
Skin and eye maximum permissible exposures (MPE) both vary by wavelength, but are generally above the
power levels required to obtain a useful diffuse optical signal at several centimeter source-detector separations; many of our instruments, for example, operate at about the same power as a common laser pointer.
These low power requirements permit design of inexpensive, portable, instruments for continuous and rapid
optical monitoring of tissue without physiological damage. MRI devices, on the other hand, are quite expensive, exclude patients with metal implants, have low throughput, and are never available at the bedside.
Ultrasound gives some of the advantages of diffuse optical measurements, but generally provides structural
or morphological tissue information, while diffuse optics provides functional information.
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This chapter discusses contrasts in tissue due to activation and disease state, focusing especially on breast
cancer (Section 3.1). Then it moves on to applications of DOT and DOS in breast cancer, placing the work
described in this thesis into context (Section 3.2).

3.1
3.1.1

Tissue Optical Contrasts
Endogenous Optical Contrasts

Devices and techniques which obtain clinically useful information without use of contrast agents are attractive, in part, because they avoid potential allergic reactions and permit frequent repetition of measurements.
Not surprisingly, most diffuse optical research has focused on the measurement of local concentrations of
hemoglobin (Hb), oxyhemoglobin (HbO2 ), lipid, and water to identify and diagnose disease states. Figure 3.1 shows the major chromophores in breast tissue and the approximate visible and NIR wavelength
ranges.
Changes in total hemoglobin concentration (Hbt =HbO2 +Hb) can identify angiogenesis and local blood
volume responses. Changes in oxygen saturation (StO2 =HbO2 /Hbt ) provide information on oxygen usage
and metabolism. The lipid/H2 O ratio provides information on tissue composition. Diffuse optics is sensitive
to micromolar concentrations of these chromophores in deep tissues; both absolute and relative measurements of chromophore concentrations are used. In addition to absolute measurements, data may be taken
‘relative’ to healthy tissue, relative to an artificial tissue reference ‘phantom’, or relative to some temporal
baseline. Scattering (µ0s ) changes provide information about cell and organelle density and structure. Relative measurements of both absorption and scattering can be made with less expensive instrumentation and
simpler analysis techniques, but this approach requires a careful choice of normalization.
Absorption Diffuse Optical Spectroscopy (DOS) can be viewed as an extension of the familiar BeerLambert Law that relates incident (I0 ) to detected (I) intensities after a beam of light passes through a
sample of length d containing a solution with a concentration (C) of an absorbing species. A schematic
is shown in Figure 3.2. (Originally, Bouguer151 and Beer152 , but also described in many modern texts, for
example, Born and Wolf153 .) The relationship between I and I0 in optically thin sample is:
I = I0 10−C10 d .

(3.1)

The diffuse optics community generally uses base e and µa = C ×e , for a chromophore at concentration
C with molar absorption coefficient of [λ]. This convention matches that typically used in discussions of the
radiative transport equation and random walks. Note that many authors tabulate the extinction coefficients
in base 10 (10 ), not the base e (e = log[e]10 ) used here. With this substitution, Equation 3.1 becomes:
I = I0 e−µa d
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(3.2)

Figure 3.1: Spectra of major breast tissue chromophores on a semi-logarithmic scale, showing visible and
NIR windows. Note that the H2 O and Lipid spectra have been scaled by a factor of 100 and that the Hb and
HbO2 spectra are for whole blood.

V
N,C

d
Figure 3.2: A schematic of a simple application of the Beer-Lambert Law. Light with intensity I0 impinges
on a vessel with thickness d and volume V from the left; photons are absorbed by the N chromophores,
and a reduced intensity I exits the vessel from the right. The concentration of the absorbing species is
C = N/V .

In the presence of tissue scattering, the path length (d) is not simply the width of the cuvette (as in
standard bench-top spectroscopy of clear liquid samples, e.g. Figure 3.2), but rather is a ‘typical’ distance
traveled by a diffusing photon from input to output. This distance can be measured or calculated from known
tissue properties. The simplest correction to the Beer-Lambert Law is to include the so-called ‘Differential
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Path Length Factor’ (DPF)154, 155 which, when multiplied by the distance between the source and detector
on the tissue surface, approximates the mean distance traveled by a photon. This distance is also sometimes
referred to as the ‘Differential Path Length’ (DP) and can be measured from the average tissue transit time
between source and detector of a brief (sub-nanosecond) light pulse94 ; Patterson et al.44 quantified this path
length in vivo in 1989. Note, these path lengths are dependent on the tissue optical properties (µa , µ0s ).
Recall from Section 2.2.5 that for the infinite medium, the average tissue transit time in terms of the
optical properties of the tissue and spatial position for a source and detector separated by a displacement r
is:
hti =

1
|r|2
√
2 D + |r| µa vD

where v is the speed of light in the medium, D =

v
3(µ0s +µa )

is the photon diffusion coefficient, µ0s is the scat-

tering coefficient, and µa is the absorption coefficient. The average photon path length in the medium is thus
v < t >. Arridge published a summary of these formulae for mean transit times for various geometries46 .
As an example, consider transport through an infinite medium with optical properties of human breast, assuming µ0s =10 cm−1 , µa =0.05 cm−1 , index of refraction of 1.4, and |r|=5 cm, we obtain < t >∼ 2.5
ns and d = c < t >∼ 53 cm. In a slab geometry with the same optical properties, < t >∼ 2.1 ns and
d = c < t >∼ 45 cm.
Calculation of < t > for a particular geometry permits simple interpretation of data from a homogeneous
turbid medium: Beer’s law (Figure 3.2) becomes
I = I0 e−µa v<t> .

(3.3)

Next we consider multiple chromophores. The absorption coefficient, µa [λ ], can be decomposed into
the sum of the products of the concentrations (Ci ) and extinction coefficients (i [λ]) of the chromophores
in the tissue of interest. In most tissues, the primary absorbers are oxyhemoglobin (HbO2 ), hemoglobin
(Hb), lipid, and water121, 156 (Figure 3.1); myoglobin can also be an important absorber in muscle tissue.
Equation 3.4 breaks the total wavelength-dependent, absorption down into the concentrations (Cx ) of these
chromophores and their extinction coefficients (x [λ]).

µa [λ] =

Nc
X

Ci i [λ]

i=1

'CHbO2 HbO2 [λ] + CHb Hb [λ]
+ CH20 H2 O [λ] + CLipid Lipid [λ]

(3.4)

Where we have assumed there are no other chromophores absorbing at the wavelengths of interest. See
Figure 3.3 for an example of this decomposition in breast tissue.
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Figure 3.3: Time Domain measurements of absorption (black diamonds) at 6 wavelengths and fits to concentrations of major chromophores using known spectra (HbO2 , Hb, Fat, H2 O) in breast tissue for a 27
year old pre-menopausal female, transmission geometry (5.2 cm thickness), homogeneous slab solution.
Unpublished data from the GenII Opt/MRI system.
Dr. Scott Prahl has tabulated the extinction coefficients of hemoglobin157–159 , water160 , porcine fat161 ,
and several other useful chromophoresi from several sources.
As per scattering, Mourant and colleagues140 suggested approximating the wavelength-dependent tissue
scattering with a power law, after the dependence of the scattering efficiency factor on λ from a simplified
version of Mie scattering theory, i.e.,
µ0s [λ] = Aλ−b .

(3.5)

Here, A is the ‘scattering prefactor’ and b the ‘scattering power’. The scattering power depends on both
the relative indices of refraction between scatterers and the bulk medium, as well as the size and number
density of these particles. Nilsson et al.162 successfully applied this approximation and it has been widely
used since31, 109 . The scattering power (b) is often assumed to be constant in order to reduce the number of
fitting parameters.

3.1.2

Intrinsic Optical Contrast in Breast Cancer

Leff and his colleagues at University College London1 have recently published an exhaustive review of
diffuse optics applied to breast cancer (studies published prior to 1 August 2006), summarizing the experimental conditions and results of some 34 studies, each having at least 5 subjects; the results of this tabulation
i Available

at http://omlc.ogi.edu/spectra/hemoglobin/summary.html, downloaded Dec. 2006.
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are summarized in Table 3.1.
Leff concentrates on Hb and HbO2 contrasts in his review, as these chromophores dominate tissue spectra (e.g. Figure 3.3). Some researchers have therefore neglected other chromophores, permitting simplification of their instrumentation. Note the significant contrast between the means of the properties of malignant
lesions and healthy tissue, and also the significant width of the distributions, especially in the malignant
lesions. Some of the variance in each chromophore is probably due to grouping all malignant cancers into
one group, as cancers are known to be heterogeneous both microscopically and between subjects. Similarly,
each of the other intrinsic parameters measured by diffuse optics has a distribution function; this complicates developing diagnostic metrics. (See Section 7.1 for a discussion of how several research groups have
attempted to resolve this difficulty.) In a recent study (not included in Leff) Choe et al.31 found a 1.25-2x
contrast between healthy tissue and 41 biopsy-confirmed malignant lesions in 3D tomographic reconstructions. Images from two of the subjects in this study are shown in Figure 3.4 and Figure 3.5; this data is
utilized in Chapter 7, where I introduce our new intra- and inter-subject statistical normalization approach
which accounts for these heterogeneities, and where I demonstrate a novel statistical technique to localize
cancers based on DOT.
Several researchers have sought to correlate the tissue microstructure to DOT findings. Pogue et al.
initiated a small study to compare DOT-reconstructed Hbt and blood-vessel density in tumors12 ; Zhu and
colleagues15 have followed up on this research. Scattering in tissues is dominated by structures approximately the same size as the light wavelength (∼1µm). The cell proliferation of some cancer types has led
some researchers to consider using µ0s as a diagnostic parameter: Li broke this down into scatterer size and
volume fraction in search of an indicator of malignancy14 and Choe et al.31 found it offered good discrimination between benign and malignant lesions. Several groups31, 74, 164 have combined the various endogenous
measurements into composite indices which enhance cancer contrast.
The vasculature of healthy tissue is organized and provides a hierarchical network for blood flow throughout the tissue volume. In contrast, angiogenesis in cancerous tissue produces blood vessels with chaotic
organization, tortuous pathways, and higher concentration, shown schematically in Figure 3.6. Blood volume and perhaps saturation may change in cancerous tissue, as noted in Table 3.1, but the change in blood
vessel organization suggests that blood flow may provide an additional contrast, as shown by Durduran51
and Zhou73 . A simple one source-detector hand-held probe, manually scanned across a cancer, showed
significant change in localized tumor blood flow (Figure 3.7).
In addition to the static breast cancer contrasts discussed above, researchers have also examined the
possibility of using external modulations of intrinsic contrast. The Valsalva maneuver (exhaling against a
closed glottis) raises pressure in the chest cavity and possibly restricts venous return from the breasts of
a woman lying in the prone position, thus increasing contrast in tumors129 . External compression of the
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Figure 3.4: DOT reconstructions of a 2.2 cm invasive ductal carcinoma. In descending rows: (top row)
Relative total hemoglobin (rHbt = Hbt / hHbt iHealthy ), relative oxygen saturation (rStO2 ), relative µ0s
rHb rµ0

t
s
at 780 nm (rµ0s ). (bottom row) A composite optical index (OI = rStO
), a 3D rendering of the tumor
2
volume, and non-simultaneous Gd-DTPA contrast enhanced MRI. Note that the DOT imaging utilized axial
compression and the MRI was performed with a sagittal compression. Image courtesy of R. Choe, data
described in Choe et al.31 .

malleable breast can force out blood, reducing Hbt , or even restrict blood flow; several groups145, 165–167 are
currently working on compression-related projects. Restricted flow impairs the delivery of contrast agents,
making this work of interest to researchers in other modalities. Additionally, several commercial companies
including DOBI Medical and ViOptix167 have or are attempting to commercialize devices using pressure
modulation. Vascular dynamics can be modified through changes to inhaled gases. A carbogen (CO2 and
O2 mixture) inhaled contrast agent has been applied to animal models by Kotz and colleagues168 and breast
cancer by Dixit169 .
We have applied DOS and DCS to mammogram-like compression145 , permitting direct measurement of
blood flow changes during the perturbation (Chapter 8).

3.1.3

Exogenous Optical Contrast Agent: ICG

Contrast agents are used in medical imaging to enhance the difference in signal between tissue of interest
and the surrounding background. In diffuse optics, contrast can be absorptive or fluorescent, and fluorescent
agents are potentially detectable at much lower concentrations170, 171 as the background signal can be much
lower. Unfortunately, only a single diffuse optical contrast agent is currently approved for clinical use in
the United States. This situation should change as additional agents are developed and shepherded through
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Figure 3.5: DOT reconstructions of a 0.5 cm fibroadenoma. In descending rows: (top row) Relative total
hemoglobin (rHbt = Hbt / hHbt iHealthy ), relative oxygen saturation (rStO2 ), relative µ0s at 780 nm (rµ0s ).
rHb rµ0

t
s
), a 3D rendering of the tumor volume, and non(bottom row) A composite optical index (OI = rStO
2
simultaneous Gd-DTPA contrast enhanced MRI. Note that the DOT imaging utilized axial compression and
the MRI was performed with a sagittal compression. Image courtesy of R. Choe, data described in Choe et
al.31 .

the regulatory process, but current clinical work focuses almost exclusively on Indocyanine Green (ICG), as
this FDA approved agent absorbs and fluoresces in the NIR. It was first applied to diffuse optical imaging of
breast cancer by Nioka126, 172 . Many animal studies have been conducted with diffuse optical contrast agents;
one of the most useful studies from the standpoint of human measurements was Cuccia and colleagues combination of optical contrasts (ICG and Methylene Blue) with MR contrast (Gd-DTPA) in rat imaging173 .
A potentially useful attribute of optical contrast agents is the ability to image these agents across multiple
scales during the course of identification and removal of a lesion. For example, a cancer could be imaged
with ∼0.5 cm resolution in DOT, ∼0.5 mm resolution during surgical resection, and at ∼1 µm resolution
during pathological examination of the excised tumor. Bhushan and colleagues, for example, have investigated an agent specific to hydroxyapatite, a calcium salt deposited in breast cancer micro-calcifications, in
the context of image guided surgery174 .
Fluorescent agents offer the potential for information beyond the agent concentration175 and even beyond
the potentially higher SNR171 . For example, the fluorescent lifetime of some agents is sensitive to the local
chemical micro-environment and can be imaged with fluorescence DOT176 . At University of Pennsylvania,
Corlu et al.89 extended the work of O’Leary177 , Culver88 and Choe et al.31 to perform 3D reconstruction of
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Healthy, pre meno
Healthy, post meno
Healthy, not spec.
Malignant lesion

Cancer to Tissue Contrasts
Hbt [µmol/L] Contrast StO2 [%]
34±9
1.9
75±2
14±0
4.6
80±4
21±6
3.1
68±5
65±34
1
66±24

Contrast
0.88
0.83
0.97
1

Table 3.1: Optically detectable physiological contrasts in breast cancer: Summary of currently published
(pre 2006) data by Leff1 , given as mean ± standard deviation. Contrasts are calculated as Ylesion /Yx . Pre(Post-) menopausal data is calculated from 3 studies with 16 (13)116 , 15 (13)121 , and 4 (19)163 subjects.
Data with menopausal status not specified was averaged over 17 studies with several hundred subjects in
total. Note that malignant lesions appear to be much more heterogeneous than healthy tissue; see text for
discussion.

Figure 3.6: Cartoon of tissue level organization of healthy and cancerous tissues. Note the hierarchical
organization of blood vessels in healthy tissue versus the chaotic vasculature in cancerous tissue- rapid
angiogenesis caused by cancer does not produce efficient blood vessels. Figure courtesy of R. Choe and Y.
K. Choe.

Figure 3.7: Example blood flow contrast in cancerous and healthy breast tissue, measured with a hand-held
scanning probe. The probe was moved across the known position of each cancer in 1 cm increments along
orthogonal lines. Figure adapted from T. Durduran et al.51 .
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ICG fluorescence in breast cancer. For reviews of fluorescence imaging, see Frangioni178 .
Sevick-Muraca and Rasmussen have recently published179 primer on molecular imaging, comparing
optics to nuclear imaging and genetic techniques. Various other commercial agents have been developed
for animal use, some with conjugating moieties, which can be attached to various ligands known to target specific disease states. Work in animals with these targeted agents, for example that by Reynolds and
colleagues180 has demonstrated in vivo detection of ∼1 cm lesions with micromolar concentrations of the
agents in canine mammary tumors. Ke et al.181 showed specific targeting of epidermal growth factor positive cells with a Cy5.5 fluorescent probe. Soubrane and colleagues 182 have demonstrated the importance
of localizing and quantifying tissue absorption heterogeneities for quantitative fluorescence spectroscopy.
Klohs183 has provided a recent addition to a substantial body of reviews on the topic.
Various NIR absorbing and fluorescent agents have been developed for animal use184 . Pre-clinical ICG
derivatives are reviewed by Tung185 and optical agents are more broadly reviewed by Licha, Schirner, and
Henry186 . Sevick-Muraca has also discussed ICG and recent developments in targeted contrast agents170 .
Indocyanine Green (ICG) is used extensively with all three generations of the University of Pennsylvania
Opt/MR imaging system (see Section 4.2). A brief introduction is included below to facilitate discussion
of these instruments and results from clinical studies. ICG is also known as Cardio-Green, available in the
United States from Akorn Specialty Pharmaceutical Company, (www.akorn.com/ ).
ICG isn’t an ideal NIR contrast agent in terms of fluorescent yield or absorption cross section, but FDA
approval, its long history of safe use in humans187 , and the lack of alternate fluorophores or chromophores
in the NIR approved for human use have rendered ICG the primary contrast agent for DOT and DOS in
humans. Diffuse optics with ICG contrast has been applied to human breast cancer5, 6, 89, 97, 126, 146, 172, 188–192 ,
human brain monitoring148, 193–195 , and the flow of lymph in human limbs179 .
Fluorescence imaging with DOT has a lengthy history at University of Pennsylvania, including early
experimental work with ICG imaging126, 172, 196, 197 and theoretical developments171, 175, 176 . Sevick-Muraca
and colleagues170 explored the limits of ICG imaging and also compared CW and FD (100 MHz) fluorescent
imaging on a phantom with a 100 µL target of 100 fM ICG at depths from 1 to 7 cm. This sensitivity is
a key advantage of optical contrast agents. Previous work in our lab by Ntziachristos combined simultaneous diffuse optical measurements of ICG and Gd-DTPA enhanced MRI in human breast using a TD5, 198
instrument. The relative sensitivities of the techniques was not apparent from the experimental protocol:
Ntziachristos describes injections of 0.1 millimoles of Gd-DTPA and 0.25 milligrams of ICG per kilogram
bodyweight. ICG has a molecular weight of 775 g, so this corresponds to an injection of 323 nanomoles per
kilogram bodyweight for ICG; a factor of 300 difference in concentrations.
ICG is quickly cleared from the blood stream by the liver, i.e., its half-life in the breast ∼3-5 minutes197 .
It is primarily a blood pooling agent (i.e. normally confined to the intravascular space), binding to albumin
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when injected intravascularly. Several researchers89, 198 have found ICG concentrations in tumors are higher
than in the surrounding tissue. Tumors are known to produce additional microvasculature (angiogenesis);
this additional vasculature is one of the sources of intrinsic DOT contrast. The ‘quickly grown’ vessels
are known to be more permeable, consistent with the hypothesized origin of ICG concentration contrast
in tumors. This heightened permeability permits ICG or even ICG-bound albumin to exit the vasculature
into tumors and produces a transient build up of ICG. The extra-vascular ICG apparently exchanges with
vascular ICG and is eliminated fairly quickly (∼10-20 minutes
the liver. However, recent results by Hagen

190

197

) and all ICG is eventually removed by

, who imaged following continuous infusion over the course

of 15-25 minutes of 39-75 mg ICG, suggest that some ICG may persist in the extravascular tumor space for
hours. Imaging at later times provided a lower signal, but higher contrast to background ratio.
The dosage of ICG required for diffuse optical measurements is well below the maximal dosages set by
the FDA. During the research described here, ICG was administered as a bolus, followed by 5 ml of saline,
and DOT data collected for ∼10 minutes. Dosage was 0.25 mg per kg of body weight, up to a maximum
of 25 mg. The typical dosage (manufacturer’s literature199 ) for an adult in an indicator-dilution study is 5
mg per injection, up to 2 mg/kg total. For hepatic function determination, the usual dosage is a bolus of 0.5
mg/kg and detection of ICG in the blood stream for tens of minutes. Ophthalmic angiography studies use a
bolus of up to 40 mg in a single injection to detect vascular damage in the eye.
Anaphylactic or urticarial reactions to ICG have been reported in patients with history of allergy to
iodides. These patients, along with pregnant women, were excluded from our study. Hope-Rosset al.187
reported adverse reactions in 1923 ICG videoangiography exams (1226 patients). The dosage in this study
varied between 1-5 mg/kg body weight and 12.5-50 mg total dosage. Hope-Ross found 0.15% mild, 0.2%
moderate, and 0.05% severe adverse events, with no deaths. Research reported in this thesis utilized at
most 0.25 mg/kg- a factor of ten less then the dosage used by Hope-Rosset al.. There have been two deaths
associated with ICG injection during cardiac catheterization, per the manufacturer’s literature199 .

3.1.4

Applications of ICG to Breast Cancer

Researchers at University of Pennsylvania have utilized ICG human breast cancer imaging for many years.
The pioneering work of Nioka126, 172 was followed by important contributions from Ntziachristos5, 6, 146 ,
Intes197 , and Corlu89 .
Several researchers have attempted to determine if ICG uptake and clearance kinetics can be diagnostic
for malignancy. Intes197 used a CW stand alone instrument described by Nioka126, 172 for monitoring ICG
kinetics in breast cancer and observed substantially different kinetic profiles between three subjects with a
different types of cancer, see Figure 3.8. In a somewhat larger study, Rinneberg et al.97 , using a TD scanning
system, did not observe a difference in ICG kinetics between types of lesions. Note that both of these studies
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Figure 3.8: Results from optical-only kinetics imaging system. This device was not co-registered with
another imaging modality and could only measure ∆µa , but had good time resolution. Data has been
adapted from Intes et al.197 .

were quite small and focused on short time (∼10 min.) kinetics. However, in later work from Rinneberg’s
group190, 192 tumor ICG kinetics at long times (∼25 min.) post injection did distinguish cancerous from
normal tissue.
Corlu and colleagues applied their 45 source, CCD detection (thousands of source detector pairs) instrument to imaging ICG deposition in cancers and published the first tomographic breast reconstructions using
ICG fluorescence89 . Examples of their images are shown in Fig. 3.9. These data were collected well down
on the tail of the kinetics curve (i.e., ∼6 minutes post-ICG-injection). Among other things, this long delay
reduces the effect of rapidly changing drug concentration on the reconstructions. This choice of imaging
timing of course reduces the total ICG signal, albeit tumor-to-normal tissue contrast is likely better at the
long delay.
Sevick-Muraca has examined the use of ICG to map Sentinel Lymph Nodes (SNL) in breast cancer
patients and found that subcutaneous injections of 10 to 100 µg ICG permitted imaging of lymph drainage
paths and the SNLs200 , comparing the technique to lymphoscintigraphy. Her work suggests ICG may help
identify those SNLs to remove for pathological examination and those lymph nodes that can be safely left
intact.
One potential point of concern for multi-modality contrast enhanced imaging is increased patient risk
or signal degradation due to interference between the optical and MR contrast agents. Several researchers
have reported joint ICG and Gd-chelate measurements without significant adverse events201–205 . During
∼50 sequential Gd/ICG injections for breast imaging at Penn, we also observed no serious adverse events.
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Figure 3.9: ICG fluorescence contrast in 3D tomographic imaging of the human breast; a single craniocaudal slice is shown for a 52 year old post-menopausal female. ∼1.5 cm diameter retro-areolar invasive
carcinoma was identified by a multi-modality (Gd-DTPA MRI, ultrasound, PET, mammogram) study. Left:
Images of Hbt , StO2 , µ0s , and ICG fluorescence. Right: Line plots, corresponding to the magenta line in
images on the left, showing the lesion contrast for each chromophore. Adapted from Corlu89 .

Figure 3.10: Test of influence of ICG on MRI signal from MultiHance (Gd chelate). (left) 0.25mM MultiHance and [12.9, 6.5, 3.2, 1.6, 0.8, 0.4, 0]µM ICG. The slight fall off in signal at the center of the image
is due to inhomogeneity in the MR coil sensitivity; this was confirmed by moving and rotating the sample
(data not shown). (right) 3.2µM ICG and [5, 0.5, 0.3, 0.25, 0.2,0.1,0] mM MultiHance.

We performed a simple test to confirm that ICG did not effect signal from gadolinium chelates using various
physiological concentrations of ‘MultiHance’ (Gadobenate dimeglumine) and ICG in normal saline. If we
assume blood is roughly 7% of female body weight66–68 , a 0.25 mg/kg body weight dose of ICG corresponds
to
0.25

mg ICG kg body
mg ICG
mg ICG 1mol ICG
= 3.571
= 3.571
' 4.6µM
kg body 0.07kg blood
kg blood
L blood
775g

for peak arterial concentration (assuming the density of blood is equal to the density of water). Figure 3.10
shows the results of this experiment.
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3.2
3.2.1

Clinical Diffuse Optics
Potential of Diffuse Optics to Improve Clinical Breast Cancer Care

Clinical advances in detection, diagnosis, and therapy monitoring for breast cancer offer potential benefit
to both sufferers and, because of the high incidence of breast cancer206 and the associated costs, to society.
Current screening techniques rely heavily on the X-Ray mammogram, a technique which detects only ∼35%
of cancers in women under age 50207 ; contrast enhanced MRI screening is much more sensitive (85%)208 , but
also considerably less common, more time consuming, lower throughput, and more expensive. Breast cancer
has attracted much attention from the diffuse optics community because, in addition to the clinical need, the
human breast is somewhat easier to probe with diffuse light than other tissues. The deformability and low
optical absorption of the breast permit researchers to use a variety of geometries (e.g. cylindrical, parallel
plate) and to make measurements through more tissue (up to ∼12 cm) than is possible with many other
organs, such as brain. This clinical need and reduced experimental difficulty may permit breast cancer to be
one of the first clinical applications of molecular imaging agents in diffuse optics. Leff et al.1 , in a recent
review of clinical applications of diffuse optics to breast cancer, suggested that ∼85% of cancers reported
in these works are detectable using intrinsic optical contrast; Chance’s study of over 100 women75 suggests
potential sensitivity and specificity above 90%, again with intrinsic contrasts. Choe et al.31 provided 3D
reconstructions of the entire breast and showed differentiation between benign and malignant lesions.
DOS/DOT also has a strong potential to be complimentary to existing clinical modalities: The tomographic reconstructions from DOT will not match the resolution of 3D images of tissue structure from MRI,
X-ray imaging, or even ultrasound; however, DOT can provide functional information on tissue metabolism,
does not use ionizing radiation, requires relatively inexpensive instrumentation, is suitable for long-term
continuous monitoring, and has the potential to be very sensitive to contrast agents.
Diffuse Optics may prove to have several uses in a clinical breast cancer diagnosis and treatment; an
example, developed in conjunction with our collaborators at the Hospital of the University of Pennsylvania,
is shown in Figure 3.11.
Diffuse optics has potential applications in screening women at high or intermediate risk of developing
cancer (i.e., as determined with the Gail model209, 210 ; (1) in Figure 3.11). This population will be screened
many times over their lives, starting as early as their twenties, and the radiation dose of annual mammograms
can be of considerable concern. Thus, applications of DOT and DOS as a non-ionizing, relatively inexpensive, screening modality imaging would be advantageous for this population. As DOT systems would almost
certainly be less expensive than an MRI, their use could be justified for lower-risk women, thereby increasing
the screening pool. Furthermore, pre-menopausal women tend to have breasts with higher mammographic
density, reducing the sensitivity and specificity of X-Ray mammography. Measurements from DOT or DOS
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(6 month follow-up)

Return to Screening
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(4) DOT
Biopsy

Enter
Treatment Regimen
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Figure 3.11: Example clinical work flow for breast cancer screening, derived from discussions with our
clinical collaborators. Possible clinical uses of diffuse optical techniques are marked and expanded upon in
the text. BIRADS: Breast Imaging Reporting and Data System (American College of Radiology).
‘adjunct’ systems could potentially be used to increase clinical imaging modality specificity. This potential
increase in multi-modal imaging specificity can also be applied to women who have a ‘probably benign’ lesion or ‘suspicious’ ((3) and (4) in Figure 3.11). ‘Probably benign’ lesions can be followed up more rapidly
and frequently with non-ionizing DOT or DOS that X-Ray.
Perhaps the most immediately useful application of DOT is for therapy monitoring ((5) in Figure 3.11).
DOT and DOS are sensitive to tissue function and therefore may be able to identify tumors response to therapy more rapidly than an imaging technique like X-Ray mammography which depends on tissue structure.
However, prior to the clinical implementation of any of the above potential uses, diffuse optical techniques must be proven. Much of the work presented in the following chapters begins to pursue this goal via
comparisons with data simultaneously acquired via magnetic resonance imaging.

3.2.2

Previous Work in Multi-Modal Imaging

Multi-modal imaging with diffuse optics can focus on validation of the diffuse optical measurement, comparison of diffuse optics with a measurement using another technique, or synthesis of different types of
information into a composite index. A validation study, for example, might compare DOT to MRI imaging
for detection of breast cancer. A comparison study might superpose functional MRI (fMRI) Blood Oxygenation Level Dependent (BOLD) imaging and functional DOS/DOT, as both signals depend on neurovascular
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Figure 3.12: Cartoon of instrument and subject placement for simultaneous DOT and MRI measurement.
This is the basic configuration of the GenIIm system, as described in detail in Chapter 4.
coupling211 . A synthesis study could use the tissue structural information from X-ray mammography or
ultrasound to constrain an optical tomographic reconstruction showing Hbt and StO2 distributions212 .
Diffuse optics can be combined relatively easily with several standard clinical techniques, such as
MRI7, 198 , ultrasound9, 28 , magnetoencephalography213, 214 and X-ray mammography10, 215 . Fiber optics are
often easily integrated into clinical devices with little disturbance to other instrumentation. For example,
fiber optics can carry light more than 10 meters to and from the tissue of interest, permitting the optoelectronic portions of diffuse optical instruments to be placed outside of the shielding of an MRI device, as
we have done with both our GenII and GenIII systems (Figure 3.12).
This ease of integration is inspiring researchers to conduct multi-modality studies. In this thesis, I focus
on applications of optical-MR multi-modality imaging for breast cancer.
Various groups have focused on combining the functional information (i.e. oxygen metabolism, angiogenesis) from optical imaging with high resolution structural information provided by other modalities. Zhu9
demonstrated that ultrasound is a natural co-modality for hand-held DOS. Both technologies are inexpensive,
easily integrated into a hand-held probe, and non-ionizing28, 216, 217 . This last point permits ultrasound and
DOS to be used for frequently repeated measurements (for example, to monitor patients during the course
of treatment73 ). Ultrasound provides structural information, permitting reconstruction of the tissue volume
to improve quantification. DOS can alert operators to changes in blood oxygen saturation, total hemoglobin,
etc.. The MGH group has combined X-ray tomosynthesis with a two wavelength FD system215, 218 and later
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Figure 3.13: Simultaneous Optical and MRI measurements of ductal carcinoma by Ntziachristos5 , showing
ICG and Gd-DTPA spatial correlation. (a) Sagittal Gd-enhanced MRI with optical field of view marked in
yellow. (b) Coronal DOT image of ICG uptake. Note that this plane is perpendicular to that shown in (a).
(c) Coronal Gd-enhanced MRI with the same field of view as (b).

incorporated an eight wavelength FD system166 by ISS Inc. in their studies of the effects of compression on
breast physiology; see Section 3.1.
Few researchers worldwide have concurrently utilized structural information from non-optical modalities and injected optical contrast agents for improved diffuse optics based diagnosis and detection. Ntziachristos, Yodh, Schnall, and Chance198 pioneered simultaneous contrast-enhanced DOT and MRI (the
University of Pennsylvania ‘GenI’ system). Figure 3.13 shows an example of co-localization of the two
agents. This work employed a TD diffuse optical instrument to obtain simultaneous optical measurements
of breast with ICG contrast and with Gd-DTPA enhanced MRI. The DOT system employed 24 sources, 8
detectors, and one optical wavelength (830 nm) across a 5x10 cm grid. Ntziachristos produced co-registered
optical and Gd-subtraction images, permitting comparison of the spatial distribution of agent uptake and
measurements of ICG kinetics. This system was later expanded to three optical wavelengths5, 6
The Dartmouth optical breast cancer group conducted a study of 11 healthy subjects, with Brooksby7, 219
performing FD-DOT constrained with spatial tissue type distribution from Gd-enhanced MRI. Carpenter8
extended this study into a cancerous subject with the addition of gadolinium contrast agent (Gd-DTPA),
applying a regularization scheme permitting gradual changes inside a tissue type and abrupt changes on the
boundaries between types. This instrument has 16 sources and 15 detectors, operated at 100 MHz, and uses
a circular geometry. Combined DOT/MR imaging systems are summarized in Table 3.2.
Practical limitations on recruitment and restrictions on modification of clinical instruments have led
many researchers to compare DOT images with sequentially acquired clinical data. Azar30 has developed
sophisticated deformation software to compare optical measurements with 3D images from other imaging
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Penn, GenI
Penn, GenII
Penn, GenIIm
Penn, GenIII
Penn, GenIII
PTB
Dartmouth

Year
1998
2004
2006
2009
2009
2005
2003

Sources
24
32
32
32
64
35
16

Detectors
8
8
8 (16)
5 (54)
16 (256)
8
15

λ
3
6
6 (1)
6 (5)
6 (6)
4
5

Type
TRS
TRS
TRS/CW
TRS/CW
TRS/CW
TRS
FD

Notes
Parallel-Plate
Parallel-Plate
Parallel-Plate
Parallel-Plate (Current)
Parallel-Plate (Planned)
Parallel-Plate220
Ring221 , later Parallel-Plate222

Table 3.2: Summary of Clinical Optical-MRI systems for breast cancer. Dates shown are year of first
publication; previous generation systems shown only for Penn. Thayer at UCI has presented a progress
report223 on the development of a new FD system.
modalities taken non-concurrently; particularly, Gd-DTPA enhanced MRI. These fused data sets offer information from or comparison of both modalities, when simultaneous data acquisition is impractical. Positron
emission tomography (PET) using fluoro-deoxyglucose (FDG) is a clinical imaging modality which shows
cellular glucose uptake and therefore offers a measurement of glycolytic cellular metabolism; combining
PET and DOT offers the opportunity to compare this to blood oxygenation saturation. At University of
Pennsylvania, Konecky and collaborators have applied Azar’s data set fusion techniques to show correlation
between optical parameters, especially total hemoglobin and scattering with FDG uptake measured with
whole body PET29 . Saturation measured by optical methods had little correlation with FDG uptake, but the
study was fairly small (N=9). These researchers also extended their study with an experimental breast-only
PET scanner to show co-localization of tumors in three subjects. Work applying this deformation technique
to hand-held optical measurements and MRI is ongoing in collaboration with University of California Irvine,
who have previously correlated sequential hand-held DOS measurements with MRI11 .

3.2.3

Practical Diffuse Optics Clinical Instrumentation

Diffuse Optical instruments differ in the quantity of spatial, spectral, and temporal information provided
(Figure 3.14). Spatially, an instrument with few source-detector pairs collects regional (a few cm3 of tissue)
information, while data from an instrument with hundreds or thousands of source-detector pairs can yield
a 3D tomographic reconstruction. Spectrally, an instrument with only a single wavelength can monitor
changes in absorption at that wavelength and therefore track the kinetics of a contrast agent, but it cannot
separate two simultaneously changing chromophores, both of which absorb at the wavelength used. A multiwavelength or even broadband instrument can distinguish between several chromophores. Instruments with
temporal information (TD or FD) can separate absorption and scattering, permitting absolute quantification
of the chromophore concentrations (Eqn. 3.4).
The information content of diffuse optical measurements therefore has dimensions of frequency (TD data
has many frequencies), source-detector pairs, and wavelength. The most basic instrument consists of a single
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Figure 3.14: Information content of diffuse optical techniques. More wavelengths, source-detector pairs,
and frequencies increase the completeness of the data set. Time domain measurements can be Fourier
transformed into many frequencies; wavelength data can be transformed into chromophore concentrations.
Cost, instrument complexity, and measurement time scale with each dimension.
source-detector combination and one wavelength, with a continuous (ω =0) light source; very similar to the
2 wavelength system described by Chance224 and later commercialized as the ‘RUNMAN’ by NIM Inc.
(Philadelphia, Pa., USA). The instrument with the most complete data set is TD (or swept frequency FD),
with many source and detector positions and wavelengths. In the ‘wavelength’ and ‘frequency’ dimensions,
the most complete data set so far reported is the 32 wavelength, TD instrumentation developed by the group
at Politecnico di Milano for scanning mammography225 and brain226 measurements. However, the laser
sources and detectors for such systems are complicated and expensive. The source-detector dimension is
maximized by Choe et al.31 (4 × 104 source-detector pairs) for human studies and 107 pairs by Konecky90
in phantom studies. However, DOT images with these systems can take 10 minutes or longer to acquire.
The cost, complexity, and measurement time are roughly correlated with each dimension and therefore the
richness or completeness of the data set. For example, a pulsed super-continuum light source for multiwavelength time domain measurements currently costs ∼$70k while a single wavelength constant output
LED might be available for $1.
The work presented in this thesis describes simultaneous contrast-enhanced DOT and MR imaging
(Chapter 4 and Chapter 5) and the development of a new modular platform for improved simultaneous
imaging. Additionally, we develop a statistical analysis technique for DOT images and apply it to data from
a stand-alone DOT imaging system (Chapter 7). Finally, we present a pilot study using unique optical data
to measure hemodynamic changes during mammographic compression.

64

Chapter 4

Instrumentation for Simultaneous
Diffuse Optical and Magnetic
Resonance Imaging
Diffuse optical measurements add unique data to MR imaging. Over the years, collaborative research between the Departments of Physics (Yodh), Biochemistry and Biophysics (Chance), and Radiology (Schnall
and Rosen) at the University of Pennsylvania has led to the development of combined MR and DOT
imaging with applications to the breast cancer problem. This research effort began with the work of
Ntziachristos5, 6, 198, 227, 228 (Generation I, or GenI for short). Since then, DOT/DOS-MRI has been explored
with and without exogenous contrast agents through three generations of optical instruments, summarized
in Table 4.1. Intes and Yu229 constructed the second generation multi-channel (GenII) system. My work has
focused on an instrumentation upgrade of the GenII system (GenIIm; Chapter 4) and clinical measurements
with the GenII and GenIIm systems (Chapter 5). This work led to my development of the third generation
(GenIII) system, as described in Chapter 6.
Construction of the GenII system229 was motivated by a need for additional wavelengths (3→6) and
source positions (24→32) compared to the GenI system227 . Additional wavelengths permit improved chromophore quantification, while additional source positions enable collection of more spatial information and
thus improved tomographic reconstructions. The MR platform was transitioned from GE MRI systems to
those of Siemens (due to a conversion at the Hospital of the University of Pennsylvania), and it was upgraded at the same time from 4 to 8 receive channels, improving spatial sensitivity uniformity. Initial work
by Nioka172 and Intes197 monitoring the pharmacokinetics of ICG using a stand-alone CW DOT system
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inspired the addition of a fast CW imaging mode in the GenII system. The resulting system (GenIIm) provided more spatial information and a significantly decreased DOT ‘frame time’ (i.e., time to collect data
from all sources) from ∼4-7 minutes to ∼14 s. The latter improvement permitted much better tracking of
the washout of ICG. Both the GenII and GenIIm systems were used in ongoing clinical research in conjunction with the Advanced Breast Imaging study (Section 5.1) in the Department of Radiology at the Hospital
of the University of Pennsylvania.
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Section 4.3

Chapter 6

GenIIm

GenIII

64
64

32

32
32
32

24
32

Sources
24

32
256

54

7
14
5

8
7

Detectors
8

6
6

5

6
1
6

3
6

λ
1

TD
CW

CW

TD
CW
TD

TD
TD

Data Type
TD

∼600
∼30-60

∼30

∼240-560
∼14
∼300

∼60
∼60

SPF [s]
∼60

Hybrid modular system for larger data sets and greatly increased flexibility in optode positioning, conversion to 3T MRI234 .
‘Current’ GenIII system with one source and one detector module in
use.
‘Complete’ GenIII system with all modules in use.

Added hybrid TD-CW system for ICG kinetics tracking230–233 .

Notes
First report of simultaneous DOT and MR Imaging, 1.5T GE Signa
MRI198, 228 .
Improved spectral information; additional subject recruitment5, 6, 227 .
Improved spectral and spatial resolution, conversion to Siemens 1.5T
MRI229 .

Table 4.1: Summary of Optical-MR imaging systems at the University of Pennsylvania. GenI and GenIm are not described in this thesis; the remaining
systems (boldface) were either used or built as part of work on this thesis. Seconds Per Frame (SPF) are given for all sources at a single wavelength. The
GenII and GenIIm system had a total of 32 source positions available, but a maximum of 21 were used in clinical measurements due to space constraints.
Data collected with the GenII system is presented in Section 4.2, the upgrade to the GenIIm system in Section 4.3, and results from both systems in
Chapter 5.

In Progress

NA
Section 4.2

GenIm
GenII

GenIII

Section
NA

System
GenI

4.1

Advantages of Simultaneous Multi-Modal Imaging

Combining Diffuse Optical with MR Imaging has advantages from both technology development and clinical translation perspectives. Optical fibers can be introduced into the MR suite (e.g. Figure 4.1) without
unduly disturbing clinical work. In terms of technology development, relatively low resolution DOT can
utilize high spatial resolution MR images of tissue as spatial a priori information to constrain optical reconstructions. The Dartmouth group has perhaps developed this idea most extensively219 ; Guven applied
Bayesian analysis235 to this problem, and Intes188 introduced simultaneous spatial and physiological constraints for the simultaneous MRI-DOT reconstruction problem.
The simultaneous measurements described herein also permit DOT to be validated against a well established clinical imaging modality. Furthermore, DOT/DOS measurements access different contrasts than
that provided by the primarily structural images in MRI (Table 4.2) or by other standard clinical imaging
modalities (X-Ray and Ultrasound). Thus, a joint measurement can potentially increase cancer sensitivity
and specificity compared to either individual modality. Finally, DOT/DOS measurements are non-ionizing
and utilize relatively inexpensive equipment, and, therefore, DOT provides additional information to the
clinician at little additional risk or patient cost.
Current work on the development of targeted contrast agents for optical imaging will further increase
the utility of optical measurements. To provide a concrete example, an untargeted (but FDA approved)
optical contrast agent ICG can readily be detected at the micromolar range or lower237 ; Gd chelates that are
typically imaged (by MRI), on the other hand, require hundreds of micromolar or higher concentrations.
Higher sensitivity to the contrast agent can translate directly into lower drug doses, an ability to target more
scarce receptors, and detection of smaller metastases. Additionally, the same optical agent utilized to detect
a tumor could be visualized by a surgeon during resection to improve margin accuracy of tumor tissue
removal. This idea has been shown to work in limited studies; for example, Sevick-Muraca200 utilized ICG
to identify sentinel lymph nodes (SNL) for resection.
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Optical
Total Hemoglobin
Blood Oxygen Saturation
Tissue Scattering
Water Concentration
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Micro-Vascular Blood Flow

Exogenous

Figure 4.1: (left) Image of the GenII platform undergoing testing. Detector fibers (black) and source fibers
(orange) are visible in this image. Note, although the GenII MR platform was adapted for the Siemens
MRI this image was taken prior to the conversion from the GE system. (right) Cartoon of instrument and
subject placement for simultaneous DOT and MRI measurement. Opto-electronics are located outside of
the magnet shielding to both reduce the effects of magnetic fields on the components and to fulfill clinical
safety requirements. This cartoon is replicated in Figure 3.12.

ICG Uptake/Washout

MRI
T1
T2
Tissue Structure (< 1 mm)
ASL Blood Flow

Gd Chelate Uptake/Washout

Table 4.2: Information content of Optical and MRI measurements of breast cancer. Note: breast ASL
has only been demonstrated in a feasibility study236 and optical DCS blood flow measurements have been
primarily in remission51 , but some transmission data is presented in Chapter 8.
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4.2

GenII Combined Time-Domain DOT and MR Imaging System

The GenII Optical-MR Imaging system at the University of Pennsylvania permitted simultaneous imaging with MRI (1.5 Tesla Sonata, Siemens) and TD DOT (summarized in Table 4.3) of both endogenous
and exogenous tissue contrast. The optical/MR imaging platform and opto-electronics associated with this
instrument are described in the following sections.

4.2.1

GenII Opto-Electronic System

The GenII opto-electronic system is composed of pulsed diode lasers coupled to a subject in an MR suite
using ∼10 m source and detector fibers and an array of photon-counting PMTs. This optical instrumentation
permits measurement of absolute tissue optical properties with each source-detector pair (with standard
assumptions).
The GenII opto-electronics components are based around pulsed diode laser heads controlled by a
common ‘Sepia’ driver-oscillator unit (Picoquant Gmbh., Berlin, Germany), an array of 16 single-photoncounting PMTs (Hamamatsu USA, Bridgewater NJ, H7422-50mod) modified to increase angle of acceptance, and a set of Time-Correlated Single Photon (TCSPC) counting PCI-cards and routers (Becker and
Hickl, Gmbh.). Individual source fibers (∼10 m long, 62.5/125 µm diameter, NA=0.17, step index) and detector bundles (5 mm active area, NA=0.33, step index, CeramOptic) couple light into and out of the tissue.
A schematic of the optical components is shown in Figure 4.2.
The input pulse to the tissue for each wavelength has a temporal Full-Width-Half-Max (FWHM) of
∼400 ps. This pulse width is substantially larger than expected from the convolution of the PMT response
time and the original laser pulse width (∼200 ps). The pulse broadening is due primarily to the fairly high
NA=0.33 of the ∼10 m detector fiber bundles, which allows propagation of multiple fiber modes all with
slightly different path lengths. However, this high NA also increases the efficiency of light collection from
tissue. In a practical sense, this pulse width constrains the instrument in this configuration to larger (>3
cm) source-detector separations and lower (µa < 0.1/cm) absorptions. Outside these limits the difference
between collected data and the IRF becomes small, and fitting to a theoretical model unreliable. Neither of
these constraints are limiting factors for transmission measurements through breast tissue, however.
An example of TD data collected with the GenII system through the breast of a healthy volunteer is
shown in Figure 4.3. Here, data is cropped at wavelength; in addition, the zero of time is adjusted using the
peak of the reference channel. These time profiles are fit to an infinite slab solution of the diffusion equation,
as described in Section 2.3.3, to derive tissue optical and physiological properties.
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Multi-channel Pulsed Diode Laser
Driver (Sepia)
Laser Diode Heads ( 690, 750, 780,
808, 830, and 838 nm)
6x2 Fiber Optic Combiner
Fiber Optic Digital Attenuator
1x32 Fiber Optic Switch
32 (21 used clinically), ∼10 m,
NA=0.17
16 (7 used clinically for TD), ∼10
m, NA=0.33
Photon Counting PMTs
1x8 Routers
TCSPC Module
CW Laser Module
CW Laser Driver
CW Laser Cooler
Back-Illuminated Frame Transfer
CCD

PDL 808

PicoQuant GmbH

LDH series

PicoQuant GmbH

Dual Window
Tree Coupler
GP700
GP700
62.5/125 µm,
step index
5 mm active
area, step index
H742250mod
HRT-81
SPC-134
TCLDM9
LCD 500
TEC 2000
iXon-887

Fiber Optic Communications Inc.
DiCon Fiber Optics
DiCon Fiber Optics
Corning
CeramOptic

Hamamatsu
Becker and Hickl, GmbH
Becker and Hickl, GmbH
Thor Labs
Thor Labs
Thor Labs
Andor Technology

Table 4.3: GenII/GenIIm Instrument Components; see text for discussion and details. Schematics are shown
in Figure 4.2 and Figure 4.6.

Figure 4.2: Opto-electronic schematic for GenII system. Note that this system uses a ‘pulse-chain’ (see
Figure 4.3 for an example) and therefore only requires a single optical switch.
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Figure 4.3: Example TD-DOS data, collected with the GenII system. Measurement (blue) and Reference
Channel (red) pulse trains, measured in the breast of a 27 year old healthy volunteer. Data is shown for 6
λ in a 80 ns pulse train, repeated at 4 MHz. The Instrument Response Function (IRF) FWHM is ∼400 and
roughly equal to the reference channel width.

4.2.2

GenII MR/Optical Imaging Platform

The GenII MR/Optical imaging platform contains bilateral optical fiber mounts and an 8 channel MR RF
receive-only array, developed by Dr. Thomas Connick (an upgrade from the 4 channel receive array238 used
in the GenI system) for the Siemens Sonata 1.5T MRI. Sources are placed in the medial plate and detectors
mounted laterally: this configuration is necessary as the source fibers are both much smaller and much more
flexible than the detector fiber bundles. As can be seen in Figure 4.4, the platform is symmetric in both
the axial and lateral dimensions and provides support for the subject’s shoulders and abdomen during the
exam. This platform was used routinely for bilateral MR imaging; however, due to lateral space constraints
in the MRI bore (∼59 cm diameter) and the large minimum bend radius (∼15 cm) of the detector fibers,
we typically only measured one breast optically in any given exam. In general, modification of the fiber
mounting scheme necessitated alterations of the MR RF electronics (see Figure 4.4).
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Figure 4.4: Images of the GenII and GenIIm optical-MRI breast platform.(left, upper) Overhead view of
GenII and GenIIm optical-MRI breast platform with padding and light drapes removed. Note the significant
bend in the black optical fibers at the top of the image. A solid phantom is positioned in place of the right
breast; orange source fibers are visible in the lower right; black cables in the left of the image connect the RF
receive coils with a pre-amplifier module (not shown). (right, upper) Overhead view of platform, with some
padding in place. The platform is oriented with the head on the left of the image. (left, lower) Back view of
MRI-Optical platform lateral compression plate containing RF coils. The detector fiber mounts have been
removed to reveal the underlying electronics. (right, lower) Cartoon of platform.
Figure 4.5 shows several additional views of the platform, along with a schematic showing fiber placement. Although the GenII platform was designed to accept multiple rows of source and detector fibers on
both breasts, in practice, space and tissue contact limitations precluded use of all but the top (i.e., closest to
the chest wall) two rows of sources and typically the top-most row of detectors. Lateral constraints of the
magnet bore generally precluded bilateral optical imaging. The tissue-fiber coupling shown in Figure 4.5 is
fairly typical: we frequently did not get good fiber coupling on the second row of sources or detectors.
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Head

LR

Figure 4.5: Optical/MRI Breast Imaging Platform schematic and images. (left,top) Top view- the left and
right MR receive coils and optical fiber mounts are mirror images. (left, bottom) Oblique view of platform,
showing fiber optic mounting holes. Note that only the top row of detectors and top two rows of sources
were reliably in contact with the subject’s skin. The lowest two rows of detector positions were unusable
in the magnet, due to space constraints caused by the curvature of the bore. (right, top) Sketch of fiber
optic positions relative to breast tissue. Sources (red) are located in a medial plate underneath the subject’s
sternum. Detectors (blue) are located on a slightly raised plate which makes better contact with the upward
curving chest.
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4.3

GenIIm HybridTime Domain-Continuous Wave DOT for Simultaneous Optical and MR Imaging

4.3.1

Rapid Continuous Wave Diffuse Optical Tomography

Exogenous contrast agents permit clinical imaging modalities to probe structures and tissue functionality
which lack significant endogenous contrast. The only NIR contrast agent currently approved by the FDA,
however, is Indocyanine Green (ICG, also called Cardio-Green). Research by Nioka172 and Intes197 at University of Pennsylvania suggested the potential for highly specific cancer diagnoses, based on local ICG
kinetics. Gadolinium kinetics are well established in the MR breast imaging community; indeed, breast
imaging guidelines require a gadolinium agent for diagnostic utility239, 240 . Imaging ICG simultaneously
with Gd contrast agents offered us an obvious opportunity to test the diagnostic utility of contrast-enhanced
DOT (CE-DOT) in direct comparison to contrast-enhanced MRI (CE-MRI). However, the DOT frame rate
of the GenII system was too slow (∼60s) to reliably image ICG washout (half-life ∼3-5 min., following
the analysis by Intes197 shown in Figure 3.8). The time resolution was sufficient, however, to obtain spectroscopic point measurements (e.g., as shown with the GenI system by Ntziachristos227 ). We therefore
undertook the task to construct a higher frame rate optical instrument utilizing a hybrid of TD and CW
technology. This combination provides both absolute optical properties and low resolution imaging. The
new instrument could therefore measure changes in absorption due to ICG with higher temporal and spatial
resolution than any previous in-magnet device.

4.3.2

GenIIm: DOT and MR Imaging at 1.5T

Figure 4.6 shows the addition of a 785 nm CW laser diode and lens-coupled CCD for detection to the
existing GenII TD system. We were able to include an additional 9 CW detector fibers in the upgraded
instrument; by manually transferring the TD detector fibers to the CW detection system, we were also able
to increase our total available CW detectors to 16. Note, although 32 source fibers were available, space
limitations usually restricted us to use of only 24 source fibers in clinical practice.
A critical specification for a kinetics monitoring system is stability; the CW portion of this system
showed ∼2% (5% maximum) fractional standard deviation from the mean of intensity during a 30 minute
kinetics imaging sequence on a static phantom. See Table 4.3 for specifications of system components.
Additionally, a number of minor improvements were made in optode mounting, padding for patient
comfort, and improved integration into the MR Exam sequence.
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Figure 4.6: Schematic of the GenIIm system. 32 Shared Sources (24 clinically), CW: 16 detectors, 1λ, TRS:
7 detectors, 6λ. Table 4.3 contains details of the components.

4.3.3

GenIIm Pharmacokinetics Phantom Measurements

The GenIIm system focused on kinetics imaging; an example of a kinetics phantom measurement and reconstruction is shown in Figure 4.7. This phantom consisted of a liquid bath, an ellipsoidal latex shell, and
two pipes for entrance and departure of a target solution. We utilized an adjustable speed syringe pump
to produce a phantom with changes over the same time span as roughly expected from ICG in vivo. The
target was formed by filling a latex balloon with a target solution with ∼3x1 absorption contrast with respect

to the background (µa =0.05 cm−1 ). Data was reconstructed using a Singular Value Decomposition (SVD)
reconstruction, Tikhonov regularization, and an infinite slab Green’s function, as introduced in Section 2.2.8.
Figure 4.7 shows the temporal change in reconstructed µa of the phantom images as well as a schematic
of the phantom. This SVD reconstruction contains significant artifacts, especially near the sources and
detectors. Nevertheless, relative changes in the target absorption are clearly visible.
Applications of this instrumentation to clinical studies will be described in Chapter 5.
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in schematic to the right.
Figure 4.7: Kinetics phantom imaging with the GenIIm system. (left) Change in µa for each slice (colors match right center diagram). We found quantitative agreement with expected values. The Region Of
Interest (ROI) was taken in the same lateral location for each plane. (right, top) Photo of inflated balloon
phantom. (right, center) Diagram of reconstructed slices. (right, bottom) schematic of source and detector
fiber placement and target location.
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Chapter 5

In-Magnet Time-Domain Diffuse
Optical Spectroscopy and Tomography
of Human Breast Cancer
The GenII and GenIIm instruments described in Chapter 4 were employed in a series of clinical studies. In
this work, we collected bulk optical property and ICG regional kinetics patient data. A summary of results
from measurements on 19 subjects with data from intrinsic and extrinsic DOT/MR imaging are given in
Section 5.1. Simultaneous contrast enhanced DOT and MR Imaging with GenIIm is described in Section 5.2.
Section 5.3 describes the lessons learned from these systems that we have applied to construction of the
GenIII system (Chapter 6).
Our subjects enrolled in the ‘Advanced Breast Imaging Study’ (ABI, NIH P01-CA-85424). The ABI focused on comparative studies of film and digital X-Ray mammography, ultrasonography, PET, and MRI241 .
Subjects were opportunistically recruited into the DOT investigations as an adjunct to the MR Exam. Our
study was approved by the University of Pennsylvania Institutional Review Board under Protocol #803468.
The ABI study recruited three groups of women: those at high-risk, those with a suspicious lesion, and
those with a recent biopsy of a malignant lesion and for whom additional imaging was required for staging.
Our study recruited primarily from the second ABI group in order to maximize the number of cancers and
minimize contamination of data due to biopsy-induced bleeding. Recruitment also focused on women with
C-cup or larger breasts, as the engineering of the GenII platform was sub-optimal for tissue contact with
smaller breasted women.
Typical exam time-lines for the GenII and GenIIm systems are shown in Figure 5.1. ICG is not a
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GenII

GenIIm

MRI

MRI

Optical

Optical

Figure 5.1: Experimental time-line for (left) GenII and (right) GenIIm simultaneous clinical optical/MRI
measurements. The entire exam, complete with a pause to inject ICG, takes ∼45 minutes Descriptions of
each scan are in text.

GenII
GenIIm

Total
Studied
27
18

Tumor
in FOV
4
3

Agreed
21
15

ICG
Kinetics
12
11

Imaging
0
5

Table 5.1: Summery of subjects studied with the GenII and GenIIm simultaneous DOT and MR imaging
systems. ‘Total Studied’ includes all subjects who agreed to participate in the study. Subjects noted under
‘Tumor in FOV’ had their tumor positioned near (∼1 cm) the DOS/DOT Field of View. ‘ICG Agreed’
includes those subjects who agreed to ICG injection; due to logistical constraints, only a subset of these
subjects actually received ICG. ‘ICG Kinetics’ enumerates subjects who had useful ICG data, but too few
source-detector pairs for ‘ICG Imaging’.

standard contrast agent in MR studies. Therefore, ICG injections were performed by an attending physician
and timing was sometimes adjusted based on the physician’s availability. ICG injection both preceded and
followed Gd-DTPA injection; we did not utilize an auto-injector for ICG.
MR imaging was broken down as follows. In the first ∼5 minutes, reconnaissance scans were carried
out to localize the breasts in the MR coordinate system and to optimize imaging volume selection. Then T1
weighted scans were carried out; these scans involved repeated MR imaging at varying relaxation times to
permit computation of a T1 map. Then a baseline MR image was obtained prior to Gd-DTPA injection, and
finally a series of kinetic imaging scans was taken to measure Gd-DTPA uptake and washout.
Optical exams began with measurements of absolute optical properties using the TD-DOS system; these
measurements were relatively slow (∼5 minutes per frame). Then optical fibers were manually moved
from the TD-PMTs to the CCD camera for CW imaging. We then collected baseline images prior to ICG
injection. Finally, we collected CW ICG scans to image ICG uptake and washout (∼30 s per frame).
The broad objective of the ABI study was to compare the current state of the art in breast imaging
techniques. Thus, over the course of the study, several modifications were made to the protocol, and the MR
data available for our analysis varied somewhat as a result. Furthermore, during the period of the study, we
converted from the GenII to the GenIIm system. Together, these factors limited the number of subjects with
directly comparable data sets. In effect, we undertook a series of pilot studies rather than a single trial.
Multi-modal imaging offers rich data sets (e.g., here, T1 , Gd-DTPA, Hbt , StO2 , and ICG uptake), but it
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is frequently challenging to obtain a complete data set for an individual subject. For example, the subject
shown in Section 5.2.1.1 was not included in the bulk property analysis (Section 5.1), because artifacts,
probably due to subject movement during the T1 -weighted image series prevented calculation of a T1 map.

5.1

Clinical Diffuse Optical Spectroscopy Results: GenII and GenIIm
Systems

5.1.1

Endogenous Bulk Optical Properties

Bulk optical properties are important both in their own right and as inputs to DOT algorithms. For all
(0)

0(0)

subjects we measured bulk optical properties prior to contrast agent injection (i.e. µa [λ ] and µs [λ ]
at six wavelengths 690, 750, 785, 800, 830, and 838 nm; see time-line in Figure 5.1) with TD-DOS. The
wavelength-dependent results were used to compute endogenous chromophore concentrations; an example
multi-wavelength fit is shown in Figure 5.2. This data comes almost entirely from healthy tissue. A few
subjects with tumors were included in this sample, but their tumors occupied a small fraction of the total
volume probed optically.
Data sets collected during the course of studies with the GenII and GenIIm systems varied somewhat
between subjects due to equipment upgrades (e.g., GenII →GenIIm), modifications to experimental protocol (e.g., ICG not injected due to physician availability), subject-specific difficulties and compliance (e.g.,
optode-skin coupling, fidgeting), and available exam time. We have extracted a group of 19 subjects for
whom consistent TD-DOS, T1 , and Gd-enhanced MR data was collected; data averaged across both subjects and population are presented in Table 5.2.
The average measured blood oxygen saturation in our data is within the range reported by others (62%
vs. 68%, e.g. as summerized by Leff1 ). During menopause, breast glandular tissue atrophies. Thus, postmenopausal women tend to have both less glandular tissue volume and reduced metabolic activity in the
remaining tissue, leading to a reduction in Hbt seen in other work. Our values for total hemoglobin are
in agreement with those presented by others for post-menopausal women; the values of total hemoglobin
concentration for pre-menopausal women were roughly half of that seen in previous studies (summarized
by Leff1 ). In fact, the distributions of Hbt and StO2 from the pre- and post-menopausal women in our
population were essentially identical and therefore these groups were combined for much of the subsequent
analysis; Figure 5.3 shows the distribution over all subjects and all source-detector pairs.
We note also that our recruitment was skewed towards women with larger breasts to improve mechanical
skin-optode coupling. Furthermore, the fat content in the breast of the included subjects was unusually high:
the average BMI of the studied group was 30.4±6.7 (the CDC obesity standard is BMI≥30) and the adipose
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Figure 5.2: Example TD-DOS measurement of bulk optical properties of breast tissue with the GenII system.
Hbt (13.5 µM), StO2 (65%), Lipid (5%), H2 O (48%) fit to six wavelength absorption data. Note that this
instrument had limited sensitivity at longer wavelengths (λmax = 838 nm) and therefore limited sensitivity
to lipid and water concentrations. Imaging data from this subject is shown in Section 5.2.1.3.
tissue fraction in the breast was ∼85% (from T1 MRI). High adipose tissue content is inversely correlated
with glandular tissue fraction and therefore Hbt concentration. Together, these factors may explain the
similarity observed between pre- and post-menopausal tissue properties in our data. Lipid and water content
fit quality varied between subjects; as this instrument had limited data at longer wavelengths (λmax = 838
nm), the analysis was less sensitive to errors in lipid and water quantification than Hbt and StO2 . Despite
this limitation in spectral sensitivity, the bulk optical Lipid fraction had a correlation of -0.62 (p<0.01) with
average T1 , consistent with the known reduced T1 in adipose tissue. Table 5.3 lists correlations between
optical properties and T1 .
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Hbt
StO2
Lipid
H2 O
µ0s [785nm]
T1 Fat Fraction
BMI
Age

14.6
62.2
18
28
10.8
85
30.4
47.4

±
±
±
±
±
±
±
±

3.4
7.9
11
14.5
4
2
6.7
14.8

µM
%
%
%
cm−1
%
kg m−2
yr.

DOS

Intrinsic

Table 5.2: Bulk TD-DOS optical properties collected on 19 joint optical/MRI subjects with more than 5
useful source-detector pairs. Data is reported as mean ± standard deviation, except for the T1 fat fraction, in
which the mean and the changes due to varying the cutoff between adipose and glandular tissue by ± 10%
are included.

Optical
Hbt
StO2
Lipid
Lipid

MR
Fat Fraction
Fat Fraction
Fat Fraction
T1 (bulk)

r
0.09
0.16
0.24
-0.62

p
0.034
< 0.01
< 0.01
< 0.01

Table 5.3: Correlations between regional DOS and MR parameters from DOS measurements in 19 subjects
using the GenII and GenIIm systems. Although these correlations are significant at the 5% confidence level,
the overall weak correlations may be a function of inter-subject variation in this small population. (Note,
p-values are not corrected for the number of correlations examined.)
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Figure 5.3: Histograms of Hbt and StO2 measured with TD-DOS for all source-detector pairs in 19 subjects.
Numbers are assigned to each source-detector pair. Note, the distributions of results from pre- and postmenopausal women were almost identical and we therefore grouped these data.
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5.1.2

Bulk ICG uptake kinetics

Data from the majority of our subjects lacked sufficient spatial information for DOT reconstruction; however,
we were still able to use these data for spectroscopic or bulk analysis, similar to the endogenous property
measurements described above. The bulk ICG uptake data set includes a few subjects with cancer in the
optical field of view, but these cancers occupy only a small fraction of the optically probed volume. We fit
ICG kinetic measurements to double exponential and two compartment models (e.g. Figure 5.4), and then
we compared the ICG kinetics to the kinetics of Gd-DTPA. Note that the kinetics can vary considerably
within a single subject (e.g. Figure 5.5), depending on the source-detector combination used.
Figures 5.4 and 5.5 demonstrate that the ICG concentrations change rapidly near the time of peak concentration and much more slowly after ∼300 s, although the total concentration (and therefore signal) is
considerably lower at longer times. ICG imaging with low DOT frame rate instruments (e.g., ∼10 min. per
frame in work by Corlu and colleagues89 ) collect data during the later period. As discussed in Section 5.2.1,
the GenIIm instrument had a frame rate of ∼14 s per frame and could produce ICG uptake images during
the entire ICG wash-in/wash-out period.
We make the simplifying assumption that the local fractional change in MR signal intensity can serve as
a proxy for Gd-DTPA concentration in the following discussion, although this relationship is known to be
non-linear. As will be discussed in Section 5.2.1, the Gd kinetics data was taken at fairly slow frame rates
(∼94 s) and short total times (∼10 min.), which effectively limits the complexity of our models; we therefore
limited our models to linear fits of the initial and terminal data points (Figure 5.6). We then extracted the
initial slope, terminal slope, and terminal intercept for comparison with ICG kinetics parameters.
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Figure 5.4: (left) ICG uptake measured at a single source-detector combination with TD information from
GenII system. (right) ICG uptake from a single source-detector combination from the GenIIm, extracted
from a CW imaging data set shown in Section 5.2.1.3. Data with double exponential (see Equation 5.2) and
two compartment (see Equation 5.1) fits are shown.
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Figure 5.5: (top) Gd-DTPA enhanced MRI showing tumor (upper center, yellow dashed circle, intersected
by magenta line, ∼0.5 cm3 ) in a coronal image slice. Color-coded lines connect the source-detector pairs
plotted in the bottom curve. (bottom) Example ICG uptake curves on a single subject with an invasive
carcinoma in the optical field of view (imaging data for this subject are shown in Section 5.2.1.3). ICG
uptake and washout kinetics varied significantly between source-detector pairs on individual subjects. (Note,
negative calculated ICG concentrations just prior to the upslope are due to the increased room illumination
required to inject the contrast agent.) The similarity between the orange and magenta curves suggests that
bulk ICG kinetics are less useful than those extracted from reconstructed images (e.g., as in Intes et al.197 ).
Fits shown are from the two compartment model described in the text. Yellow scale bar is 1 cm.
We utilized a pair of ICG kinetics models: a two-compartment model from Cuccia173




κ
κ
2cmpt
CICG [t] =A1 Hbt ζ +
+ A2 Hbt ζ +
e−α2 t
kout
kout − α2
 



κ
κ
− A1
+ A2
e−kout t
kout
kout − α2

(5.1)

and an empirical double exponential model

Exp
CICG
[t] = A −e−k1 t + e−k2 t .

(5.2)

The quantities in these models are defined in Table 5.4 and 5.5; the models are explained in more detail in
Appendix A.
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Figure 5.6: Example kinetics model fit to fractional changes in local MR image intensity due to Gd-DTPA
uptake. The low temporal resolution of this data limits the complexity of kinetics models which may be
applied. Note, the MR signal intensity is non-linearly related to the Gd-DTPA concentration. Data are solid
blue circles.

A1

Pre-factor in two compartment model

A

Pre-factor in double exponential model

A2

Pre-factor in two compartment model

C

Total ICG concentration

α1

Liver elimination constant 1

k1

Rate constant

α2

Liver elimination constant 2

k2

Rate constant

Ce

ICG concentration in EES

Cp

ICG concentration in Plasma

C

Total ICG concentration

Hbt
κ

Table 5.5: Parameters in Equation 5.2.

Total Hemoglobin Concentration from DOS
Ve kin

kin

Rate constant from Plasma to EES

kout

Rate constant from EES to Plasma

Ve

Volume of EES

Vp

Volume of Plasma

ζ

Conversion factor between Hbt and Ve
Table 5.4: Parameters in Equation 5.1.

After various approximations and simplifications, A1 , the pre-factor on the leading order term is seen to
be related to the magnitude of ICG uptake. Data for each source-detector pair was fit separately to obtain
ICG absorption as a function of time; this information was then converted into ICG concentration and fit
to the models. Only source-detector pairs with both ICG and Gd data were retained. We then calculated
correlation coefficients between all ICG and Gd parameters.
Several ICG and Gd-DTPA parameters were mildly correlated locally as shown in Table 5.6. However,
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there were no significant correlations between bulk ICG and Gd-DTPA uptake (i.e., ICG parameters averaged over all source-detector pairs and Gd-DTPA parameters averaged over the optical field of view) in each

Two Compartment

ICG

DoubleExponential

subject.

r

p

Initial Slope

0.29

< 0.01

k2

Terminal Intercept

0.45

< 0.01

k2

Fat Fraction

-0.3

< 0.01

A2

Initial Slope

0.21

< 0.01

A2

Terminal Intercept

0.26

< 0.01

A2

Fat Fraction

-0.21

< 0.01

kout

Initial Slope

0.2

< 0.01

Optical

MR

k2

Table 5.6: Correlations with |r| > 0.2 between regional DOS and MR parameters from 8 subjects using the
GenII and GenIIm systems. Note, p-values are not corrected for the number of correlations examined.

None of the correlations between localized MR and DOS results presented in Table 5.6 are strong: the
highest correlation (between k2 and the Gd fit terminal intercept) is 0.45. However, ICG (775 Da) is known
to bind to blood albumin (66 kDa) while Gd-DTPA (590 Da) behaves as a small-molecule agent. Thus,
while the molecular weight of both agents is similar, the effective molecular weight of the agents in the blood
differs by ∼2 orders of magnitude, and therefore differences in the pharmacokinetics are to be expected (due
to, for example, size-dependent differences in vascular permeability). Furthermore, each DOS measurement
includes a weighted average across multiple tissue types. The spatial information in DOT reconstructions
reduces this partial volume effect and enables more direct comparison of the effects of measured contrast
agent uptake to tissue physiology on contrast agent dynamics. As will be discussed in Section 5.2.1, our
DOT reconstructions of ICG uptake did correlate with the spatial distribution of Gd-DTPA, consistent with
the results of Ntziachristos5, 6 .
The models of ICG kinetics presented above differ in assumptions from that recently used by Hagen et
al.190 ; most importantly, as Hagen collected data over tens of minutes to hours, he did not approximate the
liver long term elimination constant as zero and included lymph circulation.
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5.2

Clinical Imaging of Indocyanine Green with the GenIIm System

A major goal of the GenIIm system was to image ICG kinetics. Examples of ‘Optical Only’ reconstructions
are given below in Section 5.2.1. Section 5.2.2 describes use of spatial information from MR images to
constrain the reconstructions. However, due to limitations in our subject interface, high quality data for
DOT reconstructions were difficult to obtain with GenII or GenIIm; the data sets useful for reconstruction
were limited. Section 5.3 describes various problems found in the GenII and GenIIm systems, and some of
the resulting solutions we applied in the GenIII system described in Chapter 6.

5.2.1

‘Optical Only’ DOT ICG Kinetics Imaging

The DOT reconstructions presented in this section utilize only optical data: no information sharing is employed for image construction. Images from the two modalities were co-registered ex post facto using
fiducial markers built into the GenII platform. These markers were visible in the MR images and rigidly
attached to the optical fiber mounts.
As noted in the introduction to Section 5.1, bulk optical properties are measured with TD-DOS for each
subject. These properties are then used to calculate a weight matrix (W) for an infinite homogeneous slab
(see Section 2.2.8, especially Equation 2.78) which can be used in the all-optical image reconstruction via
SVD matrix inversion (Section 2.2.8.2). This single step linear reconstruction technique has the advantage
of requiring only a single computationally expensive inversion step. Additionally, as we are interested in
changes between the images due to the contrast agent, use of a single inversion matrix across all time points
reduces some systematic errors associated with multiple iterations (i.e., iterative DOT) for each frame.
The GenIIm system was designed to take advantage of the higher DOT frame rates available from CWDOT. This choice permits tracking of ICG pharmacokinetics with much greater time resolution (e.g. ∼15
seconds vs. ∼5 minutes with TD-DOT in GenII). In this analysis, we utilize the Rytov formalism (Section 2.2.8.1), wherein input reconstruction data is normalized by a background or homogeneous data set.
For imaging ICG kinetics, we used the average of a set of pre-injection data frames as our background data
set. The remaining data frames are normalized to this pre-injection time period. In other words, for each
time point, intensity data from each source-detector pair (Is,d [t]) is divided by the average intensity of the
0
same source-detector pair during the pre-injection period (Is,d
). Recall from Equation 2.73 that under the

Rytov formulation, we write the total measured fluence rate due to an input fluence rate U0 as
Ut [r] = U0 [r]eφs [r] .
In our approximation (Section 2.2.8.1), the detected signal is proportional to the fluence rate, so we can
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calculate φs (Equation 2.75) as:
0
Is,d
= hIs,d [t]i0≤t<tinj
#
"
Is,d [t]
φs [rs , rd , t] = ln
0
Is,d

(5.3)

for an injection time of tinj . Using W as defined in Equation 2.78, we transform this measurement vector
into a 3D change in absorption map (δµa [r, t]) during the injection and washout of ICG.
The remainder of this section presents three example cases of simultaneous contrast enhanced MR and
DOT imaging. In the first, we show data collected following a mock ICG injection (Section 5.2.1.1); in the
second, we show data from a subject without a cancer in the optical field of view (Section 5.2.1.2); the third
section includes data from a subject with an invasive carcinoma in the optical field of view (Section 5.2.1.3);
finally, we summarize our results (Section 5.2.1.4).
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5.2.1.1

Simultaneous Contrast Enhanced MRI and DOT: Mock Injection for System Validation
(‘Zero Image’)

The ICG imaging protocol presented above measures the change in absorption with respect to a pre-injection
image. This differential measurement requires the skin-optode coupling to remain consistent throughout the
exam. In this study, we show a time series of data collected without ICG injection, but otherwise with the
same protocol (see Figure 5.1). The results shown in Figures 5.7 through 5.9 show that the GenIIm system
was stable under these conditions (note that the color scale in Figure 5.8 is the same as that in Figure 5.14).
Sagittal

(a)

(c) Coronal View

Coronal

(d) ∆µICG
a

(b) Sagittal View

Figure 5.7: (a) Cartoon of image geometry. Gd-enhanced MRI sagittal (b) and coronal (c) of a subject with
a previous positive core biopsy, but without any clinical findings in the optical field of view (d). (d) DOT
image of ∆µa without ICG injection. This particular subject did not receive an ICG injection; however, we
utilized the same optical measurement protocol. The yellow boxes in the MR images mark the optical Field
of View reconstructed in Figure 5.8; contrast agent uptake in the marked circles is shown in Figure 5.8 and
5.9; cyan dots are optical detector fibers and red squares source fibers. All scale bars are 1 cm.
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Figure 5.8: Mock ICG imaging (i.e. no injection) of a subject during an MRI. (top) Note that the scale on
these images is the same as that in Figure 5.14. Data from two healthy tissue regions (magenta and orange
circles) are presented in the time traces below. (bottom) Time trace of ∆µa in two healthy regions (magenta
and orange circles) on 2 absorption scales: one scale limited to the dynamic range of this data set, showing
small fluctuations about zero, and the other scale chosen to match data shown in Figure 5.14. No significant
changes in absorption were observed (as expected). The white scale bar is 1 cm.
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Sagittal
Coronal

Figure 5.9: Example of Gd kinetics imaging. (top) Single coronal slices of Gd subtraction imaging reconstructions at eight time points. Images show differential enhancement to a baseline, pre-injection, image.
MR image is cropped to match the Field of View for optical reconstruction as shown in Figure 5.7. Optical
source (red squares) and detector (cyan dots) positions are marked. (bottom) Time trace of Gd uptake in 2
example healthy regions marked with magenta and orange circles. Note, the washout time for Gd-DTPA is
much longer than the duration of the study. The yellow scale bar is 1 cm.
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5.2.1.2

Simultaneous Contrast Enhanced MRI and DOT with no cancer in optical field of view

This subject had a biopsy-confirmed invasive carcinoma positioned well outside of the optical field of view
(see Figure 5.10 for the measurement geometry). As expected, we observed a small diffuse increase in
absorption during ICG injection (Figure 5.11), but no focal enhancements except some artifacts near the
sources and detectors. The limited source-detector pairs available for this reconstruction resulted in little
sensitivity to absorption changes near the edges of the reconstructed image and therefore the lower reconstructed absorption change near the superior-inferior boundaries (left-right in Figures 5.10 through 5.12).
Gd-DTPA uptake for the same region is shown in Figure 5.12; again, there is no focal enhancement. Note
that the color scale in Figure 5.11 is the same as that in Figure 5.14.
Sagittal

(a)

(c) Coronal View

Coronal

(d) ∆µICG
a
(b) Sagittal View
Figure 5.10: ICG and Gd Contrast Enhanced Imaging; invasive carcinoma outside of optical field of view. (a)
Cartoon of image orientation. (b) Sagittal Gd-enhanced MRI view of an invasive carcinoma, ∼10 minutes
post injection, showing the optical Field of View in yellow; cyan dots are optical detector fibers and red
squares source fibers. The tumor is clearly visible in the lower right of the image, but it is well out of the
optical Field of View. (c) Same MR data as in (a), coronal view. (d) DOT image of peak ∆µa ICG in the
optical Field of View marked in yellow on the MR images. The DOT color scale is chosen to match that in
Figure 5.14. Note that only those sources and detectors used in the reconstruction are shown in these plots.
Two regions, marked by magenta and orange circles in (c) and (d), will be used for kinetics analysis below.
All scale bars are 1 cm. Data is co-registered across modalities using fiducial markers on the source and
detector plates.
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Sequential DOT frames at 13.3 s intervals during ICG injection.
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Figure 5.11: Example of ICG kinetics imaging: single coronal slices of SVD reconstructions at 16 time
points of ∆µa due to ICG uptake in a healthy tissue region of a subject with an invasive carcinoma. Field
of View for optical reconstruction is shown in Figure 5.10. The color scale for ∆µa is chosen to match
Figure 5.14. (bottom) Kinetics traces of the regions marked with magenta and orange circles in two scales:
one selected for this data set and one matching that in Figure 5.14. Data is co-registered across modalities
using fiducial markers on the source and detector plates. Time stamps and 1 cm scale bars are marked in
white in each frame.
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Figure 5.12: Example of Gd kinetics imaging: single coronal slices of Gd subtraction imaging reconstructions at 7 time points subject with an invasive carcinoma out of the optical Field of View; MR image is
cropped to match the Field of View for optical reconstruction as shown in Figure 5.10. Data is co-registered
across modalities using fiducial markers on the source and detector plates. Optical detectors (cyan) and
sources (red) are marked. The average Gd enhancement for the regions marked in magenta and orange
circles is shown at the bottom. The yellow scale bar is 1 cm.

94

5.2.1.3

Simultaneous Contrast Enhanced MRI and DOT of an Invasive Carcinoma

This subject had a biopsy-confirmed invasive ductal carcinoma, positioned between the two rows of detector
fibers in the GenIIm system (see Figure 5.13 for the measurement geometry). ICG influx and washout is
clearly visible in Figure 5.14, despite some artifacts near the source and the irregular tissue boundary (lower
right of the image; clearly visible in Figure 5.13(c)). Gd-DTPA uptake for the same region is shown in
Figure 5.15. This subject showed focal uptake of ICG (Figure 5.14). The limited number of useful sourcedetector combinations in this data set severely limited medio-lateral resolution (top-bottom in Figures 5.13
through 5.15), resulting in a ‘blurring’ of reconstructed absorption in this direction and displacement of the
peak ICG uptake imaged in DOT ∼1 cm from the focal Gd-DTPA enhancement (Figure 5.15).
(c) Coronal View
Sagittal

(a)

Coronal

(d) ∆µICG
a
(b) Sagittal View

Figure 5.13: ICG and Gd Contrast Enhanced Imaging; invasive carcinoma in optical field of view. (a)
Cartoon of image orientation. (b) Sagittal Gd-enhanced MRI view of an invasive ductal carcinoma, ∼10
minutes post injection, showing the optical Field of View in yellow; cyan circles are optical detector fibers
and red squares source fibers. The tumor is clearly visible near the center of the image. (c) Same MR data
as in (a), coronal view. Scale bar (yellow) is 1 cm. (d) DOT image of peak ∆µa ICG in the optical Field of
View marked in yellow on the MR images. Source artifacts are visible in the lower right of the image, close
to the irregular air boundary visible in the coronal MR. Regions of peak uptake of Gd-DTPA (magenta),
along with a healthy region of the same size (orange), are marked with circles. Uptake kinetics from these
regions is shown below. Note that only those sources and detectors used in the reconstruction are shown in
these plots. All scale bars are 1 cm. Data is co-registered across modalities using fiducial markers on the
source and detector plates.
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Sequential DOT frames at 13.3 s intervals during ICG injection.
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Figure 5.14: Example of ICG kinetics imaging: single coronal slices of SVD reconstructions at 28 time
points of ∆µa due to ICG uptake in a 51 year old post-menopausal woman (BMI 34.4) with an invasive
ductal carcinoma. Field of View for optical reconstruction is shown in Figure 5.13. Images reconstructed
using a hard spatial constraint are shown in Figure 5.17. Kinetics traces of the tumor (magenta) and example
healthy (orange) regions marked with circles are shown at the bottom. Data is co-registered across modalities
using fiducial markers on the source and detector plates. Time stamps and 1 cm scale bars are marked in
white in each frame.

96

Sagittal
Coronal

∆ IGd [%]

200
Tumor
Healthy

100

0
0

5

10
Time [min.]

15

Figure 5.15: Example of Gd kinetics imaging: (top) single coronal slices of Gd subtraction imaging reconstructions at seven time points in a 51 year old post-menopausal woman (BMI 34.4) with an invasive
ductal carcinoma. MR image is cropped to match the Field of View for optical reconstruction as shown in
Figure 5.13. Data is co-registered across modalities using fiducial markers on the source and detector plates.
The tumor (magenta) and an example healthy region (orange) are marked with circles. Optical detectors
(cyan) and sources (red) are marked. The yellow scale bar is 1 cm. (bottom) Gd-DTPA uptake kinetics in
the regions marked with circles.
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5.2.1.4

Discussion and Conclusions: Human ICG Kinetics Imaging

Data presented in Section 5.2.1 demonstrates the capacity of the GenIIm system to successfully image
ICG in human subjects during clinical MR imaging. Sequential imaging allows extraction of ICG pharmacokinetics and therefore spatially registered comparison of contrast agent uptake in each modality. In
Section 5.2.1.3, we demonstrated simultaneous contrast enhanced imaging of a malignant cancer. Note that
the data presented here were reconstructed using a fairly basic linear reconstruction technique (SVD matrix
inversion). This choice of reconstruction technique, along with the inherent low resolution of DOT limits
the utility of these DOT reconstructions. In Section 5.2.2, we utilize the MRI spatial information to model
the tumor as a sphere in otherwise homogeneous tissue and reconstruct ICG uptake in each region

5.2.2

DOT with a priori Segmentation from MRI

5.2.2.1

MR Tissue Segmentation

A significant advantage of multi-modality imaging is the ability to utilize the strengths of one modality to
improve the image quality of the other. Perhaps the best known example of this technique in clinical imaging
is PET-CT: by constraining the PET reconstruction with the high resolution tissue imaging provided by CT,
greatly improved maps of glucose metabolism can be reconstructed (∼1 mm), a far cry from the ∼6-10 mm
resolution in stand-alone PET imaging. Similarly, MRI provides high resolution (∼0.3 mm in plane, ∼3
mm through plane) structural images of soft tissue, while diffuse optics provides hemodynamic functional
information, but is limited to ∼0.5 cm spatial resolution in a typical breast imaging geometry90 .
The MRI data sets collected during this study contained a series of T1 -weighted images at various delay
times, enabling calculation of T1 maps. A simple T1 -threshold was used to separate glandular and fatty
tissue with a reasonable degree of accuracy, producing images such as can be seen in Figure 5.16.
Similar masks are used in Section 5.2.2.2 to form ‘hard priors’ for DOT reconstruction, i.e., reconstructions in which all tissue of a particular type (glandular, adipose, tumor) is assumed to have identical optical

T1 Map

Adipose Segmentation

Glandular Segmentation

Figure 5.16: Example segmentation of breast tissue into fat and glandular regions in a cancer-free breast.
Data was collected at 1.5T; glandular tissue was defined as any regions with T1 >450ms. The region shown
is ∼6 cm medio-lateral (vertical in images) and ∼10 cm superior-inferior (horizontal in images).
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properties.

5.2.2.2

DOT Reconstruction with Geometry Extracted from MR Tissue Segmentation

If we assume that each tissue type defined by MRI has uniform ICG pharmacokinetics, then we can reduce
the DOT inverse problem to calculation of ICG uptake in each tissue type. This transformation reduces
unknowns in the reconstruction from the properties of hundreds or thousands of voxels to changes in the
properties of 2-5 tissue types. Thus, the constrained approach yields a significantly simpler inverse problem
(at the cost of some simplifying assumptions). Figure 5.17 shows an example of such an analysis. Generally
speaking, a T1 image can be used to calculate a glandular/adipose mask. The particular subject shown in
Figure 5.17 however, had effectively no glandular tissue in the optical field of view. Since this subject was
both post-menopausal and obese (BMI=34.4), this lack of glandular tissue is not surprising. (A similarly
fatty breast from a different subject is shown in Figure 5.21.) Gd-DTPA uptake was used to segment out the
tumor (note, in this subject, the tumor was also visible in T1 ).

T1

Gd-DTPA

Mask

Figure 5.17: Segmentation of Adipose and Tumor tissue (no glandular tissue present) using MRI data (T1
and Gd-DTPA uptake). This segmentation was utilized in the reconstruction shown in Figure 5.18. Images
reconstructed without spatial constraint are shown in Figure 5.14. The region of high Gd-difference signal in
the lower left is due to a skin artifact and possibly subject movement between the imaging and baseline scan.
Note the field of view has been shifted slightly compared to the unconstrained images shown in Figure 5.13.
Scale bars are 1 cm.
Figure 5.18 shows a comparison of the ICG and Gd-DTPA uptake in the regions demarcated in Figure 5.17. Both ICG and Gd-DTPA uptake in the tumor are substantially higher than the surrounding tissue,
corroborating the earlier results of Ntziachristos5 . One of the advantages of the DOT technique compared
to current clinical contrast-enhanced MRI protocols is the much higher frame rate: a DOT image in Figure 5.17 was collected every 13.3 s, while the MR images were collected every 94 s. This relatively slow
frame rate can cause difficulties in fitting pharamacokinetic models to the Gd uptake. Recent work on high
speed image acquisition (including that by several of our Hospital of the University of Pennsylvania collaborators on rotating frame methods242 ) may eventually improve this MR frame rate. However, this frame rate
is ultimately a function of contrast agent sensitivity. This and other DOT studies utilize an ∼300-fold lower
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Figure 5.18: Comparison of ICG and Gd-DTPA kinetics, using tissue segmentation (Figure 5.17) as a hard
(0)
spatial prior. DOT data is presented as ∆µa = µa [t]−µa . MRI data is presented as the fractional change in
signal intensity ((I − I0 )/I0 ). Note that the frame time for the DOT images was 13.3 s, while the MRI data
took 94 s to acquire per frame. MR signal intensity is non-linearly related to local Gd-DTPA concentration.

blood concentration of ICG compared to the Gd-DTPA dose used clinically (see Section 3.1.1).
The T1 and Gd-enhanced adipose-glandular-tumor segmentation discussed here is a simple initial application of rigid spatial priors in DOT reconstruction; previous theoretical work (e.g. Brooksby7 ) including
from the University of Pennsylvania188 suggest paths for future integration of spatial information from MR
images with optical data from the GenIII Opt/MR Imaging system described in Chapter 6.

5.3
5.3.1

Lessons from the GenII and GenIIm systems
Tissue Contact

Diffuse optical measurements rely upon a stable physical connection between fiber optics and the tissue
being measured. A key failing of the GenII/GenIIm platform is the difficulty in obtaining good optode-skin
coupling for most subjects. A schematic axial view of the tissue compression plates used in the GenII and
GenIIm systems is shown in Figure 4.5. A similar view, with a to-scale MR image in place of the cartoon
of the breast, is shown in Figure 5.19. This particular subject had a fairly large breast (self reported: C/D
cup), but even in the center of her breast, the second row of sources in the medial plate failed to make skin
contact.
The poor source-detector skin coupling of the GenII Opt/MR platform (e.g. Figure 5.19) prevented
DOT imaging in most of the subjects examined, as there were too few source-detector pairs to reconstruct
an image. Our GenIII platform seeks to correct this difficulty both by placing many more source-detector
pairs against the breast and by allowing optodes to be positioned individually for each subject.
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Figure 5.19: Schematic and axial T1 image showing fiber optic coupling of the GenIIm Opt-MR platform.
The T1 slice is through the center of the breast (nipple is out of the image plane). The second row of sources
is not in contact with the skin even in the center of this fairly large breast (C/D cup as reported by subject).
Note that this is the ‘best contact’ axial plane: both rows of sources and detectors are not in contact ∼3 cm
superiorly and inferiorly of this slice. Sources are denoted by red boxes, detectors by blue boxes, and yellow
lines dashed lines are included to show alignment.

5.3.2

Tissue Shaping

In an attempt to improve optode-skin coupling, we began a pilot study to determine if we could mold
breast tissue against the compression plates (containing the optodes) without degrading the clinical imaging.
Figure 5.20 shows an example of this work, in which a foam block was placed under the nipple, pushing
tissue up and out against the compression plate. In the few subjects we had the opportunity to study, this
scheme improved optode coupling without significant degradation in diagnostic information.

5.3.3

Fiber Placement

A second major failing of the GenII/GenIIm platform is limited flexibility in optode placement: sources
and detectors were each confined to a pair of lines running parallel to the axis of the body (Figure 5.19).
Figure 5.21 shows an egregious example of this problem wherein we had perfect skin-optode coupling, but
the cancer was far away from optode locations.
The GenIII system permits adjustment of the vertical position of fiber optic modules. This flexibility, for
example, would have facilitated imaging of the cancer shown in Figure 5.21.

5.3.4

Lessons applied to the GenIII system

In clinical experiments, we had little flexibility in the spatial placement of optical fibers, especially the
roughly 2.5 cm diameter armored detector fiber bundles (0.5 cm diameter active area). Figure 4.4 (lower
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Right

Axial

Sagittal

Left

Figure 5.20: Example of application of tissue shaping inserts in a single subject, tested with the GenIIm
platform. The left breast had no inserts, while the right breast had a ∼4 cm thick foam block positioned
under the nipple. The foam does not show up in the MR image; it has been schematically shown in yellow.
Note how the right breast has better contact with the compression plates then the left breast. See also Figure
5.19.

Figure 5.21: Example of difficulties with fiber optic placement in the GenII and GenIIm systems. Many
cancers were missed due to the fixed location of the optodes using the GenII/GenIIm platform. The fixed
position of the sources (red dots) and detectors (red circles) precluded imaging this cancer. With the very
largest breasts, the optical fibers have sufficient clearance from the curving magnet bore only in the top row.
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left) shows the available locations for mounting the detector fibers in the lateral compression plate. Note
that the physical supports which hold the detector fibers in position have been removed for this photo. In
addition to limited mounting points, these fiber bundles had a minimum bend radius of ∼15 cm. This
constraint, together with the spatial limitations of the walls of the MRI bore (see Figure 4.1), forced us to
place the detector fibers in the top two rows of holes seen in Figure 4.4. The size of the fibers and the
placement of the RF electronics also limited how close to the chest wall the detector fibers could be placed.
Together, these restrictions resulted in many cancers falling outside the optical field of view (Figure 5.21
shows an MRI image of a particularly dramatic case).
Furthermore, the size of these detector fibers was such that they could not be bundled together and still fit
through the waveguides in the MRI room shielding. The GenII and GenIIm systems were constrained by the
need to protect the photon-counting PMTs, which require shielding even when powered down. Together,
these constraints necessitated complete removal of the detector fibers from both the PMTs and Opt/MRI
platform during the setup/take-down of each experiment. Operators found this GenII instrument to be quite
difficult to prepare and dismantle within the time allotted to us by the clinical team.
Additionally, the individual mounting of the fiber bundles directly on the compression plates made modification of the fiber layout very difficult, as it effected the RF electronics (shown in Figure 4.4). The
GenII/GenIIm platform was constructed primarily of white PVC, which exacerbated light shielding difficulties.

5.4

GenII and GenIIm Results Summary

The GenII and GenIIm systems demonstrated the ability to make multiple DOS measurements of breast tissue simultaneously with MRI. Additionally, we were able to perform DOT imaging with the GenIIm system
in a few subjects, demonstrating simultaneous contrast enhanced DOT and MR imaging. The limitations of
the GenIIm system motivated the construction of the GenIII system, described in Chapter 6.
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Chapter 6

Development of a Modular Hybrid
Diffuse Optical and Magnetic
Resonance Imaging Platform (GenIII)
Simultaneous breast cancer imaging with Magnetic Resonance Imaging (MRI) and Diffuse Optical Tomography (DOT) combines non-invasive and non-ionizing modalities which provide complimentary information
(Section 3.2.2). Briefly, MRI provides high resolution (<0.5 mm) images, but only limited functional information through Gadolinium contrast agents. DOT provides 3D maps of hemodynamics and optical contrast
agent uptake, but at limited spatial resolution (∼6 mm in a 6 cm thick phantom90 ). Thus, combining DOT
and MRI provides several scientifically interesting, and potentially clinically useful, opportunities.
This chapter describes further development of the University of Pennsylvania GenIII Diffuse OpticalMagnetic Resonance Imaging Platform, building off of the GenII and GenIIm instrumentation and the results
described in Chapter 4 and 5. Future studies will validate the clinical utility of DOT through direct comparison of spatially co-registered DOT with MRI, especially in the context of neoadjuvant chemotherapy
monitoring. In the course of these studies, we expect to utilize combined imaging, employing MR imaging
to spatially constrain DOT reconstructions and thus improve DOT resolution and quantification. We have
taken the first step towards these goals by developing a modular diffuse optical imaging system for simultaneous DOT and 3T MRI; the instrument permits optimized optode positioning for each subject and develops
opto-electronics compatibility with future 7T MRI platforms. This system provides the largest in-magnet
DOT spatial data sets yet reported.
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The GenIII system is specifically designed to improve the collection of clinical imaging data by addressing difficulties with the GenII and GenIIm systems discussed in Section 5.4. In designing the GenIII
system, we sought to eliminate or reduce these limitations through the inclusion of adjustable fiber modules,
improved support for the subject’s body, and acquisition of much more spatial optical data. Additionally, we
included an option to utilize the GenIII platform for MRI-guided biopsy, permitting better integration into
the clinical research work flow and thus increased recruitment.

6.1

GenIII Instrumentation

Our experience with the GenII and GenIIm system guided the modular design for fiber mounts in the GenIII
system. We separated the optical mounts from the RF electronics, permitting the fibers to be repositioned or
replaced independently of the electrical components. This design has the additional advantage of permitting
the same optical components to be potentially used in several MRI platforms (e.g. 1.5, 3, and 7T available
at Hospital of the University of Pennsylvania), despite the different MR electronics.
We also increased the number of source and detector positions, thereby increasing the spatial information
content of our data. In order to accomplish this goal, we reduced the TD detector fiber bundles from 5 mm
to 3 mm diameter active area and did not individually armor the fibers (as was done with the GenII and
GenIIm systems). This permitted us to introduce many 1 mm diameter CW detector fibers. The initial pair
of modules constructed to test our designs contain 32 source and 54 detector fiber positions compared with
24 source and 14 detector positions for DOS/DOT in the GenIIm system, in roughly the same spatial area.
Eventually, when the full compliment of fiber optic modules are added to the GenIII system, we will have
64 sources and 256 CW detectors in modules we can position individually for each subject based on known
or imaged tumor locations. Additionally, the GenIII modules will contain optics for DCS measurements (10
sources and 10 detectors in the initial pair of modules). The joint imaging platform is shown with the fiber
optics mounted in Figure 6.1.

6.1.1

GenIII MRI Platform Design and Implementation

The MR components of the GenIII Optical-MR Imaging platform were developed by Dr. Thomas J. Connick, building off his earlier work on the MR platform in the GenII system238 (Section 4.2.2), while adapting
the design for 3T.
This platform contains an 8-coil SENSE (sensitivity encoding) surface coil array (2 lateral and 2 medial
coils on each breast). The medial coils have local preamplifiers; the lateral coils currently use an external
preamplifier box. Preamplifiers will be added to the lateral coils in the near future; we prioritized using
our limited available supply of these specialized and long lead time components on the medial coils as the
105

Figure 6.1: Photos of GenIII Optical-MR Imaging platform. A detector fiber module is mounted on the left
breast lateral compression plate; a source fiber module is mounted on the medial plate (source fiber tips are
visible as white dots on the medial plate in the left image).

Figure 6.2: Several views of the GenIII Optical-MR Imaging platform. (right) Platform without padding or
linens. (left) Platform with minimal padding and linens in place; with the linens in place the weight bearing
elements of the platform are colored white to minimize the possibility of damage to the platform through
excessive load on the mobile compression plates.
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Figure 6.3: Images of the lateral compression plates in the GenIII system. (left) Left lateral plate with a
fiber optic module blank (i.e. before machining for fiber optic mounting) in the center position. (right)
Right lateral plate with a biopsy plate mounted. The cable visible in the bottom of the images connects the
right lateral posterior coil to the external preamplifier box out of the frame to the right. The copper lateral
coils are visible through the clear Plexiglas cover surrounding the biopsy plate.
coupling between these coils is problematic.
Portions of the RF electronics are visible through the clear Plexiglas covers of the lateral plates in
Figure 6.3. A schematic of the space allotted to electronic and optical components is shown in Figure 6.4
and the entire platform in the MRI suite in Figure 6.5. The limited space for electronics created a number of
practical difficulties and considerable effort was expended to maintain the large area of access for the optical
modules.
MR phantom imaging (Figure 6.6) demonstrated that the system has sufficient resolution for clinical
research use by our collaborators Drs. Angela DiMichele and Mark A. Rosen in the ISPY-2 triali .
As mentioned above, the GenIII platform utilizes fiber optic modules, permitting fast and simple repositioning of fibers. These modules also greatly reduce system set-up time in the clinic, a critical concern with
tightly scheduled clinical instruments; designes are shown in Figure 6.7 and Figure 6.8. We have currently
constructed one pair of source and detector modules to fully validate the design; we will construct the others
after we have recruited several human subjects for simultaneous DOT and MRI. These initial modules (photos shown in Figure 6.9 and Figure 6.10) contain 5 TD and 54 CW detector fiber positions and 32 source
i www.ispy2.org
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Figure 6.4: A schematic of the compression plates for the GenIII system. Blue areas are available for the
RF electronics; red areas are cutouts for the placement of optical fiber modules; white areas were reserved
for mechanical support and mounting. Note the upper optical access region, which permits optodes to be
placed a few mm from the chest wall. Dimensions are in mm.

Figure 6.5: Photos of the GenIII Opt/MR platform during a phantom imaging study. The fiber optic modules
were not mounted when these photos were taken.
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Figure 6.6: Example MR Imaging with GenIII platform. (left) Images of copper sulfate phantom and
human forearms, showing the fiducial markers used for image co-registration. (center) A phantom composed
of ground turkey, vegetable shortening (Crisco), and saline (phantom suggested by Dr. Sarah Englander,
based on earlier work on breast tissue quantification243 ) atop a phantom of cooking oil and saline. (right)
Joint Optical/MR phantoms composed of gelatin, Liposyn, and ink, with inclusions containing Gd chelate
(MultiHance) and ICG.

Figure 6.7: Example detector fiber module for the GenIII system. (left, top) Schematic of side view, showing
(blue) optical fiber, mounting plate, and protective cover; bottom view, showing placement of 1 mm (CW)
and 3 mm (TD) fiber optics. (left, bottom) Top view of detector module, showing the layout of fiber optics
the larger, 3 mm, holes are for the TD detectors. The walls of the protective cover (magenta) are made of
1/16th inch PVC; 1/4th inch PVC is used for the end pieces. (right) Photos of fiber optic modules without
protective back cover. The tissue face of this module is shown in Figure 6.9. Dimensions are in mm.

positions, a significant improvement over other reported systems (Table 3.2). Note, the current source module has additional fibers pre-positioned to be utilized for additional CW/TD sources (12) and single mode
fibers for use as DCS detector fibers (12).
In addition to the changes in the fiber optical mounts, we attempted to utilize the information gathered
over the course of our study to improve subject comfort during the exam: not only would this reduce the
strain on our subjects, but comfortable subjects are less likely to move during the exam, improving our data
quality. The most common complaint from our subjects was neck pain due to laying on the right or left side
109

Figure 6.8: Example of GenIII source fiber module. Source fibers were inserted at 20 or 30 degree angles
to reduce the bending radius of the fibers. The walls of the protective cover (blue) are made of 1/16th inch
PVC; 1/4th inch PVC is used for the end pieces. The tissue face of this module is shown in Figure 6.9.
Dimensions are in mm.

Figure 6.9: GenIII source and detector fiber modules, both 3.5x18 cm. The source plate includes thirty two
CW/TD multi-mode source fibers and ten single mode DCS detector fibers; the detector plate holds fifty
four 1 mm CW detector, ten 1 mm DCS source, and five 3 mm TD detector fiber bundles. Schematics of the
detector and source modules are shown in Figure 6.7 and Figure 6.8.

of the head. We addressed this by installing a ‘face-pillow’ from a massage table in the GenIII platform.
The second most common complaint focused on the portion of the subject’s weight which rested on her
sternum. We addressed this by supporting both the shoulders and the abdomen in the updated platform (see
Figure 6.2 and Figure 6.5) and by widening the sternum support from 5 to 5.5 cm.
The GenII platform was constructed of white PVC plastic which permitted considerable light reflection/scattering. Unfortunately, most black plastics utilize carbon black as a pigment; when tested, they all
proved to cause artifacts in MR images. Note, this effect is related to the quantity of plastic used and the
few grams of black Delrin and PVC in our fiber coverings have little effect on the MR signal. We therefore
chose to construct the GenIII system out of gray PVC as a compromise between MR compatibility and stray
light reduction.
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Figure 6.10: GenIII detector modules and compression plates. (left, top) a schematic of 5 detector modules
(A, B, C, D, and a fixed module near the chest wall) mounted in the lateral compression plate. (right, top;
bottom) Photos of a detector module (A in the left, top schematic) mounted in the imaging platform. This
module is also shown in Figure 6.7 and 6.9. A source module is visible in the lower left and upper right
images.

6.1.2

GenIII Opto-Electronics Design and Implementation

The GenIII TD opto-electronics are based on those of the GenIIm system; the critical changes are improved
PMT cooling and the inclusion of shutters to protect the PMTs when fibers are not in direct tissue contact;
David L. Minkoff and Han Y. Ban were instrumental in the construction of the PMT module and design
of the shutter control system. Currently, we have both 830 and 838 nm lasers; we plan to replace the
830 nm with a 905 nm laser to improve quantification of lipid and water concentrations. The GenIII CW
system is significantly different than the GenIIm CW components, using several additional wavelengths and
significantly more spatial detector positions; these improvements are described below.
Figure 6.11 shows a schematic of the current GenIII opto-electronic system. As discussed above, a single
pair of source and detector modules is currently undergoing testing; additional source and detector channels
shown in Figure 6.12 will be added along with additional planned modules. Currently all CW detector
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Figure 6.11: Schematic of GenIII current optical-MRI system. Six pulsed lasers and five steady-state lasers
are multiplexed through a 12x1 wavelength and a 1x32 position switch and coupled through optical fibers
to tissue. 54 CW detector fibers are lens-coupled to an Andor iKon-L CCD camera, permitting ∼0.5s per
source position and wavelength measurements of absorption. 5 TD detector fibers are coupled to photon
counting PMTs and TCSPC electronics.
fibers are lens coupled to a single CCD (Andor, iKon-L; see Figure 6.13) for absorption measurements.
Figure 6.12 also shows a fluorescence imaging system; as additional CW detector fibers become available,
we will utilize a subset of the eventual 256 CW fibers for fluorescence imaging. The fluorescence CCD
(Andor iXon-887 back illuminated) is currently integrated into the system, however, we have not yet begun
collecting fluorescence data. Figure 6.14 shows the opto-electronic rack and components.
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Figure 6.12: Schematic of GenIII complete optical-MRI system. Six pulsed lasers and six steady-state
lasers are multiplexed through a 12x1 wavelength and a 1x64 position switch and coupled through optical
fibers to tissue. 256 CW detector fibers are split between a pair of CCD cameras, permitting simultaneous
measurement of both absorption and scattering. 32 TD detector fibers are coupled to photon counting PMTs
and TCSPC electronics. GenIII has added CW λ = 915 nm and will add TD λ =905nm to those available
in the GenII system to permit stable measurement of H2 O and Lipid.

Figure 6.13: CW detector optics for GenIII system. (left) Diagram of CW Detection fiber bundle mount.
(right) Fiber mount in use, coupling ∼20 of 128 possible fibers to the CCD.
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Figure 6.14: Photos of the mobile opto-electronics system for GenIII. Of special note are the CW CCD
(Andor iKon, visible in upper left of right image), TD Laser Driver (Picoquant Sepia, second row in right
image), Control Computer (containing the Becker and Hickl SPC-134 TCSPC cards), and shock-absorbing
pneumatic wheels.
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6.2
6.2.1

GenIII Results
Testing and Certification

After ∼30 minutes warm up, the CW laser intensity were stable to < 1%; remaining power variations were
normalized using the low power arm of a 97:3 splitter placed between the wavelength and position optical
switch. The position switch exhibited similar stability. The time domain system requires ∼4 hrs. to stabilize,
primarily due to jitter in the laser diode driver oscillator.
DOT image reconstruction requires both forward and inverse calculations (see Section 2.2.8). We used
Finite Element Modeling (FEM) to compute the forward problem, with an optimized mesh created with TetGen (http://tetgen.berlios.de/ ). The inverse problem was solved using the Time-resolved Optical Absorption
and Scattering Tomography (TOAST85, 86 ) package made available by Arridge and collaborators at University College London. We chose to utilize Conjugate Gradient (CG) reconstruction as this permitted us to
reconstruct more voxels (i.g. larger volumes or smaller voxels) at a lower computational cost. However, this
technique is known to effectively provide a low pass spatial filter over heterogeneities (e.g., as in Corlu244 )
reducing the apparent contrast. Future work will include reconstruction with the more computationally
intensive Levenberg-Marquardt (LM) method.
Simultaneous imaging with DOT and MRI also provides the opportunity to utilize the MR data in constraining the DOT reconstruction by setting spatial bounds on tissue types (e.g. so-called hard priors, as
in Carpenter et al.8 ) or by incorporating MRI information into a reconstruction, but not assuming perfect
alignment of contrasts across modalities (e.g. so-called soft priors, as in Intes et al.188 and Guven et al.235 ).
The phantom data presented below was collected using a Siemens TIM Trio 3T clinical MR scanner and
the joint optical/MR imaging platform, using clinical research imaging protocols. We constructed various
phantoms from Liposyn, sodium chloride, various inks, ICG, gelatin, and water. Recipes are described in
Appendix C.
We undertook a set of measurements with sealed liquid phantoms and a suspended balloon target. The
background Liposyn and saline solution had optical properties of µa =0.04 cm−1 and µa =8 cm−1 at 800
nm. ICG was added to the target solution create a 4:1 optical contrast along with ∼0.5 mM MultiHance
(clinical Gd-Chelate contrast agent) to create an MR contrast. A latex balloon (∼8 cc) was filled with the
target solution and suspended partially in the optical field of view. Data was normalized to measurements
performed on the phantom without the target balloon in place; optical reconstructions were performed using
TOAST85, 86 . Figure 6.15 shows preliminary reconstructions from both modalities. Note that the optical
reconstructions in Figure 6.15 do not utilize spatially dependent regularization as this has not yet been
implemented in the current incarnation of TOAST.
We also produced a pair of semi-rigid gelatin phantoms, ∼16x16x6.3 cm, with µa =0.04 cm−1 and µa
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Figure 6.15: GenIII phantom imaging: Slices through the target center in a 3D reconstruction of a multimodality phantom from MR (a,b,c) and DOT (f,g,i) imaging; (d,e,h) show schematics of the phantom geometry. Sources (red diamonds) and Detectors (yellow circles) are marked in all images. All dimensions are in
mm. MRI is 3D T1 -weighted spoiled gradient echo imaging with fat saturation. (a,h,i) are axial, (b,e,f) are
coronal, (c,d,g) are sagittal slices. See text for details.
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Figure 6.16: Example phantom reconstructions from the GenIII system. (left) Phantom Schematic. (center)
3D T1 -weighted spoiled gradient echo imaging with fat saturation; slice through a gelatin-saline phantom
with Gd chelate (0.5 mM MultiHance) in targets. (right) Optical reconstruction using TOAST (see text).
Optical contrast is 4:1; background does not contain any MultiHance MR contrast agent.

=8 cm−1 , at 800 nm. Cylindrical inclusions were cut in one of the phantoms and filled with a gelatin mixture
similar to the background, to which ICG to create a 4:1 optical contrast and ∼0.5 mM MultiHance for MR
contrast had been added. These phantoms were reconstructed utilizing spatially dependent regularization
as described in Section 2.2.8. Gelatin phantoms are convenient for measurement in the MRI suite, but are
vulnerable to air bubbles and are difficult to integrate into dynamic phantoms.
The results presented above demonstrate that the GenIII system can generate DOT images during simultaneous MR data acquisition. Reconstruction and data collection are not optimized however. Future data
sets will have more optode positions, extending over a greater vertical distance (posterior-anterior, currently
∼4 cm), additional spectral data as more laser wavelengths are added, and improved data collection protocols. Future reconstructions well benefit from our expanding spatial regularization techniques, optimized
reconstruction parameters, and improved data pre-processing.
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Figure 6.17: Initial human subject MR imaging with GenIII Opt/MR imaging platform. No optical data
was collected during this MR certification test, but source and detector fiber modules were in place. Source
modules are mounted in the medial 5 cm space; a fiducial marker on the source plate can be seen in this
image. This bilateral MR scan is intended for Gd-Uptake imaging (3D T1 -weighted spoiled gradient echo
imaging with fat saturation- fat produces less signal and is therefore darker).

6.2.2

Initial Human Subject Data

We are currently awaiting recruitment of our first human subject; research has been approved by the University of Pennsylvania Institutional Review Board under protocol 809792. MR only imaging from a healthy
volunteer is shown in Figure 6.17. In addition to the phantom measurements discussed in Section 6.2.1, a
single source-detector pair of the GenIII opto-electronic system has been utilized in the compression studies
discussed in Section 8.4.

6.3

Future Work with the GenIII system

Microvascular blood flow can be measured using Diffuse Correlation Spectroscopy, as discussed in Section 3.1.1. During construction of the GenIII system, we provided for the opportunity to collect DCS data
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Figure 6.18: GenIII system with DCS upgrade. An additional long coherence length laser source (CrystaLaser) is coupled into the breast tissue; single mode fibers collect light from the opposite side. Due to the
space constraints in the Optical/MR platform, the source and detector plates were switched for DCS compared to the DOT measurements as the single-mode DCS detector fibers are better able to fit into the medial
plates than the ∼1 mm DCS source fibers. The APD array (Perkin-Elmer) and multi-channel correlator (correlator.com) have already been interfaced with existing instrumentation for the compression measurements
described in Section 8.4.

simultaneously with MRI with up to 20 sources and 48 detectors when the complete set of optical modules
has been constructed. This large data set, especially utilizing MR images for spatial constraint of reconstruction, is potentially a significant step towards Diffuse Correlation Tomography (DCT). Such optical
reconstructions of tissue blood flow are of especial interest at University of Pennsylvania as our colleagues
have previously shown the feasibility of measuring blood flow in breast tissue using ASL MRI236 (Arterial
Spin Labeling). The modular nature of the GenIII system permits potential adaptation to 7T MRI (available
at Hospital of the University of Pennsylvania Center for Magnetic Resonance and Optical Imaging) where
ASL MRI is expected to have higher SNR. A schematic of this system is shown in Figure 6.18.
The GenIII system will allow acquisition of significantly more DOT spatial data than previously reported systems. This additional information will allow comparison of independent DOT reconstruction to
MRI and enhancement of DOT reconstruction using MRI spatial information. The first allows direct validation of DOT results with clinically established contrast-enhanced MRI; the second permits exploration of
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improvements to sensitivity and specificity through combined data. We will explore both of these avenues.
We have previously developed a computer aided detection algorithm for stand-alone DOT data, sequentially
registered with MRI245 (see Chapter 7). Simultaneous DOT and MRI allows advancement of this work by
providing near perfect co-registration of modalities and by allowing use of both DOT and MRI data in the
algorithm.

6.4

Hints and Pitfalls in Combining DOT and MRI

This section informally summarizes some of the challenges associated with building a diffuse optical imaging system to function in a 3 T MRI in the hopes of easing the paths of future researchers.
Materials Choice
The high magnetic fields in an MRI preclude the use of ferrous materials. During an MR imaging
session, the magnetic field of the gradient coils oscillates at radio frequencies (e.g., hydrogen imaging is
conducted at 63 MHz for 1.5 T and 127 MHz for 3 T magnets). The oscillating magnetic fields will induce
currents in conducting materials placed in the magnet bore. These currents can quickly heat conducting
materials to hazardous levels. Furthermore, conducting materials may form current-carrying loops with
portions of a subject’s body, potentially resulting in burns. In addition to these safety hazards, conducting
materials locally perturb the magnetic field and therefore result in artifacts in the reconstructed images.
Materials one wouldn’t normally consider conducting can still have sufficient conductivity to perturb the
local magnetic field. For example, many black plastics use carbon black as a pigment. Our GenII combined
imaging platform was made out of white plastic. In an attempt to reduce reflection of stray light, I originally
intended to make the GenIII platform out of black plastic (e.g., black Delrin). However, after testing a
wide variety of available plastics, I determined that the quantity of black plastic necessary to construct the
platform in its entirety would cause significant MR image artifacts. These artifacts are local: I could have
chosen to use black plastic to form those portions of the platform well away from the imaging volume,
but did not follow this path. I chose to use gray PVC for the entirety of the platform, including the breast
compression plates. PVC is somewhat troublesome to machine, but utilizes an organic dye and does not
cause image artifacts.
I note that the MR signal from small amounts of black plastic can be quite useful- the ∼0.1 mm thick
black Delrin cladding on my optical fibers makes them visible in MR images.
I utilized nylon screws to secure the sections of the platform. These screws are delicate- one can easily
strip threads or remove the screw head using a hand-held screwdriver. They will also snap, especially if
sheared. This property can provide a ‘mechanical fuse’ or known break-point for some portions of the
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platform which might be subject to high stress. Snapped off nylon screws are generally quite easy to remove
by tapping an appropriately sized straight screwdriver into the screw shaft.
Glues
Certain glues give a significant MR artifact in standard clinical imaging pulse sequences. Moreover, the
signal from some of these glues changes significantly with time. I strongly suggest testing glues in your
particular application prior to use.
Fiducial Markers
Co-registration of DOT and MR images is a critical component of simultaneous imaging. The transformation matrix between coordinate systems must be measured for each exam. I accomplished this task by
rigidly fixing fiducial markers to the fiber optic mounting plates and locating these markers in MR images.
Vitamin E pills are often used clinically, as they can easily be taped onto the surface of the breast. However,
they tend to be large (∼1x0.5 cm), which reduces the accuracy to which they can be located, and are not
suitable for rigid mounting to an optical module. The GenII system utilized ∼2 mm NMR tubes, cut to ∼2
cm long and capped, full of coper sulfate solution. I later made plastic versions of these tubes to increase
durability. Despite sealed caps, the water in the copper sulfate solution evaporated over the course of ∼6
months and needed to be replaced. The most useful commercial fiducials I have found is the multi-modality
markers from ONC Solutions (Acton, MA), which are ∼1 mm in diameter and ∼1 cm long. These metal
‘beads on a string’ can easily be included in one’s mechanical design.
Metal Chips
Small chips of metal can be transfered to your plastic components during machining. This is especially
true if you use a set of files without first giving them a thorough cleaning. Small metal chips from the file
can become embedded in the plastic and produce MR image artifacts. I suggest purchasing a new set of files
and using them solely for plastics.
Fiber Optic Components
The source fibers are based around 10 m flat 48 strand optical cables (Molex Inc.). The proximal ends
are broken out into 48 FC connectors and attach to an optical switch. The distal ends terminate in MPT
male connectors. MPT female connectors then connect ∼1 m break out cables terminated with plastic
and ceramic LC/PC connector ferrules (e.g., Figure 6.8), which are in turn embedded in the gray PVC
fiber modules. The MPT connectors have small metal parts, but we were able to remove the largest spring
without damaging the functionality and the remaining metallic components are both small and embedded
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in larger objects. Additionally, these components are ∼40 cm from the imaging volume. Through testing,
we determined that these small pieces of metal would not in practice cause either safety issues or artifacts
in the MRI. The MPT connectors allow swift disconnection of source modules attached to the cumbersome
10 m fiber optic bundle connection with the opto-electronics. This ability to disconnect the source without
removing the source modules from the optical platform greatly reduces the in-magnet setup/take-down time
of the platform, as the source modules can be pre-positioned and left in place when the imaging platform is
removed from the MR suite.
I chose to utilize standard fiber optic terminators for all of my source fibers, rather than custom ferrules
(e.g., as used in the GenI and GenII systems). This choice allows considerably more flexibility in which
venders undertake to supply these fibers.
The CW detector fibers are 1 mm diameter bundles, 12 m long, terminated on the proximal end with
stainless steel tubing and on the distal end with a fixed 90 degree bend and a thin cladding of black Delrin.
The TD detector fibers are 3 mm diameter bundles, otherwise identical to the CW fibers.
In both source and detector modules strain relief is critically important to reducing breakage at the distal
fiber tips. I find self adhesive silicone tape (red and black examples of which are visible in Figure 6.9) to be
quite helpful in protecting optical fibers under the transition between loose fibers and semi-rigid spiral wrap
used to protect the length of the fiber optic bundles. These spiral wraps are in turn mechanically connected
to the body of the fiber optic modules and therefore prevent mechanical stress from being transmitted to the
fiber-module joint. At the proximal end, the spiral wrap around each fiber optic bundle is connected to the
opto-electronics rack with an elastic cord.
Tools
Beryllium copper (BeCu, copper beryllium, beryllium bronze, or spring copper) tools allow you to safely
adjust your imaging platform in the MR suite.
Certain brands/colors of permanent (‘magic’) markers can cause MR artifacts when used inside imaging
field of view. I suggest testing prior to making marks on a finished part.

6.5

Conclusions

The current GenIII DOT system provides the largest spatial optical data set for simultaneous DOT and
MRI. When the fiber optic module design is validated through human use and additional modules are constructed, it will provide as many source-detector pairs as a number of existing stand alone DOT systems.
Six wavelength TD data will provide bulk optical properties; CW absorption data will permit reconstruction
of endogenous chromophores. CW fluorescence data will permit imaging of both ICG and any additional
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contrast agent which becomes available over the next several years. Simultaneous collection of Diffuse
Correlation Spectroscopy data with MRI may permit development of clinically useful Diffuse Correlation
Tomography protocols.
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Chapter 7

Statistical Approaches for Automated
Tumor Localization: Towards DOT
Computer Aided Detection (CAD)
7.1

Introduction

In this chapter, I will describe my work searching for multi-parameter optically-derived signatures of breast
cancer. I have developed techniques to calculate a probability of malignancy in each voxel (volume element) of a DOT image, as described in a recent publication245 and several conference presentations246–248 .
Specifically, a logistic regression model employing tissue Hbt , StO2 , and µ0s is used to calculate a probability of malignancy in 3D reconstructions of breast tissue in subjects drawn from a clinical study by Choe
et al.31 . This chapter, besides introducing the new ideas, will focus on applications of the approach for
computer-aided detection of malignancies in diffuse optical tomographic images.

7.1.1

Diffuse Optics and Automated Cancer Diagnosis

While current incarnations of multi-wavelength DOT provide three-dimensional (3D) images of several
physiological parameters associated with cancer metabolism and growth, unambiguous 3D maps of healthy
and malignant tissue are sometimes elusive. DOT images beg for interpretation of multi-parameter data at
each spatial point. DOT images also sometimes exhibit significant inter- and intra-subject variation in the
absolute and relative values of these parameters. Together, these factors limit DOT image analysis to skilled
practitioners. In this chapter, we introduce a novel algorithm which makes possible automated identification
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of malignant and healthy tissue; this approach is based on a statistical analysis of diffuse optical data from a
population of known cancers.
The requirement for skilled readers is not unique to optics; most clinical imaging technologies have
similar constraints and various techniques for automated breast cancer detection and diagnosis have been
explored to ameliorate this situation. Computer Aided Detection (CAD) in X-Ray mammography screening,
for example, relies upon high-spatial-resolution 2D intensity projections to automatically identify tumors in
images based on structural features such as spiculation and micro-calcification249–251 .
The formalism presented herein for DOT-CAD employs multi-parameter, multi-voxel, multi-subject
measurements to derive a simple function which transforms DOT images of tissue chromophores and scattering into a ‘probability of malignancy’ tomogram. Importantly, the formalism incorporates both intra-subject
spatial heterogeneity and inter-subject distributions of physiological properties derived from a population of
cancer-containing breasts (i.e., the ‘training set’). We ultimately extract a weighted combination of physiological parameters from the training set to define a ‘Malignancy Parameter’ (M), with the weighting factors
optimized to separate training-set voxels of healthy tissue from those of cancerous tissue. We then examine
the utility of M, using 3D DOT images from additional subjects (i.e., the ‘test set’).

7.1.2

Limitations in Current Diffuse Optical Imaging Analysis

To better appreciate the potential value of DOT-CAD, consider the typical breast cancer analysis scheme
currently employed in the field. First, the lesions in each subject are identified, then tissue is divided into
‘healthy’ and ‘lesion’ regions, and then average optical properties are computed for each region. Finally,
these regionally averaged optical properties and differences thereof are assessed across the population. With
this approach, the spatial information from DOT images is reduced to a few numbers, e.g., one for normal
tissue and one for the lesion. Such an analysis ignores the spatial heterogeneity of cancers252–254 and healthy
tissues116 .
Grand averages of DOT data across multiple studies1 suggest that malignant lesions can be differentiated
from healthy tissue by Hbt . In recent work31 we performed such regional averaging from DOT images, and
we demonstrated that benign and malignant lesions could be separated with a univariate analysis of the ratio
of mean lesion to healthy tissue Hbt , µ0s , and an empirically derived optical index combining Hbt , µ0s , and
StO2 . For example, this work found that the benign and malignant lesions had a statistically significant
different ratio of Hbt region means (e.g.,

<Hbt >Lesion
<Hbt >Healthy ).

Volume element histograms of rHbt (rHbt =

Hbt
<Hbt >Healthy )

contain more information than distribution

means, of course. Histograms of Hbt in two subjects are shown in Figure 7.1. Figure 7.1a shows an optimal
subject wherein the lesion is clearly distinguishable from healthy tissue. Figure 7.1b shows a problematic
subject; here variations in the healthy region (which include possible image reconstruction artifacts) extend
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(a) Optimal Subject

(b) Problematic Subject

rHbt

rHbt

Figure 7.1: (Top row) Slices from 3D tomograms from subjects with breast cancer. Lesions are denoted
by the thick black line. Histogram of rHbt for Healthy (Middle row) and Cancer (Bottom row) Voxels,
Hbt
segmented as shown in top row. Data are normalized as rHbt = hHb
for each subject. This is a typical
ti
H

normalization for DOT analysis, as used in our previous work31 . The left column (a) shows a lesion clearly
separated means and distinct distributions; the right column (b) shows a subject wherein the the healthy rHbt
distribution overlays that of the cancer region. This normalization approach is standard in the ‘typical’ DOT
analysis, and the example is taken from our previous work31 .

into the range of cancer tissue rHbt . The first lesion (Figure 7.1a) can be readily identified with the simple
normalization procedures described above and a cut-off of rHbt = 1.2. The same procedure and cut-off for
case two (Figure 7.1b), however, would miss the cancer completely; furthermore, adjustment of the cut-off
to include the tumor causes incorrect assignment of some healthy regions. These observations suggest that
a more sophisticated analysis using all available subject and spatial information is desirable. Additionally,
simple thresholding in a single optical parameter ignores the potential utility of multi-parameter data and
ignores possible spatially heterogeneous signatures of cancers and healthy tissues.
Thus far, a few groups have applied statistical analysis techniques to multi-parameter optical measurements, including applications to arthritic joints255 , high-risk256 or high mammographic density257, 258 breast
tissue, and to various ‘endoscopic’ measurements or excised tissues259 . The data sets employed thus far,
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however, have limited spatial information and orders of magnitude fewer measurements per subject than,
for example, the breast tomograms utilized in the analysis to be presented herein. A few researchers have
implemented automated image methods with DOT to identify lesions in a particular subject260–262 . This
per-subject analysis, however, neglects information about the common signatures of cancer across a population. Still other researchers (including our lab) have pursued hypothesis-driven multi-parameter optical
metrics with DOS74, 164 and DOT29, 31 . Such metrics are dependent on underlying hypotheses, however, and
are often empirically chosen combinations of equally weighted parameters. Chance et al.75 have explored
two-parameter signatures of breast cancer, graphically identifying malignant lesions, but the separation lines
were manually selected for the specific data set (i.e., the test and training sets were identical).
Thus, previous studies fall into two groups. Some have considered spatial variation in cancers, but
neglected common signatures across a population. Others have considered population signatures, but have
used only regionally averaged measurements. Furthermore, few, if any, have applied statistical optimization
techniques to multi-parameter optical signatures of cancer across a population. By contrast, the methods
we introduce and demonstrate herein utilize data from many voxels in many subjects in order to statistically
optimize a multi-parameter ‘probability of malignancy’.

7.1.3

Existing Statistical Analysis of Breast Cancer DOS/DOT Data

As mentioned above in Section 3.1.1, clinical diffuse optical measurements frequently attempt to separate
one group from another using endogenous contrasts or combinations thereof. In breast cancer studies, these
groups are often malignant tumors from benign lesions or healthy tissue. Several groups have developed
indices which combine two or more of the parameters measured through DOT/DOS to enhance the contrast between malignant lesions and normal tissue. Researchers at the University California at Irvine have
developed and clinically tested a ‘Tissue Optical Index’ (TOI)263 combining Hbt , H2 O, StO2 , and lipid,
and later modified to H2 O, lipid, and Hb74 . Similarly, Choe et al.31 have shown the ability to distinguish
10 benign from 41 malignant lesions (all biopsy-verified) using a CW/FD tomographic device and an ‘Optical Index’ (OI) combining relative values of Hbt , StO2 , and µ0s (for each parameter, the relative value,
rX =

X
<X>Healthy ).

Choe found tumor-to-bulk contrast of ∼1.8 using this OI and the UCI group reported a

tumor contrast of ∼3 using their TOI. (Note, both approaches consider equally weighted linear combinations
of optical parameters or their inverses.)
Kukreti and colleagues264 have developed ‘double differential spectroscopy’ in their search for the signatures of malignant tumors. This technique examines the difference between spectra measured on a lesion,
spectra of healthy tissue measured on the same subject, and a linear combination of known chromophore
spectra. The ‘double differential spectra’ output from their algorithm contains spectral features specific to
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malignancy. Lilge’s group256–258 has developed ‘Transillumination Breast Spectroscopy’ (TIBS) in an attempt to determine the risk of future cancer development in women with high breast density. Both of these
techniques rely upon spectroscopic data at many wavelengths and do not extract chromophore concentrations directly.
An empirical approach to separate lesion types that relies on plotting multi-dimensional data and then
looking for clusters corresponding to lesion types was explored by Chance et al.75 , using manual segmentation in rHbt and rStO2 . Automated cluster analysis schemes permit consideration of more dimensions and
more complicated weighting schemes (e.g., work by Klose255 on optical measurements of rheumatoid arthritis). Wang and colleagues262 utilize a support vector machine analysis of the refractive index, µa , and µ0s
to identify and separate malignant from benign breast lesions, with a sensitivity of ∼82% and a specificity
of ∼92%. Such techniques permit multi-dimensional weighting of parameters. Finally, Song, Pogue, and
colleagues260, 261, 265 have demonstrated some statistical image processing tools to determine the detectibility
of a lesion in a tomographic reconstruction using contrast-to-noise considerations.

7.2
7.2.1

Methods
The Breast Cancer Data Sets

The hand-held techniques described in Section 2.3.2 do not use (or give) spatial information about the
lesion, beyond the probe placement. As cancers are known to be heterogeneous252, 253 in gene expression
and metabolism254 , this approach has obvious limitations. Furthermore, in our discussion of lesion mean
optical properties, we have so far ignored how the lesion was localized and segmented from healthy tissue
in the first place. Tomographic reconstructions for each of several chromophores in 3D present multiparameter signatures of malignant lesions that are generally difficult to fully grasp. Additionally, DOT
reconstructions sometimes have image artifacts, especially when only a single chromophore is visualized
and/or when lesions are near instrument boundaries.
Our data set consists of 3D tomograms of total hemoglobin concentration (Hbt ), blood oxygen saturation
(StO2 ), and reduced scattering coefficient (µ0s ) in 35 biopsy-confirmed cancer-bearing breasts. DOT images
from these subjects were collected with a parallel plate optical imaging system described in previous work31 .
This present data sample is somewhat smaller than that reported by Choe et al.31 (total: 51) as we excluded
subjects with multiple (1) or benign (10) lesions. Additionally, a few subjects with very little healthy tissue
or large reconstruction artifacts in the optical field of view were excluded from both test and training sets
(5). Table 7.1 contains the demographics and clinical diagnosis of the population used in this analysis.
The cancers in this analysis had an average volume of 6.7 ± 5.2 cm3 , corresponding to 841 ± 656 image

voxels. The average size of the entire breast was 374 ± 231 cm3 , corresponding to 4.7 × 104 ± 2.9 × 104
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#

Diagnosis

8
2
2
22
1
35

IDC
DCIS
ILC
IDC & DCIS
DCIS & LCIS
All

Age
[yrs]
44±11
60±4.9
62±3.5
49±10
39±0
49±11

BMI
[kg/m2 ]
27±6.2
29±6.6
22±2
28±7
19±0
27±6.5

Tumor Size
[ cm3 ]
2.9±1.2
0.7±0.28
1.4±0.35
1.8±0.97
5±0
2.1±1.2
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Table 7.1: Demographic breakdown of cancers in this study. IDC: Invasive Ductal Carcinoma; DCIS: Ductal
Carcinoma In Situ; ILC: Invasive Lobular Carcinoma; LCIS: Lobular Carcinoma In Situ; BMI: Body Mass
Index. Numeric data are given as mean ± standard deviation. 16 subjects were pre-menopausal and 19 were
post-menopausal.
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Figure 7.2: Intra-subject data normalization brings inter-subject data distributions close to a normal distribution. The top row shows, for the full population, absolute values of Hbt , StO2 , and µ0s [785 nm]; the
bottom row shows the population distribution of Z-transformed variables after intra-subject normalization;
see Eqn. 7.1 and note that each subject is normalized individually. Each trace represents the healthy region
of one subject. For clarity of presentation, the vertical axis is normalized to the total number of voxels in
each subject. Section 7.5 shows similar plots for Hb and HbO2 .

image voxels (mean ± standard deviation). Note, for each parameter, traditional regional averaging analysis

of this data, as described above, reduces these ∼5 × 104 data points per subject to two numbers (cancer and
healthy region averages). Figure 7.1 shows sample intra-subject spatial heterogeneity of these regions and
Figure 7.2 plots the distribution of Hbt , StO2 , and µ0s [785nm] for the healthy regions of all subjects.
We demonstrate our new statistical analysis method with a leave-one-out cross-validation (e.g. as described by Hastie et al.266 ), in which 34 of our 35 subjects serve as the training set and the remaining subject
provides the test data. Permuting these sets, such that each subject serves as the test set once, provides 35
training/test data combinations and enables an estimation of classification accuracy. Note, Gold-Standard
segmentation of the DOT images into tumor and healthy regions is required for the training set and is required for the test set classification validation (i.e., to assess how well the classifier performed compared to
the gold-standard).
Both training set normalization (described below) and testing of our method require ‘gold standard’
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Figure 7.3: Example of masks applied to segment breast tissue for CAD; a slice through the center of the
tumor is shown. The background matching fluid (blue) is first segmented from the remainder of the tissue
and the chest wall removed from the data set (the chest wall is not shown in this figure). The remaining
data is the breast tissue (cyan). This is further segmented into the tumor region (red). The healthy region
(yellow) is defined as that breast tissue 2 cm away from the lateral sides of the image and from the tumor;
voxels within 1 cm of the source and detector planes were also excluded.

spatial localization of the cancers; a full description of the procedure utilized to identify cancer regions is
given by Choe et al.31 . Briefly, a traditional clinical imaging method, typically MRI, was used to approximately locate each tumor. We then selected nearby regions of high optical contrast as the starting point for a
region-growing algorithm to identify the spatial extent of the tumor. A 2 cm border region about the tumor
(e.g. Figure 7.3) and voxels within 1 cm of the source and detector planes were excluded from the training
data; the remainder of the breast is defined as healthy tissue. We exclude these boundary regions to reduce
the effect of physiological changes near the tumor, errors in tumor positioning, and optode artifacts. In the
training set, we assume perfect segmentation into malignant and healthy tissue. In the test set, gold standard
segmentation is used only to determine the accuracy of our malignancy prediction.

7.2.2

Algorithm to Calculate Probability of Malignancy

The image analysis has two parts: first, we determine the ‘probability of malignancy’ function based on
a population of known cancers. Then, we test the resulting function on another data set. We iterate this
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Figure 7.4: Flow chart of CAD data processing for a single training subject. Segmentation is based on
clinical imaging (e.g. MRI). Note that data is normalized for each subject individually prior to combination
across all members of the training set.

process, exchanging members of the training and test sets to improve the generalizability of our results.
We chose Hbt , StO2 , and µ0s as our fundamental physiological variables. We also tested the combination
of Hb, HbO2 , and µ0s , but little difference was found (see Section 7.5).

7.2.2.1

Intra-Subject Normalization

The first step of this analysis is to normalize the tomographic data across the training sample, as distributions
of optical properties vary significantly between subjects. A schematic of this process is shown in Figure 7.4;
Figure 7.5 provides an overview of the normalization, analysis, and testing protocol.
We carry out this normalization procedure for each physiological parameter in both healthy and cancer
tissue. To illustrate, we consider total hemoglobin concentration, Hbt . Figure 7.2a shows reconstructed Hbt
for all healthy tissue voxels in all subjects. We see that the spread of Hbt values is quite large, complicating
use of such data across the sample. Therefore, for each subject, we compute X = ln [Hbt ], the healthy
tissue mean hXiH , and the healthy tissue standard deviation σXH . Note hXiH and σXH are calculated
individually over the healthy regions in each subject, thereby capturing both inter- and intra-subject tissue
heterogeneity. A similar set of data (i.e., X = ln [Hbt ]) is obtained for malignant tissue in each subject in
the training set. Together, these quantities permit calculation of the ‘Z-Score’ for each physiological variable
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in each voxel of each subject, e.g.,
(s,k)

zHbt d

=

(s,k)
Xd

s

− hX iH
=
s
σXH

h
i
(s,k)
ln Hbt d
− hln [Hbt s ]iH
σ [ln [Hbt s ]]H

.

(7.1)

A schematic of this process for a single subject and optical property is shown in Figure 7.4. Here, the
subscript index, d = H, M , specifies healthy (H) and malignant (M) regions; the superscript index, s = 1 to
(s,d)

Ns , specifies a subject in the training set, and the superscript index, k = 1 to Nv

, specifies a voxel within

the healthy or malignant region in each subject. Note that the Z-Score for both the healthy and malignant
regions depends on the mean and standard deviation of the corresponding tissue property in the healthy
region of the same subject.
After the Z-Score procedure, the distributions of physiological parameters in each voxel across subjects
in the sample are much more similar and well behaved. Figure 7.2b shows this for Hbt in the healthy regions
across 35 subjects. Note that this intra-subject normalization brings the inter-subject voxel chromophore
distribution close to a zero-centered Gaussian distribution, permitting us to more sensibly combine data
across multiple subjects.
A particularly attractive feature of this data normalization is the explicit inclusion in the normalized
variable of the subject-dependent characteristic spatial fluctuations in each parameter via the distribution
width (σXH ). Previous work in the field31, 121, 125, 130, 163, 267–273 accounts for the wide variation in mean
parameter values between subjects, but it ignores the differences in optical parameter distribution widths
found in each subject’s healthy tissue. With the normalization scheme described here, lesion contrast is
scaled to the variation in healthy tissue. Similarly, we compute the Z-score for StO2 and µ0s (data shown in
Figure 7.2).
For the remainder of this chapter, we will be computing and manipulating the normalized (i.e., Z-score)
(s,k)

physiological variables: zHbt d
(s,k)
zµ0s d ,

(s,k)

, zStO2 d

(s,k)

, and zµ0s d

(s,k)

. Results using zHbd

(s,k)

, zHbO2 d

, and

that have not been reported in the literature, are included in Section 7.5.

Since we use identical sized voxels for all subjects, we expect that each tissue type (H, M ) in each sub(s,d)

ject to have a different number of voxels; i.e., Nv

is not constant. In order to avoid weighting the data

(s,d)

unduly towards healthy or malignant tissue, we set Nv

= Nv = 40. Therefore, the same number of vox-

els randomly selected from each region and each subject is used for the next level of our analysis. We chose
Nv = 40 because the smallest tumors in our data set had ∼140 voxels and our analysis scheme depends on
independent measurements from each voxel. With this choice for Nv , the median voxel separation in the 35
tumor regions was 1.2 cm. We therefore do not expect spatial correlations due to finite DOT resolution to
strongly affect the results (i.e., by reducing the independence between voxels).
Drawing Nv = 40 voxels from the tumor and healthy regions in each of 35 subjects provides a set
of 1,400 tumor and 1,400 healthy voxels defined by our gold-standard segmentation. We utilize this set
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a

b

c
d
Figure 7.5: Flow chart of data analysis scheme. (a) A test subject is selected from the population and the
data from this subject is normalized to an empirically chosen healthy tissue region (Section 7.2.3; i.e., the
subject’s Z-scores are determined). (b) Data from the remaining 34 subjects is individually normalized
(Section 7.2.2.1) and a subset of the healthy and malignant region data is extracted. These data subsets
are combined for all training subjects and logistic regression is used to identify the parameter weighting
vector (β) which best separates the two groups of voxels. (c) The probability of malignancy (P [M]) for
the normalized test subject data is calculated using β from the training set. P [M] is then tested against the
clinical imaging based segmentation to calculate the classification rates (see Section 7.3). (d) The average
classification rates are calculated for all test-training set combinations, using a leave-one-out protocol.
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of voxels in our leave-one-out protocol, removing all voxels of the test subject from the total data set so
that the remaining 1,360 voxels from each region serve as the training set for classification. The trained
classification rule is then applied to the test set to predict malignancy. The entire procedure is then repeated
for the other test subjects. Choosing an equal number of voxels from each region improves our estimate of
the accuracy of our classification technique under the leave-one-out cross-validation protocol, which will be
discussed in Section 7.3.

7.2.2.2

Training Set Analysis Procedure

The tomographic data of all subjects in the training set, i.e., data from all chromophores in Nv voxels of
the healthy and malignant regions of each of Ns subjects, are combined into a single matrix. Using a
logistic regression model with the known malignancy status of each voxel as the outcome and the normalized
tomographic data (Z-parameters) as predictors, we fit a weight vector β = [βzHbt , βzStO2 , βzµ0s , β0 ] and
(s,k)

compute the vector Md

, whose elements define a malignancy parameter (a scalar) for each voxel in

each region of each subject. For the logistic regression model, M is the log odds of malignancy.

(s,k)

In forming Md

, we thus account for measurements taken across multiple subjects and measurements

taken across multiple spatial locations in each subject. The right most column of 1’s in the Z-matrix relates
to β0 and introduces an offset that could, in principle, include effects from additional parameters (e.g.,
variations in tissue fat content, age, etc.) not considered in the present analysis; see Pepe274 and Breslow275
for more details on this latter point.
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From M, we compute a probability of malignancy using the function:
h
i
(s,k)
P Md
=

1
1+

(s,k)

e−Md

.

(7.3)

Our goal is to identify a weighting vector β which maximizes the difference in probability between voxels
 h
i
 h
i
(s,k)
(s,k)
in healthy P MH
and malignant P MM
regions in our training set. In performing this
logistic regression, we assume each element of M is independent. β is optimized by minimizing the
difference between P [M] and the gold standard diagnosis, plotted against M; see McCullagh276 for a more
detailed description of logistic regression (optimization was performed with the mnrfit function from the
h
i
h
i
(s,k)
(s,k)
' 0 and P MM
' 1.
Matlab c Statistics Toolbox). This approach results in a β such that P MH
Optimized M and P [M] are shown in Figure 7.6 for typical training and test sets.
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Probability of Malignancy (P [M])
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Figure 7.6: Example of training (34 subjects, top row) and test (1 subject, bottom row) set M and P [M].
Nv = 40 voxels were randomly selected from each region in each subject, as described in Section 7.2.2.1
(i.e. 1360 voxels from each of the training healthy and tumor regions and 40 voxels from the healthy
and tumor regions of the test subject). The malignant regions were defined based on clinical imaging and
malignancy confirmed via biopsy. Left column: Malignancy Parameter (M) for each subject (s), voxel in
(s,k)
(s,k)
training set (k), and diagnosis Md . Right column: Optimized probability of malignancy P [Md ],
as calculated on β derived from the training set. The test subject is also shown in Figure 7.1a; note the
improved separation between the malignant and healthy regions.

7.2.3

Test Subject Normalization

The output from the logistic regression described in Section 7.2.2.2 is the parameter weighting vector, β,
which we then apply to data from an independent test subject (i.e., DOT data from the ‘leftover’ subject).
Such an application derives a predicted ‘probability of malignancy’ for each voxel in the test subject.
Normalization of the test data set is slightly more complicated than that of the training data, as we must
not assume knowledge of the cancer location in the test subject’s breast. We therefore empirically define the
healthy region as those voxels in which both Hbt and µ0s are less than the whole-breast mean plus 2 standard
deviations. This particular choice of cutoff values was determined by the nature of the data distribution:
both malignant regions and artifacts tended to skew towards larger values; Figure 7.7 and 7.8 show several
examples where the upper values are greater than 3 standard deviations from the mean. Note the results
turned out to be only mildly sensitive to the particular choice of ‘healthy’ criterion, as the cancers usually
do not occupy a large fraction of the breast.

136

Figure 7.7: An example of distributions of tissue optical properties in a single subject. The horizontal green
line designates the region designated as ‘healthy’ for test subject Z-score normalization. The solid red line
designates the mean, the heavy dashed lines the first standard deviation from the mean, and the light dashed
lines the second standard deviation from the mean.

Figure 7.8: A second example of distributions of tissue optical properties in a single subject. The horizontal
green line designates the region designated as ‘healthy’ for test subject Z-score normalization. The solid red
line designates the mean, the heavy dashed lines the first standard deviation from the mean, and the light
dashed lines the second standard deviation from the mean.
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7.3

Identification of Malignant Regions in Diffuse Optical Tomograms

Figure 7.9 shows P vs. M for two subjects; example slices through the center of the cancers for the same
subjects are shown for relative optical properties, M, and P [M] in Figure 7.10. A probability cut-off
is readily applied to the data (i.e. a horizontal line in Figure 7.9) in order to provide a concrete criterion
to create spatial masks of regions that are highly suspicious for malignancy (Figure 7.10). One can then
compare these masks to the gold standard malignant and healthy regions for each test subject.
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Figure 7.9: Example Probability of Malignancy (P [M]) calculated for two test subjects. The function
P [M] (blue line) is derived from the training set, as described in Section 7.2.2.2. This function is then
applied to the remaining test subject in each case; using the gold standard segmentation described in Section
7.2.1, voxels are labeled as healthy (green crosses) or malignant (red diamonds). Image slices from the same
subjects are shown in Figure 7.10. For clarity, only every hundredth voxel is plotted. (a) Typical invasive
cancer that shows very good separation between healthy and malignant regions. (b) Case Study: In situ
lesion; this lesion is not as well separated from the background healthy tissue. P [M] for this in situ lesion
is more heterogeneous, with a lower average than the invasive lesion and more overlap between malignant
and healthy tissue.
To quantify the quality of spatial maps of M, such as those shown in Figure 7.10, we examine the
distributions of M and P [M] for Nv = 40 voxels in gold standard healthy and malignant regions across
the entire set of test subjects; for this task we use the same randomly selected voxels as described in Section
7.2.2.1. Figure 7.11a shows a histogram of M drawn from test subject healthy and malignant regions in
each iteration of the leave-one-out protocol; Figure 7.11b is a box plot of the P [M] distributions. Notice
that the voxels from the tumor region are distributed narrowly about P [M] ∼ 1, but the distribution has a
small tail of outliers. Similarly, the healthy region voxels are concentrated near P [M] ∼ 0.1, but the central

quartiles of the distribution extend from ∼0.01 to ∼0.2 and the 4th quartile extends to ∼0.6, with outliers up
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to ∼1. This wide distribution of values in the healthy region can also be seen in Figure 7.9; this distribution
carries over into the probability of malignancy, as shown in Figure 7.12.
We next impose a probability of malignancy cut-off, Pcut : voxels with probability above Pcut are predicted to be malignant, those below Pcut are predicted to be healthy. Finally, we compare this prediction to
the gold-standard diagnosis. For each value of Pcut , some test subject voxels are malignant and correctly
predicted to be malignant (true positive, TP); some test subject voxels are malignant, but incorrectly predicted to be healthy (false negative, FN); some test subject voxels are healthy, but incorrectly predicted to be
malignant (false positive, FP); and some test subject voxels are healthy and correctly predicted to be healthy
(true negative, TN).
These quantities can be expressed as rates by dividing each of these classifications by the total number of
voxels in the healthy or malignant regions. We can thus calculate true and false positive rates (True Positive
Rate= T P/(T P + F N ), False Positive Rate= F P/(T N + F P )) and true and false negative rates (True
Negative Rate= T N/(T N + F P ), True Positive Rate= F N/(F N + T P )) functions of Pcut . The Receiver
Operator Characteristic (ROC) curve plots TPR against FPR; ROC curves are shown in Figure 7.13. Note,
these quantities are often referred to as sensitivity (TPR) and specificity (1-FPR). Rates are averaged over
35 permutations of our training/test subjects. Average TPR, FPR, FNR, and TNR across all test subjects for
several values of Pcut are tabulated in the insets of Figure 7.13.
For the purposes of cancer detection, FNR is critical, as this determines how many cancers are missed.
With the sample used in this analysis, a probability cut-off of Pcut = 0.95 yields FNR of 11%. At the same
cut off, 89% of the voxels predicted to be cancerous are correctly classified (TPR) and 6% of the voxels in
the healthy region are incorrectly predicted to be cancerous (FPR) while the remaining 94% of the healthy
region voxels are correctly labeled. The cut-offs can be tuned to suit particular clinical needs; see insets to
Figure 7.13 for classification rates corresponding to other values of Pcut .
Since the Z-Score is in ‘units’ of standard deviation, we can directly compare the magnitudes of derived
coefficients β to determine the relative importance of each parameter for identifying malignancy. Averaging
over 35 combinations of 34 subjects in the training set gives (mean ± standard deviation), hβzHbt i =
0.83 ± 0.06, hβzStO2 i = −0.19 ± 0.04, and βzµ0s = 2.68 ± 0.12, suggesting that of the three optical
parameters, difference in µ0s offers the strongest evidence of malignancy. It should be noted that the weights

are coefficients derived from a logistic regression model and can be interpreted precisely in terms of changes
in the log odds of malignancy. For example, a one unit change in zµ0s implies an estimated 2.7 fold increase
in the log odds of malignancy for that voxel, or equivalently a 14.9 fold increase in the odds of malignancy.
However, when β is calculated across all 35 subjects, we find the significance (‘p-value’) of each element
in β to be < 0.005, suggesting that all three parameters should be retained in the model.
The analysis described above assumes that each 2x2x2 mm voxel in the 3D tomogram is independent of
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Invasive

In Situ

(a) Hbt [µM]

(b) StO2 [%]

(c) µ0s [ cm−1 ]

(d) P [M]

(e) Mask

Figure 7.10: Slices from 3D images of subjects in Figure 7.9, showing total hemoglobin concentration (a,
Hbt ), blood oxygen saturation (b, StO2 ), reduced scattering coefficient (c, µ0s ), Probability of Malignancy
(d, P [M]), and a binary cancer mask (e) using a cut-off of P [M] = 0.95. The in situ lesion in the left
column provides an interesting case study, with the P [M] falling between the malignant lesions and the
healthy regions.
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Figure 7.11: (a) Histogram of M for the healthy and tumor regions of 35 test subjects, used to generate
the box plot on the right. (b) Box plot of probability of malignancy (P [M]) of Nv = 40 voxels from
all test subjects (red lines mark median values, 50th percentile; boxes denote interquartile range, 25-75th
percentiles; and lines indicate outer 2 quartiles, ∼1st -99th percentiles; and crosses mark outliers). See the
insets to Figure 7.13 for a tabulation of mean classification rates at several values of Pcut . Median P [M]=
0.998 for tumor voxels and 0.019 for healthy voxels. Both of these plots show 1400 healthy and tumor
voxels.
the others. However, it is known that the spatial point spread function of light transport in tissue limits DOT
spatial resolution to ∼0.5-1 cm90, 277–279 in breast tissue at biological contrast levels. Furthermore, there are
likely to be physiological correlations between different spatial locations in the breast (e.g. all voxels drawn
from adipose tissue). To this end, we explored a simple model of correlated voxels, in which we identified
‘clumps’ of the same size as the tumor in each breast and then compared the average value of the probability
of malignancy in these clumps to that of the tumors. Interestingly, we found the distribution of P [M] to
have fewer outliers than Figure 7.11 and values in the confusion matrix to be within ∼±5% of the per-voxel
values presented in the insets of Figure 7.13 at Pcut = 0.95.
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Figure 7.12: Box plot of calculated probability of malignancy for each tumor voxel in all 35 malignant cancers, separated by diagnosis. Note the significant intra- and inter- subject variation in the output probability.
IDC: Invasive Ductal Carcinoma. DCIS: Ductal Carcinoma In Situ. ILC: Invasive Lobular Carcinoma.
LCIS: Lobular Carcinoma In Situ.
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Figure 7.13: (a) Average ROC curve for all healthy and tumor voxels for each of 35 test subjects. (a, inset)
Classification Rates calculated using all voxels from cancerous and healthy tissue, as defined by our gold
standard. Black diamonds mark TPR[Pcut ] vs. FPR[Pcut ] values for Pcut given by the numeric labels.
(b) Rates calculated only using the Nv = 40 training voxels from each region in each subject. (b, inset)
Average Classification Rates calculated over Nv voxels. (insets) Mean True Positive Rates (TPR), False
Positive Rates (FPR), False Negative Rates (FNR), and True Negative Rates (TNR) as a function of Pcut .
Healthy voxels are defined as P [M] ≤ Pcut . Note, a low FNR is desirable for cancer diagnosis. Rates are
averaged over all test subjects used in the leave-one-out protocol and given as percentages.
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7.4

Application to Benign Lesions

As shown above, DOT-CAD can separate healthy from malignant tissue. In our limited data set, we lacked
sufficient subjects to apply the analysis described above to benign lesions. However, we could examine
the results when we applied the weighting vectors calculated from the 35 malignant subjects described
above to 8 benign subjects in our data base. These subjects did not have a biopsy prior to the DOT exam.
Demographics are broken down in Table 7.2; we note that with only 8 benign lesions and 4 different types of
lesions, all conclusions will be tentative. However, we consider it promising that the calculated probability
of malignancy for benign lesions is intermediate between malignant and healthy lesions (Figure 7.14). This
trend becomes more obvious when we average the probability over the tumor and similarly sized healthy
regions in each woman, as shown in Figure 7.15.
The range of voxel and regionally averaged probability of malignancy (Figure 7.16) inside individual
and between types of benign lesions suggests that the binary (health/malignant) classifier used in this study
is less than ideal.
The results shown in Figure 7.15 suggested we may be able to utilize the formalism developed above
to produce maps of cancerous, suspicious, and healthy regions. An example of such a plot is shown in
Figure 7.17, wherein we have preserved the definition of malignant tissue as those voxels with P [M] ≥
0.95. ‘Suspicious’ tissue is defined as 0.5 ≤ P [M] < 0.95 and healthy tissue as P [M] < 0.5.
Note that the in situ lesion shown in Figure 7.17 is identified as suspicious and that a cutoff of P [M] ≥
0.5 would identify all of the malignant lesions shown in Figure 7.15 as ‘suspicious’ or ‘malignant’ and
the majority of benign lesions as ‘suspicious’. The relatively simple binary (tumor/healthy) classification
scheme used to generate the probability maps would identify all but one of the benign lesions shown in
Figure 7.14 as ‘suspicious’. We hope to improve this identification with improved classifiers in future work,
in particular by implementing a trinary classification scheme (tumor/benign/healthy) on a larger data set.
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Figure 7.14: Comparison of voxel calculated probability of malignancy for cancerous, benign, and healthy
regions, using weighting coefficients calculated for healthy/malignant voxels as described in the text. Note
that the healthy and cancerous voxels from subjects with malignant lesions are the same as shown in Figure 7.11. Red lines mark median values, 50th percentile; boxes denote interquartile range, 25-75th percentiles; and lines indicate outer 2 quartiles, ∼1st -99th percentiles; and crosses mark outliers.

#

Diagnosis

1
4
1
2
8

LCIS
Fibroadenoma
Fibrocystic
Cyst
All

Age
[yrs]
57
34±12
47
43, 53
42±12.3

BMI
[kg/m2 ]
30.9
23.8±3.7
36.7
25, 21.6
26.2±7.6

Tumor Size
[ cm3 ]
1.8
1.7±1.2
NA
0.4, 0.8
2.1±1.4

Table 7.2: Demographic breakdown of cancers in this study. LCIS: Lobular Carcinoma In Situ; BMI: Body
Mass Index. Numeric data are given as mean ± standard deviation. 4 subjects were pre-menopausal and 4
were post-menopausal.
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Example Regional Isosurfaces

Box Plot of Regional P [M]
Comparison of Voxel Probability of Malignancy
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Figure 7.15: Regionally averaged comparison of probability of malignancy between cancerous, benign, and
healthy regions. Weighting vectors were calculated for the malignant and healthy voxels only, using the
leave-one-out protocol described above; benign lesions were weighted with the weighting vector calculated
for all 35 malignant tumors. (left) Example segmentation of a malignant tumor (red), along with 3 nonoverlapping regions of healthy tissue with equal volume (blue). Note, the healthy region volume is set to
match the tumor volume for each subject individually. (right) Regionally averaged probability of malignancy (P [M]) over malignant and benign lesions, compared to three healthy regions of the same volume
in the healthy region of each subject’s breast. Red lines mark median values, 50th percentile; boxes denote interquartile range, 25-75th percentiles; and lines indicate outer 2 quartiles, ∼1st -99th percentiles; and
crosses mark outliers.
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Figure 7.16: Distribution of probability of malignancy by type of benign lesion. LCIS: Lobular Carcinoma
In Situ. FA: Fibroadenoma. FC: Fibrocystic disease. Red lines mark median values, 50th percentile; boxes
denote interquartile range, 25-75th percentiles; and lines indicate outer 2 quartiles, ∼1st -99th percentiles;
and crosses mark outliers.
Invasive

In Situ

P [M]

Mask
Figure 7.17: Examples of a three level mask of Probability of Malignancy segmenting healthy (P [M] <
0.5), suspicious (0.5 ≤ P [M] < 0.95), and malignant (0.95 ≤ P [M]) regions. These are the same
subjects as shown in Figure 7.10.
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7.5

Statistical Analysis with Alternate Optical Data

This section includes results obtained by applying the analysis described in the preceding sections to HbO2 ,
Hb, and µ0s , instead of Hbt , StO2 , and µ0s . Each figure is referenced to the corresponding figure with its
description in the analysis described above. This analysis produced overall similar results to that using Hbt ,
StO2 , and µ0s , although the regionally averaged results shown in Figure 7.22 show more, but less extreme,
outliers. Similarly, the voxel level analysis shown in Figure 7.19 has a slightly (0.012 vs. 0.019) lower value
for M of healthy voxels, but more outliers than Figure 7.11.
Hb, HbO2 , and µ0s data is shown in Figure 7.18, along with the corresponding Z-Score normalized
parameters. As with the parameters shown in Figure 7.2, the intra-subject normalization decreases the intersubject variability in parameter distributions.
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Figure 7.18: Intra-subject data normalization brings inter-subject data distributions close to a normal distribution. The top row shows, for the full population, absolute values of HbO2 , Hb, and µ0s [785 nm]; the
bottom row shows the population distribution of Z-transformed variables after intra-subject normalization;
see Eqn. 7.1 and note that each subject is normalized individually. Each trace represents the healthy region
of one subject. For clarity of presentation, the vertical axis is normalized to the total number of voxels in
each subject.
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Figure 7.19: (left) Histogram of M for the healthy and tumor regions of 35 test subjects, used to generate
the box plot on the right. (right) Box plot of probability of malignancy (P [M]) of Nv = 40 voxels from
all test subjects (bold lines mark median values, boxes denote interquartile range, dashed lines indicate
outer 2 quartiles, and squares mark outliers). Median P [M]= 0.998 for tumor voxels and 0.012 for healthy
voxels. Both of these plots show 1400 healthy and tumor voxels. Analysis using Hbt , StO2 , and µ0s is shown
in Figure 7.11. Red lines mark median values, 50th percentile; boxes denote interquartile range, 25-75th
percentiles; and lines indicate outer 2 quartiles, ∼1st -99th percentiles; and crosses mark outliers.
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Figure 7.20: Box plot of calculated probability of malignancy for each tumor voxel in all 35 malignant cancers, separated by diagnosis. Note the significant intra- and inter- subject variation in the output probability.
IDC: Invasive Ductal Carcinoma. DCIS: Ductal Carcinoma in situ. ILC: Invasive Lobular Carcinoma. Analysis using Hbt , StO2 , and µ0s is shown in Figure 7.12. Red lines mark median values, 50th percentile; boxes
denote interquartile range, 25-75th percentiles; and lines indicate outer 2 quartiles, ∼1st -99th percentiles;
and crosses mark outliers.
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Figure 7.21: Distribution of probability of malignancy by type of benign lesion. LCIS: Lobular Carcinoma In Situ. FA: Fibroadenoma. FC: Fibrocystic disease. Analysis using Hbt , StO2 , and µ0s is shown
in Figure 7.14. Red lines mark median values, 50th percentile; boxes denote interquartile range, 25-75th
percentiles; and lines indicate outer 2 quartiles, ∼1st -99th percentiles; and crosses mark outliers.
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Figure 7.22: Regionally averaged comparison of probability of malignancy between cancerous, benign,
and healthy regions. Weighting vectors were calculated for the malignant and healthy voxels only, using the leave-one-out protocol described above; benign lesions were weighted with the weighting vector
calculated for all 35 malignant tumors. (left) Example segmentation of a malignant tumor, along with 3
non-overlapping regions of healthy tissue with equal volume. Note, the healthy region volume is set to
match the tumor volume for each subject individually. (right) Regionally averaged probability of malignancy (P [M]) over malignant and benign lesions, compared to three healthy regions of the same volume in
the healthy region of each subject’s breast. Analysis using Hbt , StO2 , and µ0s is shown in Figure 7.22; the
magenta boxes marked in this figure are the same as those in Figure 7.22. Red lines mark median values,
50th percentile; boxes denote interquartile range, 25-75th percentiles; and lines indicate outer 2 quartiles,
∼1st -99th percentiles; and crosses mark outliers.
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Figure 7.23: (a) Average ROC curve for all healthy and tumor voxels for each of 35 test subjects using Hb,
HbO2 , and µ0s as inputs to the classification algorithm. (a, inset) Classification Rates calculated using all
voxels from cancerous and healthy tissue, as defined by our gold standard. Black diamonds mark TPR[Pcut ]
vs. FPR[Pcut ] values for Pcut given by the numeric labels. (b) Rates calculated only using the Nv = 40
training voxels from each region in each subject. (b, inset) Average Classification Rates calculated over Nv
voxels. Results using Hbt , StO2 , and µ0s are given in Figure 7.13.

7.6

Applications of Statistical Approach in Pilot Study of Chemotherapy Monitoring

Neoadjuvant chemotherapy is an important clinical technique to reduce tumor burden prior to excision for
women with locally advanced breast cancer. An especially important aspect of neoadjuvant chemotherapy
is the opportunity to image the primary tumor during therapy, using changes in the primary tumor as a proxy
for effect on potential micro-metastases280, 281 . A critical question in any clinical therapy choice is how
effective it is for a particular subject; initial results in small pilot studies72, 115, 138 suggest diffuse optics may
be a useful technique for early detection of therapeutic impacts on tissue metabolism, through hemodynamic
contrasts.
The data presented here are a single subject pilot study, not a complete analysis of the effectiveness of
DOT-CAD in chemotherapy treatment monitoring. The example subject shown here withdrew from our
study after 2 DOT imaging sequences; furthermore, clinical imaging data was collected at different time
points than DOT, and no MR imaging was performed. This subject 47 year old post-menopausal subject
with a BMI of 22 began chemotherapy with a large mass (4x4x4.5 cm in heterogeneously dense tissue
in mammograms; 3 cm in ultrasound), identified as invasive ductal carcinoma using core biopsy. DOT
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imaging was performed prior to the first round of chemotherapy (9 days after core biopsy) (adriamycin
doxorubicin and cytoxan cyclophosphamide; AC) and, again, after the third round. After the completion of
chemotherapy, X-Ray and ultrasound imaging showed the primary tumor significantly smaller (Table 7.3)
and the core biopsy diagnosis was confirmed by resection.
We utilized the same form of analysis described in Section 7.2, but replaced the population of subjects
with cancer in the training set with the initial DOT image and all time points as the test set. As this calculation
is performed on the same subject, we are interested primarily in changes, not the absolute value of the
calculated probability of malignancy. The steps for this analysis are enumerated below.
1 Use clinical imaging to segment the pre-chemotherapy DOT images into healthy and cancerous regions for the training data.
2 Normalize the training data using the Z-score (Equation 7.1).
3 Extract a subset of the healthy and malignant data and perform logistic regression (Section 7.2.2),
providing a weighting vector β.
4 Normalize the post-chemotherapy DOT images (Section 7.2.3).
5 Apply β to the training and test data to produce a set of spatial probability of malignancy maps for
each time point (P [M, r, t]).
6 Apply a cutoff to each map to define a tumor volume, compare tumor volumes as a function of time.
Note that the pre-chemotherapy data set is used both as the training set and as the baseline for comparison
of later time points. This is a point of concern, but the current analysis uses 40-100 data voxels from the
entire 3D tomogram of the pre-chemotherapy time point (many thousands of voxels). These data will not
be entirely independent measurements, but are certainly not identical. Similar concerns are discussed in
Section 7.3.
As shown in Figure 7.25, the change in the ‘high probability’ (as calculated using logistic regression)
volume is reduced during the course of chemotherapy, as is the tumor volume in the clinical imaging modalities (Table 7.3). Note that we do not expect direct correspondence between structural (e.g. X-Ray and
Ultrasound) imaging and DOT, as DOT is much more sensitive to hemodynamic rather than structural information. However, we find these pilot results, of significant volume change in the DOT-CAD calculated
tumor volume considerably in advance of the structural imaging modalities, to be indicative of the potential
utility of the approach in cancer therapy.
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Figure 7.24: Slices of 3D probability of malignancy map, thresholded at P [M] > 0.85 at pre- (top) and
after 3 chemotherapy treatments (bottom) time points. Pre-chemotherapy measurement are used as a training
set.

Probability Cutoff: 0.85
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Figure 7.25: Change in volume of high Probability of Malignancy (>85%) calculated from DOT-CAD,
using the pre-chemotherapy measurement as a training set, showing chemotherapy measurements. Red
lines indicate chemotherapy treatments; blue diamonds indicate calculated ‘high probability of malignancy’
volume derived from DOT measurements described in the text.

Modality
Ultrasound
X-Ray
DOT-CAD

Percentage
Volume Change
-85%
-50%
-57%

Week
15
15
5

Table 7.3: Comparison of change in tumor volume determined by DOT-CAD and clinical imaging modalities. DOT-CAD volume is calculated as those voxels with probability of malignancy (> 85%), using the
pre-chemotherapy measurement as a training set.
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7.7

Discussion: Utility of CAD in DOT of Breast Cancer

The work described in this chapter demonstrates the potential for population-based statistical image processing of diffuse optical data. We have utilized logistic regression of three optically measured physiological
parameters (Hbt , StO2 , and µ0s ) and a leave-one-out paradigm for 35 subjects to classify malignant/healthy
tissue with an average true positive rate (TPR) of 89% and false positive rate (FPR) of 11%.
In Section 7.3, we noted

βzµ0s

> |hβzHbt i| > |hβzStO2 i|, and therefore zµ0s is the most important

parameter for identification of malignancy, followed by zHbt . The value of βzµ0s and βzHbt differed little
between training sets. hβzStO2 i, on the other hand, was both smaller than the other coefficients and had a
much larger variation between subjects (∼20% vs. ∼5%). StO2 is thus less important for differentiation of
malignant regions in this data set, an observation consistent with our earlier results31 .
Interestingly, for the small number (3, see Table 7.1) of in situ cancers contained in our sample, we
have noted a lower value of the malignancy parameter, M, than for the more numerous invasive cancers
(see Figure 7.9 for an example). Initial results also suggest that this type of data analysis may be useful for
suppression of image artifacts, but we have not yet systematically studied the issue.
This preliminary study has several limitations and areas of potential concern, which are described and
addressed in the remainder of this section.
The most significant limitation of this study is the small sample size. The small total number of subjects
led us to select a ‘leave-one-out’ protocol to test the utility of the classification scheme. Future work with
larger samples will use ‘leave-Q-out’, for Q > 1, a better approach to probing the generalizability of the
method.
A more subtle issue that deserves further exploration was our assumption that each voxel used in the
training is independent. As we discussed at the end of Section 7.3, we expect spatial correlations from both
biological sources and reconstruction artifacts from DOT mammography. The logistic regression classification scheme assumes independent measurements; future work will utilize more sophisticated classifiers
to take advantage of the biological correlation (e.g., between voxels from glandular tissue) and minimize
the effects of correlation arising from DOT (e.g., resolution limits). Use of correlated measurements in the
training set will result in underestimation of the variance in β; however, our classifier does not use this
variance: we only apply the point estimate of β, which is unbiased even when the data are correlated, to the
test set. Therefore, the classification rates remain valid, even through we did not explicitly take into account
potential correlation between adjacent voxels. Roughly, correlation between our data points will narrow the
distribution of values in β, but will not effect hβi. However, this correlation in our data set is of concern for
any future classifier we adopt, including those which utilize variation in β or similar metrics.
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We also explored possible effects of DOT resolution on this analysis technique by eliminating the smallest tumors from our data set. The smallest tumor included in the sample has a total volume of 1.1 cm3
(139 voxels). The median separation between the Nv = 40 randomly chosen voxels is 0.85 cm with an
interquartile range (IQR) of 0.71 cm; this separation is within the expected ∼0.5-1 cm resolution of the optical reconstruction technique. For comparison, in the same subject, the median separation in the Nv = 40
healthy tissue voxels was 4.5 cm and the IQR 3.5 cm. We then repeated the leave-one-out protocol described
above on a sample of the 31 subjects with tumor volume greater than 2 cm3 (250 voxels). We found the
classification rates at Pcut = 0.95 changed very little (i.e. ∼1%). Furthermore, β remained consistent,
within our calculated error. We also tested the possibility of over-weighting small tumors through correlated
measurements by extracting a fixed percentage (10%) of the total tumor voxels from each subject and using
10% of the total tumor voxels, up to a maximum of 40. These shifts in the training set selection changed the
classification rates at Pcut = 0.95 by only ∼2%. Alternately, we could select voxels from a sparse grid in
the tissue regions to enforce a consistent or minimal voxel separation.
To test the effects of our random voxel selection, we repeated our analysis on the data sample five times,
randomly selecting new training voxels with each iteration. The standard deviation of β extracted from the
entire training set was σβ0 = 2%, σβzµ0 = 6%, σβzHbt = 11%, and σβzStO2 = 29%. Recall, βzStO2 had
s

the smallest magnitude and most variation between different training sets (∼20%).
Another potential source of error is the imperfect tissue segmentation we relied upon as the gold standard
for assignment of each voxel as healthy or cancerous. This segmentation relies upon both non-concurrent
clinical imaging (e.g. MRI) to locate the tumor and a region growing algorithm on each subject’s optical
tomogram to define the tumor boundaries, therefore potentially introducing discrepancies in the tissue segmentation. We excluded a 2 cm thick boundary region about each tumor from the corresponding healthy
region to reduce effects of errors in spatial localization of the tumor boundary on the training healthy tissue
data.
Although the analysis includes more spatial data than typically used, most of the data was still discarded,
i.e. Nv = 40  4.5 × 104 voxels drawn from the healthy region in each subject. We chose this limit for
data selection in order to weight tumor and healthy regions equally and take only ∼30% of voxels from the
smallest tumors. This choice permits a more intuitive interpretation of P [M] and improves quantification of
classification accuracy. We are currently exploring other weighting schemes which permit use of all or most
of the healthy tissue voxels, for example, by course graining the DOT healthy region to utilize larger voxels,
thus averaging over small local variations. Additionally, no healthy subjects or benign lesions were included
in the analysis presented in Section 7.3; inclusion would raise false positive rates, as the relative optical
properties of some benign tumors overlapped those of cancers in our previous work31 and the calculated
probabilities of malignancy with this binary classifier for some of the benign data presented in Section 7.4
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are similar to malignant lesions.
Logistic regression is a fairly simple binary classification scheme, which permits use of both continuous and classification variables. The analysis presented here did not include other classification variables
(menopausal status, age, etc.), as our total sample is fairly small and classification based purely on optical
data was sufficient to discriminate malignant from healthy tissue. For the same reason, we did not attempt
to separate cancer types; we will apply such analysis to larger samples in future work. More sophisticated
classification techniques, for example, could include more than two output categories (e.g. image artifact,
malignant, benign, and healthy regions); again, sufficiently large data sets will permit us to differentiate
between types of benign and malignant lesions.

7.8

Future Work: Expansions of Statistical Techniques to other Data
sets and Applications

Arguably, the most interesting near-term project is to pursue the results of our chemotherapy tracking pilot
study using the GenIII Optical/MR Imaging system described in Section 6. The first application of this work
will be in conjunction with our collaborators’ work on the ACRIN I-SPY 2 trial, measuring multiple time
points on a single subject. This study will allow us to track the temporal evolution of our probability of
malignancy metric during chemotherapy. Further, as we accumulate subjects in this chemotherapy tracking
study, we will utilize the precisely co-registered concurrent DOT and MRI images of pre-chemotherapy time
points to enhance and expand our statistical analysis data base. The precision co-registration of these data
will improve our training set segmentation and therefore improve the quality of the classifier.
A second important arena for progress concerns potential of the method in the context of non-tomographic
(’hand-held’) data, such as that collected by Dr. Bruce Tromberg’s group at University of California Irvine74 .
These studies are less demanding on subject compliance and thus frequently provide data sets with more
subjects than tomographic studies, albeit with much less spatial information. Tromberg’s group in particular
utilizes a combination of optical properties (the Tissue Optical Index, TOI) to identify and track cancers.
The method described in this chapter extracts a maximally effective malignancy index for a particular instrument/data set combination. We plan to test the generalizability of these indices across both instrumentation
and different patient pools, with the goal of producing a general optical index of cancer.
Finally, future work will implement classification approaches such as support vector machines or neural
networks that have demonstrated predictive capability in other applications, as in Klose255 .
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7.9

Conclusion

This work introduced a new multi-subject, multi-voxel, multi-parameter statistical analysis of diffuse optical
data and demonstrated its capability to identify and localize malignant tissue. This relatively simple statistical classification approach allows us to reproduce most of the results described by Choe et al.31 without
a lengthy analysis of each subject by a skilled researcher. This technique is therefore a significant step in
the automated analysis of DOT images, producing an average true positive rate (TPR) of 89% and false
positive rate (FPR) of 11%. Initial studies on a few benign lesions suggest the potential of increased specificity in DOT diagnosis. Intriguing results from pilot study on chemotherapy tracking has encouraged us to
undertake further study and comparison with established modalities.
Together, these results are a starting point for development of diffuse optical tomography CAD algorithms. Such multi-parameter optical signatures of cancer may enhance the utility of an adjunct or standalone optical device in the clinical imaging environment.
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Chapter 8

Blood Flow in Human Breast during
Mammogram-like Compression
Tumor growth is often associated with angiogenesis, i.e., the formation of additional blood vessels in and
near the tumor. Tumor blood vessels tend to be less well formed than those in healthy tissue, with leaky and
chaotic networks282 (see Figure 8.1). Thus, it is generally believed that blood vessels in tumors, and thus
tumor blood flow, will respond differently to external perturbations than will healthy tissue. Furthermore,
we expect these responses to change during the course of anti-angiogenic chemotherapy. The hemodynamics of breast tissue, therefore, potentially offer unique contrasts which have been the subject of many
investigations129, 165–167, 212, 283 . The primary focus of the present chapter is to characterize blood flow responses of healthy breast tissue to compression. We use a mammogram-like compression, similar to that
performed in clinical mammograms and current work on contrast-enhanced X-Ray tomosynthesis. The data
presented here provide the first direct measurements of microvascular blood flow changes during compression, providing insight into healthy breast tissue response. Additionally, this data may provide guidance on
contrast agent injection during X-Ray tomosynthesis.
X-Ray mammography is the standard of care for breast cancer screening in the United States284 and
around the world285, 286 . During this procedure, the breast is placed between two parallel plates and pressure
applied. Typically, the breast is compressed to ∼5.5±1.5 cm (e.g. Klein287 ). Radiographs are collected
at several compression angles and these planar images are interpreted by a radiologist. Recent work in
digital X-Ray Tomosynthesis (few-angle computed tomography), which often images the compressed breast
before and after injection of a contrast agent288, 289 , has brought forth yet another reason for understanding
blood flow in breast tissue during compression. Depending on the scale of local changes in blood flow and
volume, compression may significantly reduce cancer contrast; anecdotal reports suggest that increasing
158

Healthy

Cancerous

Figure 8.1: Cartoon of blood vessel growth (angiogenesis) in cancer compared with the normal hierarchical
structure of blood vessels in healthy tissue. Note the blind ends and tortuous pathways in the cancerous
tissue. From the Angiogenesis Foundation www.angio.org/.

breast compression prior to MR-guided biopsy can significantly reduce Gd-DTPA contrast compared to
images of uncompressed tissue. As discussed in Section 2.2.7, Diffuse Correlation Spectroscopy (DCS)
permits direct measurement of microvascular blood flow.
In DOT, several research groups utilize ‘parallel-plate’ breast imaging geometry in an axial31, 88, 130, 212, 218 ,
medio-lateral5 , or adjustable96, 97, 132, 220, 290, 291 orientation. In practice, this involves placing breast tissue under mild compression between two parallel plates; however, the effects of this compression are not generally
considered in the analysis of the DOT results, despite various researchers’ observations showing compression effects on the optical and physiological properties of breast tissue129, 165–167, 212, 218, 283, 292, 293 .
We have utilized our DCS instrumentation to measure blood flow in breast tissue under pressure perturbation. These measurements offer the first direct optical measurement of relative blood flow (rBF) under
compression. In addition, we measured concentrations of HbO2 and Hb by DOS. Our results show significant changes in Hbt and rBF. In a pilot study of 15 healthy subjects, we observed average changes of 47%
in Hbt , 3% in StO2 , and 65% in rBF (Section 8.3.2) in response to a step increase in applied pressure to the
breast.
We note also that these results143–145, 233 demonstrate the first transmission measurements of microvascular blood flow all the way through a human breast and therefore represent an important step towards Diffuse
Correlation Breast Tomography (DCT). Volumetric imaging of microvascular blood flow with non-invasive,
non-ionizing DCT is of potential interest to clinicians and researchers in diverse fields (e.g., neurology,
cancer therapy response, and diabetes management). Clinical researchers at University of Pennsylvania are
already applying regional measurements of rBF to brain hemodynamics and metabolism294 , stroke and brain
injury monitoring 141, 294–296 , muscle function monitoring70, 142 , cancer therapy72 , and breast tumor detection
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and characterization51 .

8.1

Compression induced changes in blood flow, concentration, and
saturation in the human breast

As discussed elsewhere in Section 3.2.1 the anatomical properties of the human breast (e.g. high fat and
water, but low hemoglobin content and therefore low optical absorption in the NIR) permit relatively simple
DOT or DOS measurements. Compression provides a perturbation to optical measurements of breast tissue,
permitting differential analysis of metabolism (through StO2 ) and study of vascular reactivity (through Hbt
and blood flow).
We measured these effects in a series of pilot studies, as described in Section 8.2, Section 8.3, and
Section 8.4. Uniquely, our optical compression study utilized Diffuse Correlation Spectroscopy (DCS) to
directly measure blood flow.
Blood flow variation under compression has not been well characterized in a healthy population: the
work described below is a pilot study performing this characterization.i
As described in Section 3.1.1, Diffuse Correlation Spectroscopy (DCS) measures fluctuations in light
intensity collected after transmission through turbid media. The blood flow indices extracted are dependent on the product of the number and speed of moving scattering bodies; a schematic is shown in Figure 2.13. Briefly, the larger the speed and number of moving scatterers, the faster the detected light field
phase changes, and the more quickly the light field temporal autocorrelation function decays. DCS flow
parameters are derived from the temporal decay rate of the diffuse light field/intensity autocorrelation function.

8.1.1

Optical Measurements of Breast Tissue Under Compression

Previous work on compression perturbation in the diffuse optics community129, 165–167, 212, 218, 283, 292, 293 has
focused mostly on absorption data (i.e. ∆µa [λ ]). These measurements directly measure ∆Hbt and ∆StO2
due to compression, but they require modeling and physiological assumptions to extract blood flow166, 283, 292 .
Diffuse correlation spectroscopy51, 57, 73 (DCS), on the other hand, permits direct measurement of blood flow.
External compression of the malleable breast can force out blood, reducing Hbt , and even restrict blood
flow into the breast; several groups145, 165–167 are currently working on optical measurements of externally
applied compression. Additionally, both DOBIii and ViOptix167 are developing commercial devices using
i Human subject work described below was performed under University of Pennsylvania IRB protocols 803468, 700394, and
806403.
ii ComfortScan c http://dobiglobal.com/dobisys1.html, now available from www.xinaomdt.com/en/.
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pressure modulation to affect diffuse optical signals.
Results from these studies are not entirely consistent (e.g., StO2 were observed to vary with pressure
and stay approximately consistent in studies at MGH166 and Dartmouth165 , respectively). Discrepancies
may be partially due to the test geometry (seated vs. prone), compression type (plate vs. ring), or simply
the small population in each of the studies. Current diffuse optical compression studies are summarized
in Table 8.1.1. The systems for measurement of the effects of breast compression presented herein are
unique in combining transmission DCS with DOS and also for using an absolute TD-DOS measurement
of baseline optical properties. Thus, accurate measurements of blood flow are combined with the more
typically measured ∆Hbt and ∆StO2 .
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Hand-held

Ring

Seated
Seated
Seated

Penn Version 2

Penn Version 3
TD/DCS

TD/DCS/FD

TD/DCS

FD

Seated

Penn Version 1

MGH166, 212, 283

FD
CW

Prone

Dartmouth165, 293

CW

Data Type

Standing

Seated

ViOptix167

DOBI & Universite
Paris Descartés

Subject
Position

Institution

∼60

∼180

∼150

30

60

∼30

12

Duration
[s]

∼120 N ∼190 kPa

<100 N

∼1.3 kPa

54 N

0.67 and 1.3 kPa

2 kPa

7.6 kPa

Peak Pressure
or Load

See Section 8.4.

See Section 8.3.

See Section 8.2.

{Hbt , µ0s , Sat} ∝ 1/P

Two-step serial compression.
produced AUC=0.81134 .

Dynamic model

{Hbt }∝ 1/P ; small changes in scattering, StO2 ,
and H2 O; strong BMI effect

∆Hbt ∼10-20% ∝ 1/P

Results

Table 8.1: Existing work on pressure perturbation of optical signals in the breast using hand-held probes, pressure changes in the pleural cavity (Valsalva
maneuver), a variable-diameter ring, and mammogram-like parallel compression plates. Optical Absorption Measurements: CW- Continuous Wave, FDFrequency Domain, and TD- Time Domain. Optical blood flow measurements: DCS- Diffuse Correlation Spectroscopy. Note, MGH measured total load
on the breast, not pressure at the skin and DOBI used a flexible membrane to support and apply pressure equally to the breast. See Table 8.2 for details on
the Penn systems.

Parallel Plates

8.2

Version 1: Pilot Study of Transmission Diffuse Correlation Spectroscopy to Measure Blood Flow During Breast Compression

8.2.1

Concept of DCS-TRS Compression Measurements

Initial experiments with a 6 cm epoxy resin slab phantom (µa ∼0.05 cm−1 , µ0s ∼10 cm−1 at 780 nm) and
transmission measurements with hand-held fibers on a human volunteer, showed that the instrumentation had
sufficient SNR for transmission DCS measurements in the human breast. This transmission DCS demonstration was an important finding that led us to the present work. Our design concept focused on permitting
easy placement of the sensors and optodes directly against the skin in almost arbitrary positions using a
mammograph-like compression scheme. During the course of our study, we developed three versions of the
system. Features of these different versions are summarized in Table 8.2.

Sources
Wavelengths
Detectors
Pressure Sensors
Total Force Gauge
0(0)
(0)
Baseline µa and µs
Continuous ∆µa
Continuous Absolute µa and µ0s
Number of Subjects
Section

Version 1
Pilot
2
6
2
1
No
Yes
No
No
2
8.2

Version 2
Preliminary
2
6 TD, 3 FD
2
4
No
Yes
Yes
No
15
8.3

Version 3
Clinical
1
6 TD
1∗
26
Yes
Yes
Yes
Yes
5
8.4

Table 8.2: Comparison of systems developed for optical measurements under mammographic compression
at the University of Pennsylvania. ∗ Version 3 uses a bundle of 8 DCS detectors at each spatial positions,
providing four times the signal to noise ratio; Version 3 allows for up to 2 sources and detectors, but initial
data was taken with only one source and detector.

8.2.2

Version 1: TRS-DCS Combined Instrument

The DOS instrumentation for this study was the GenIIm TD system described in Section 4, with the 9 m
x 5 mm detector fiber bundles replaced by 3 m x 3 mm bundles. Additionally, we utilized 2 channels in a
modular eight channel DCS system developed in our lab and previously used for hand-held breast cancer
studies51, 73 . This system consists of an eight channel, multi-τ correlator (correlator.com), eight photoncounting APD’s (Perkin-Elmer), and a pair of long coherence length lasers (CrystaLaser); the modular
system is shown in Figure 8.2.
The compression platform is based off a woodworking viseiii . The centers of the cast iron plates were
iii Pony

27090, Adjustable Clamp Company, Chicago, http://www.adjustableclamp.com/
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1 mm
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Figure 8.2: Modular DCS system: (top) photograph and (bottom) schematic, as described in the text. Photographs courtesy of Dr. Erin Buckley.

cut out and replaced with clear acrylic plates ∼0.70” thick. These acrylic plates were drilled and tapped for
9/16”-12 bolts, cut to ∼0.710”, in a quasi close packed pattern; a schematic is shown in Figure 8.3, along
with a photograph of a balloon phantom in the device. (Phantoms for the compression study are described
further in Appendix C.2.) Several bolts were in turn used to create fiber and pressure sensor holders; these
bolt-adapters can be inserted into the grid, then optodes secured into the bolt-adapters using nylon set screws.
Subjects were seated on a rolling lab chair and secured to the lab bench with a seat-belt; pillows and
other padding were placed such that the subject’s arms were fully supported.
The edges on the sides and toward the subject were cut into a radius and all holes counter-sunk to prevent
scratching subjects. The platform was mounted on a laboratory bench such that the plates were horizontal
with the fixed plate underneath. Sources and detectors were mounted in adapters inserted into the top and
bottom plates, respectively. Additionally, a pressure sensor was placed in a similar adapter in the top plate.
This sensor consisted of a ‘button load cell’ (Honeywell) held in a bolt-adapter (similar to the fiber optics)
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Figure 8.3: (Left) Compression plates Version 1, with balloon phantom and source fibers (green) mounted;
detector fibers are hidden underneath the balloon phantom. (Right) Schematic of positioning a pair of optical
fibers in compression plates for Version 1 and Version 2; as described in Section 8.5 below, Version 3 utilized
a bundle of 8 DCS detector fibers and 26 pressure sensors. During all studies, the optodes were placed in
the line of positions closest to the chest wall.

coupled to the tissue using an aluminum piston. Measurements of skin pressure proved problematic. Briefly,
versions 1 and 2 of our compression system had significant issues with skin-sensor coupling and therefore
sensor reliability. For example, as shown in Figure 8.9 for Subject 80228.1, the sensor did not record an
increase in pressure during the second and third compression periods. Our phantom measurements suggest
these difficulties may result from the piston becoming jammed in its track due to shear force. During data
collection with version 2, we shifted to a significantly more reliable set of sensors (Tactilus R Free Form
Sensors (Sensor Products Inc., Madison NJ). These flat resistive sensors enabled direct mounting on the
compression plates and eliminated the coupling piston.

8.2.3

Version 1: Human Subjects Experimental Procedure

After explaining the procedure to the subject and obtaining informed consent, the subject was seated in a
rolling chair and the height adjusted such that the inferior side of her breast was level with the top of the
lower compression plate. The compression device was fully opened and the subject’s breast placed upon the
lower plate, centered on the optodes and pressure sensors. The upper compression plate was lowered until
it was in light contact with the breast and all optodes were firmly in contact.
The experimental time-line for Version 1 of our compression system was dictated by our equipment
limitations. The TD system used in this study lacked shutters in front of the PMTs, and therefore we were
required to physically remove the TD detector fibers from their PMTs prior to collecting DCS data. Further,
the DCS laser source was so much more powerful then the TD sources that even switching off the TD PMTs
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Figure 8.4: Time-line for compression study, Version 1. DCS measurements are collected continuously,
except during TD-DOS data collection (red bars in schematic). DCS measurements are shown in Figure 8.6
and TD measurements in Figure 8.5.

during DCS measurements resulted in a significantly higher noise level in subsequent TD measurements.
This restriction on rapid switching between TD-DOS and DCS measurements dictated our experimental
protocol: long data collection intervals with each instrument and therefore, rather discontinuous data acquisition. We chose to alternate between TD and DCS measurements at each of several compression levels.
The long integration time (∼10 s) required to obtain a reasonable SNR with the DCS system led us to
restrict the DCS measurements to the static compression times in our protocol, while the TD system (∼3 s
integration) was used before, during, and after the periods in which we changed compression. This protocol
is shown graphically in Figure 8.4; results for one subject are shown in Figure 8.5.

8.2.4

Version 1: Pilot Study Results

Our initial studies were performed on two healthy pre-menopausal female volunteers. Data from one of
the volunteers was not useful: this subject had B-cup breasts and the compression instrument was unable
to properly interface with her tissue. The second volunteer had D-cup breasts and fit into the compression
instrument well; all results in this pilot study are from this 26 year old subject (BMI 21.5). Based on the
results of our Version 1 pilot study, we biased our recruitment to women with C-cup or larger breasts in
subsequent research. See Table 8.3 for a breakdown of demographics for subjects studied with Version 2 of
the system.
TD measurements provided absolute values of µa and µ0s for each compression step at 6 wavelengths
(690, 750, 780, 808, 830, and 838 nm; see TD description in Section 4.3.2). Hbt , StO2 , [Lipid], [H2 O],
and µ0s [λ ] are computed from µa [λ]; A and b are computed from µ0s [λ] (see Section 3.1.1). Changes
166

1.2

1.15
1.1
1.05
1
0.95
5.2

2

5

4.8

5.5

5.2

5

4.8

5.5

5.2

5.06

1.1
rFat

rSat

1
0.8
5.2

5.06

1.1
1

1
0.9

0.9
5.2

∆ Scatter Prefactor

5

4.8

5.5

∆ StO2

5.2

5.06

5.2

5

4.8

5.5

∆ Lipid

5.2

5.06

∆ Scatter Power ∆ Scatter Prefactor

∆ H2 O
rH O

rHbt

∆ Hbt

1.2
1
5.2

5

4.8

5.5

5.2

5.06

5

4.8

5.5

5.2

5.06

1.1
1
0.9
5.2

∆ Scatter Power

Figure 8.5: TD measurements of chromophore changes during compression of human breast tissue. Horizontal axis is the separation between compression plates in cm. See Figure 8.6 for the corresponding
measurements of rBF. Data points correspond to red lines in Figure 8.6. The scatter power (b) and scatter
prefactor (A) parameterize µ0s =Aλ −b in the NIR range140 (see Eqn. 3.5).
in these quantities from the baseline are given in Figure 8.5. Here, we observe ∼10% change in each
parameter during 0.4 cm (7.5%) change in plate separation. Blood flow changed much more dramatically:
Figure 8.6 shows a roughly 60% change in blood flow from baseline during the ∼10% change in plate
separation. Additionally, we observe a ∼60% reactive hyperemia upon releasing the compression, consistent
with published reports of DCS measurements of blood flow in human muscle142 .
In summary, this study demonstrated that we could obtain DCS signal in transmission through more
than 5 cm of breast tissue. Furthermore, the results from this pilot study suggest that blood flow can change
dramatically under mammogram-like compression.
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Figure 8.6: Relative Blood Flow (rBF) measurements in a 1 subject pilot study of transverse TD-DOS and
DCS in the human breast. Blue dots are individual measurements; the average blood flow in each window is
marked in green. Red lines indicated breaks where we paused DCS data collection and took TD-DOS data
during the actual compression/release of the tissue. (Time line runs only during DCS measurements.) Black
numbers above each window indicate the separation between compression plates. Note: a change in plate
separation of 0.4 cm led to ∼60% ∆rBF.

8.3

Version 2: Continuous DOS and DCS Measurements of Serial
Breast Compression

The results from the Version 1 instrument discussed in Section 8.2 encouraged us to continue our transmission blood flow measurements of breast tissue. Our pilot study, however, failed to tightly integrate the
optical instrumentation for continuous measurements. As a result, the DCS measurements were almost
continuous, but the TD-DOS measurements were collected in narrow time windows ∼3 minutes apart. We
therefore chose to add an additional instrument for our follow up study. Instead of stopping DCS collection
and manually shifting fibers to collect absorption and scattering (Hbt , StO2 , Lipid, H2 O, and µ0s ) data, as
with the Version 1 system, the Version 2 system used the TD instrument to establish absolute measurements
of baseline optical properties, but then monitored differential changes continuously with a FD-DOS/DCS
instrument.
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Figure 8.7: Time line for Version II instrumentation for continuous measurement of optical properties during
mammographic compression. See Figure 8.8 for an example of Hbt , StO2 , rBF, and pressure versus time.

8.3.1

Version 2: Experimental Protocol

During this study, we chose to utilize repeated compression-relaxation cycles (Figure 8.7) rather than a single
compression. X-Ray mammograms are typically performed with several compressions, each in a different
plane. Our study consisted of a TD-DOS baseline measurement, then dynamic FD-DOS/DCS measurements
of three cycles of compression and relaxation (each lasting three minutes), and finally another static TDDOS measurement. The baseline was taken at ‘light compression’, similar to that typically used in parallel
plate DOT imaging. We note that these data were not collected from uncompressed breasts, but rather at a
compression level where the breast tissue was in good contact with the optodes and a minimal acceptable
SNR was obtained with DCS. (We attempted to address this potential confounding factor in our research in
our Version 3 instrumentation; see Section 8.4.) Maximum compression levels were determined by subject
comfort and compliance. Measurements of relaxed tissue were performed at the same plate separation as
the baseline measurements.

8.3.2

Version 2: Results from Preliminary Study of 15 Subjects

The TD-DOS+FD-DOS/DCS instrument permits collection of both an absolute baseline and reasonably high
temporal resolution (3-10s) data continuously during serial compression. Additionally, pressure sensors now
permit monitoring of applied pressure at several points on the skin. We have determined that these pressure
measurements were only useful for relative pressure monitoring, as calibration of the sensors used in Version
2 proved unstable; the Version 3 instrument replaced both the sensors and the read-in electronics to resolve
this issue. Example data (pressure, Hbt , StO2 , and rBF) collected with this instrument are shown in Figure
8.8 and Figure 8.9.
The values of Hbt and StO2 for the subject shown in Figure 8.8 return to baseline very quickly after each
compression. Note the small change in StO2 compared to Hbt ; this was a common observation across our
population, although there was some scatter (see Figure 8.9 for individual time-traces and Figure 8.11 for
population averaged results). Blood flow changed dramatically in this subject, to roughly 15% of baseline,
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Figure 8.8: Example data from a single subject during breast compression. (Top) Pressure readout. Blue
shading indicates a baseline or ‘released’ state; magenta indicates compression. (Center) Hbt and StO2 .
(Bottom) The green bars show mean±standard deviation of the blue dots in each time window. The first
window (∼0-3 minutes) was used as a baseline. See text for details.

and it didn’t recover significantly during the compression period. However, blood flow in some subjects
did show significant recovery during the compression period (e.g. subject 80304.1 in Figure 8.9). DCS
(0)

0(0)

data was analyzed using µa and µs

(from TD-DOS) and ∆µa [t] (from FD-DOS). However, we were not

able to measure changes in scattering as a function of time. The increase in blood flow following the first
compression is known as reactive hyperemia. Data from additional subjects are shown in Figure 8.9.
Our results demonstrated a hysteresis effect in the response of some subjects, indicating sequential compressions could not, in general, be combined. In other words, changes in Hbt , flow, and surface pressure
were inconsistent across repetitions. Figure 8.8 shows this inconsistent pressure response, but consistent
Hbt and rBF responses, to compression in a single subject. We observed a reduction in tissue surface pressure, both between compressions and during each compression period (e.g. Figures 8.8, 8.9, and 8.10) We
suspect these changes are due to tissue remodeling in response to compression.
Although the pressure calibration in the Version 2 system was inconsistent, we could monitor relative
pressure changes reasonably well. Recall that the Version 2 protocol calls for step compression: once the
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Figure 8.9: Example data from breast tissue in six subjects during mammogram-like compression. (Top)
Pressure readout. Blue shading indicates a baseline or ‘released’ state; magenta indicates compression.
(Center) Hbt and StO2 . (Bottom) The green bars show mean±standard deviation of the blue dots in each
time window. The first window (∼0-3 minutes) was used as a baseline. The pressure readout for Subject
80228.1 displayed the lack of reliability for the ‘piston ’ pressure meter discussed in the text. Subject
80304.2 exhibited very noisy DOS data, but much higher SNR DCS data; this was possibly due to poor
coupling between the DOS optodes and skin, as typically DOS SNR is much greater than DCS SNR.
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Compressed

Compressed

Figure 8.10: Pressure readings during the first of three 3 minute long compressions for subjects 80304.2
and 80326.1. Note the significant difference in the shape of the response. Blue shading indicates baseline
period; magenta indicates compressed period. See more examples in Figure 8.9.

compressed period started, the plate separation is kept constant, but the load on the breast is permitted to
vary. Figure 8.10 shows a comparison between a subject who maintained ∼60% skin pressure throughout
the 3 minute compression period and a subject whose skin pressure fell off by ∼85%. This significant
change in response to load may be due to tissue remodeling.
The results of our preliminary study of 15 subjects suggest relatively mild compression can induce significant changes in Hbt (∼47%) and rBF (∼65%), but that StO2 is minimally effected. Due to instrumentation
limitations, µ0s was only measured with the TD-DOS system before and after the series of compressions.
Attempts to reduce the large degree of scatter observed in this data (∼30% in Hbt and rBF) by separating
our subject population into demographic groups (e.g pre- and post-menopausal) were not fruitful (data not
shown), probably due to the small size of our population. The demographic breakdown of our study is given
in Table 8.3.
Bra Sizes
<Chest Size> 36.1±4.4 in.
Cup
#
B
2
C
5
D
4
DD
3
DDD
1
Plate Separation
<d>
5±1 cm

Demographic Information
< Age >
38±13
yrs
< BM I > 28.3±6.3 m/kg2
Menopausal
Pre: 11
Post: 4

Table 8.3: Demographic data for 15 subjects in Version 2 compression study, as described in Section
8.3.2.(left) Average values across 15 subjects for preliminary study of compression effects on DOS and
DCS data . Numeric values are given as mean ± standard deviation. (right) Breast sizes and compression
plate separation. < d > is the average starting plate separation.
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Data taken from the change in optical properties between baseline and the first compression were found
to be most reliable; this data is presented in Figure 8.11. In this analysis, we chose to use the fraction of
change in plate separation as a proxy for load/pressure on the breast; this choice probably contributed to
some of the scatter shown in Figure 8.11. Results from simultaneous measurement of the change in plate
separation over the baseline plate separation (∆d/d), pressure, and load with our Version 3 compression
system are discussed in Section 8.4.3.
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Figure 8.11: Scatter plot of changes in Hbt , StO2 , and rBF in breast during compression from the Version 2
system. Compression measurements are expressed as percentage change in plate separation from the ‘lightly
compressed’ baseline described in text and denoted by superscript 0 (X 0 ). Compression measurements
are taken from the first of 3 compressions and designated by superscript 1 (X 1 ). Data from 15 subjects,
with 2 measurements per subject are shown. (a) Percentage change in total hemoglobin concentration:
0
1
t
. (b) Percentage change in blood oxygen saturation: ∆StO2 = StO20 − StO21 . (c)
∆Hbt = 1 − HbtHb−Hb
0
t
1

rBF
Percentage change in relative blood flow: ∆rBF = 1 − rBF
0 . (d) Table summarizing results from Section
8.3.2; data is presented as mean ± standard
deviation
of
the
fractional
change in each parameter divided by
D
E
∆X/X
the fractional change in plate separation
.
∆d/d

The observed reduction in compression-induced blood flow change may be important for future studies
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of contrast agents injected under compression, as in X-ray tomosynthesis. For example, a protocol could include 3 ‘sham’ compressions prior to the imaging and contrast agent injection compression. The distribution
of blood flow responses to each compression is quite wide (Figure 8.11). This heterogeneity of response to
compression suggests the potential use of the blood flow monitoring technique described above to optimize
therapy or even contrast agent injection for individual subjects. However, we note that our study described
above is limited to 15 subjects.

8.4

Version 3: Time Domain Diffuse Optical and Diffuse Correlation
Spectroscopy of Stepped Breast Compression

In collaboration with our colleagues Dr. Andrew Maidment and Dr. Predrag Bakiciv , we designed an improved study to more directly simulate hemodynamics during mammography. In particular, we shifted our
compression metric from the fractional change in plate separation to total load applied, as in clinical systems. Additionally, we attempted to make a more accurate measurement of total hemodynamic change
during mammographic compression by using a minimal level of compression for our baseline measurements. This reduction in baseline compression was possible due to the increased SNR in the Version 3
DCS. Our experimental timing was also shifted: instead of compressing one breast three times as in Section 8.3, we instead focused on bilateral compression at roughly one half and the full recommended load for
mammography (60 and 120 N); the study protocol is described in Section 8.4.2.

8.4.1

Version 3: Instrumentation for TD-DCS Hemodynamic Measurements

Version 3 of the compression study took advantage of the inclusion of PMT shutters in the GenIII Opt/MRI
system (Section 6.1.2) to integrate six wavelength TD-DOS measurements of absolute optical properties
and DCS measurements51, 73 of microvascular blood flow at ∼5s temporal resolution. Additionally, we
obtained a bundle of eight single mode optical fibers for our DCS measurements. Each fiber was connected
to an individual APD and an independent autocorrelation function measured. Averaging across these fibers
increased our SNR and permitted measurements at large plate separations.
A key limitation in the results presented so far in this chapter is our use of fractional change in plate

separation ∆d
as our measure of compression, i.e., as a surrogate for pressure inside the breast tissue.
d
We do not expect the pressure on the surface of the breast to be consistent: ‘external’ geometry (e.g., the
breast is wider nearer the chest wall), connective tissues (e.g., the rib cage is essentially rigid and attached
to the breast), and ‘internal’ geometry (e.g. glandular verses adipose tissue, internal breast ligaments) all
iv Hospital

of the University of Pennsylvania Department of Radiology, Physics Section

174

Figure 8.12: Design for multi-sensitivity, multi-position pressure mapping compression plate with 2 source
and 2 detector positions. Pressure sensors are modular: we can choose to use up to 32 different sensors
with arbitrary positioning. Both the plates are clear acrylic, permitting the operator to visually adjust the
placement of the breast under the optical sensors. All dimensions are in inches. The sensitivity of the
pressure sensors varies with area (Sensor Products Inc.).

suggest the presence of pressure inhomogeneity. Furthermore, the internal structure of the breast may lead to
pressure differentials inside the breast volume. The latter is beyond our capacity to address non-invasively,
but we seek to map the surface pressure distribution using a customized sensor array from Sensor Products
Inc. (Madison, NJ); Figure 8.12 shows an example layout of the pressure sensors. In order to mount
these additional sensors, we reduce the number of potential source/detector mounting positions, as shown in
Figure 8.13.

8.4.2

Version 3: Experimental Prococol

Subjects were sequentially assigned to begin with the right or left breast. After the instrument was properly
adjusted for the subject, we collected baseline measurements of load, pressure, TD-DOS, and DCS. Note,
these DCS measurements had a relatively low SNR. The baseline plate separation was used for subsequent
‘relaxed’ measurements between compressions. We then applied a step compression to ∼60 N load (or
maximum permitted by the subject), collected data for ∼45 s, and returned to the baseline plate separation.
After ∼90 s, we applied a step compression of ∼120 N (or maximum permitted by the subject), collected
data for ∼45 s, and returned to baseline plate separation. We then repositioned the subject’s other breast
in the instrument and repeated the above, except the objective load was 120 N during both repetitions. A
time-line of this process is shown in Figure 8.14.
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Figure 8.13: Updated compression plate system for optical measurements during mammographic compression. This design has been optimized to measure spatial variations in the surface pressure on the breast by
eliminating all but 2 source and detector positions, thus permitting additional locations for pressure sensors.
Pressure sensors are not shown in this image; a schematic can be found in Figure 8.12. Optical fiber adaptors
are in position, but the fibers themselves have been removed for this photograph.
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Figure 8.14: Schematic of the experimental time-line for the Version 3 mammographic compression study.
The initial compression was to a nominal load of 60 N and the subsequent compressions were 120 N. Both
of these loads were limited by subject compliance.

8.4.3

Version 3: Results from Combined TD-DCS Pilot Study

We conducted a pilot study with the Version 3 instrument; the healthy subjects presented here are described
in Table 8.4. These initial data suggest that the fractional change in plate separation is not linearly related
to either total load or peak skin pressure, especially at large compressions. Measured StO2 changed little
during compression, but Hbt and rBF did change significantly. Example results from two subjects are shown
in Section 8.4.3.1; the combined results across all subjects are shown in Section 8.4.3.2.
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Bra Sizes
<Chest Size> 38±4.6 in.
Cup
#
C
4
D
1
Baseline Plate Separation
<d>
6.1±0.5 cm

Demographic Information
< Age >
35.2±13.9
yrs
< BM I >
29.8±9.1
m/kg2
Menopausal Status
Pre: 5
Post: 0

Table 8.4: Demographic data for 5 subjects in Version 3 compression study, as described in Section 8.4.3.
(left) Average values across all subjects for preliminary study of compression effects on DOS and DCS
data . Numeric values are given as mean ± standard deviation. (right) Breast sizes and compression plate
separation. < d > is the average starting plate separation.
8.4.3.1

Example Individual Results

Data from two healthy volunteers during the entire experimental sequence (Figure 8.14) are shown in Figures 8.15 and 8.16. These data are consistent with the results observed in the Version 2 system (e.g. Figure 8.9). However, unlike the Version 2 system, the Version 3 data provide calibrated pressure, total load,
and absolute optical properties (Hbt , StO2 , and µ0s ) throughout the experimental protocol.
The Version 3 system has higher DCS SNR, enabling us to collect ‘baseline’ data at lower load levels
to better approximate the completely uncompressed breast. Note that the average baseline plate separation
Table 8.4 is 6.1±0.5 cm while the Version 2 data (Table 8.3) is 5±1 cm. However, the ‘baseline’ and
‘relaxed’ windows were both susceptible to motion artifacts, as the breast was not held firmly, and the
optical signals had lower SNR than in the ‘compressed’ time windows. These factors led to the considerably
wider observed distribution of calculated parameters in the ‘baseline’ and ‘relaxed’ periods relative to the
‘compressed’ windows.
Hbt and StO2 are calculated from six-wavelength TD-DOS data (opto-electronics from the GenIII system, Section 6.1); the absorption and scattering coefficients are then used in the analysis of the DCS data.
Optical properties are not calculated during the transition periods as the exact plate separation is not known
and the ambient light levels are significantly elevated. Clear reductions in Hbt and rBF are observed in both
of these subjects; changes in StO2 data are less consistent.
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Figure 8.15: Time traces of (a) Load and Plate Separation (d), (b) Pressure and µ0s [785nm], (c) Hbt and
StO2 , and (d) rBF for an example subject (28 years old, BMI= 19.6 kg m−2 ) during sham mammographic
compression. Left axes correspond to blue trace; right axes to red. Baseline time periods are marked with
green in (a), relaxed periods with cyan, and compressed periods with magenta. Load and Pressure data are
collected continuously; the remaining data types are not calculated during transition periods. Pressure data
is the averaged across the five sensors with the highest readings during compression. Data are averaged over
the time windows to produce the average results described in Section 8.4.3.2.
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Figure 8.16: Time traces of (a) Load and Plate Separation (d), (b) Pressure and µ0s [785nm], (c) Hbt and
StO2 , and (d) rBF for an example subject (54 years old, BMI= 37.3 kg m−2 ) during sham mammographic
compression. Left axes correspond to blue trace; right axes to red. Baseline time periods are marked with
green in (a), relaxed periods with cyan, and compressed periods with magenta. Load and Pressure data are
collected continuously; the remaining data types are not calculated during transition periods. Pressure data
is the averaged across the five sensors with the highest readings during compression. Data are averaged over
the time windows to produce the average results described in Section 8.4.3.2.
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8.4.3.2

Population Averaged Results

We have so far collected data on five subjects with the Version 3 compression system; data from all subjects
is included in the graphs below. We collected useful data sets from both breasts in only one of these five
volunteers; we are currently improving our data collection protocol to increase volunteer compliance and
data robustness. These data are preliminary; we are currently in the process of expanding the data set.
Changes in tissue physiological properties across the available subjects are shown in Figure 8.17, 8.18,
and 8.19. We observed a small decrease in saturation during compression (Figure 8.17), but significantly
greater changes were observed in both Hbt (Figure 8.18) and rBF (Figure 8.19). The current ∆StO2 and
∆Hbt data are shown with linear fits in Figure 8.17 and 8.18; this is function unphysical, as both quantities
must approach -100% at sufficiently high external loads (i.e., total hemoglobin and blood oxygen saturation
must be zero if all the blood is forced out of the breast). However, the data shown in Figure 8.18 and
particularly Figure 8.17 is noisy. Furthermore, additional error is introduced as these data are averaged over
time windows corresponding to significant changes in physiological properties (e.g., Figure 8.15 and 8.16).
Our current data set contains only five volunteers; as our data set expands, we will segment the population
by menopausal status, body mass index (Body Mass Index), and other factors. Additionally, we will group
pre-menopausal women by the timing of the measurement in their menstrual cycle, as this may effect both
mechanically297 and optically298 measured physiological properties.
The current rBF data suggests that a simple exponential function of load, fractional change in plate
separation, or pressure may describe the reduction in blood flow. We note that applied average loads of
roughly one half that used in X-Ray mammography (60 N) reduced blood flow by 90%. This reduction in
flow would significantly hamper the delivery of a contrast agent administered during compression.
The lack of a clear functional form connecting Hbt with load or pressure and a clear relationship between ∆Hbt and ∆d/d0 suggests the possibility of plate separation-dependent cross talk in the TD-DOS
measurements. In measurements of a compressible homogeneous phantom (Section C.2), we identified a
∼5-10% change in absorption during ∼30% change in plate separation. This change is at lease partially due
to boundary motion (i.e., the breast or phantom flattens out and the skin-air boundary changes position). We
attempted to minimize the effect of this change in the boundary conditions by centering the optodes on the
breast. However, as shown in Figure 6.17, glandular tissues are concentrated in the center of the breast and
adipose on the periphery. External compression therefore may significantly change the fraction of glandular
vs. adipose tissue probed optically, although we expect the transmission measurements described here to be
less effected than remission measurements. Data from the Version 2 compression system (e.g. Section 8.3.2)
is concentrated between ∆d/d0 ≈ 15 − 20% and each subject was measured at a single compression. Both
of these factors could potentially mask the phenomena observed in the Version 3 data and complicated direct
comparisons between data sets.
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Figure 8.17: Observed changes in blood oxygenation (StO2 ) versus Load, Pressure, and change in plate separation (∆d/d0 ) in 6 measurement series (see Figure 8.14) on 5 subjects. Pressure reported is the average
between the five sensors with highest pressure readings for a particular subject. Data from the first compression (green), second compression (blue), and baseline (red) periods are plotted separately, with corresponding individual and joint (black) fits. Normal systolic (magenta) and diastolic (cyan) blood pressures66 are
included for comparison. Dashed lines indicate 95% confidence intervals of the fit parameters.
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Figure 8.18: Observed changes in total hemoglobin concentration (Hbt ) versus Load, Pressure, and change
in plate separation (∆d/d0 ) in 6 measurement series (see Figure 8.14) on 5 subjects. Pressure reported
is the average between the five sensors with highest pressure readings for a particular subject. Data from
the first compression (green), second compression (blue), and baseline (red) periods are plotted separately,
with corresponding individual and joint (black) fits. Normal systolic (magenta) and diastolic (cyan) blood
pressures66 are included for comparison. Dashed lines indicate 95% confidence intervals of the fit parameters.
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Figure 8.19: Observed changes in relative blood flow (rBF) versus Load, Pressure, and change in plate separation (∆d/d0 ) in 6 measurement series (see Figure 8.14) on 5 subjects. Pressure reported is the average
between the five sensors with highest pressure readings for a particular subject. Data from the first compression (green), second compression (blue), and baseline (red) periods are plotted separately, with corresponding individual and joint (black) fits. Normal systolic (magenta) and diastolic (cyan) blood pressures66 are
included for comparison. Dashed lines indicate 95% confidence intervals of the fit parameters.
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The Version 1 and Version 2 compression systems utilized the fractional change in plate separation as
a proxy for load and skin surface pressure. The preliminary results of the Version 3 system, shown in
Figure 8.20, suggest that these experiments may have probed a regime (∆d/d0 < 20%) where ∆d/d0 was
linearly related to total load/surface-pressure. However, more data is needed to fill in the ∆d/d0 ∼ 10%
portion of the curve in the Version 3 data. Load and surface pressure (averaged over five central detectors)
appear to be linearly related over the range studied. Surface pressure was measured with discrete sensors of
fixed area and should be less effected by geometrical factors (e.g., stretching skin and tendons away from the
chest wall, increasing skin-plate contact area as the load increases). The linear relationship between surface
pressure and load suggests that these geometrical factors do not dominate the load measurement. Note that
the load and pressure signals vary (fall off quickly) during compression (Figures 8.15 and 8.16); averaging
over this physiological change contributes to the calculated error. Additional plots showing fit results for the
first and second compression data separately are included in Appendix B.
The various component tissue types in the breast have different strain responses to applied stress. In the
linear regime, these quantities are expected to be related by the familiar Young’s Modulus (Y ):
Y =

σ
F/A0
=



(8.1)

where F is the applied force, A0 is the initial cross-sectional area of the sample, σ is the stress, and  is the
strain. Several groups have measured the mechanical properties of excised breast tissue299–302 and modeled
the displacement of tumors during external conformation changes303–305 . Elastography306, 307 creates 3D
maps of tissue mechanical properties, exploiting these differences in mechanical properties between tissue
types (e.g., cancers are stiffer than fat or fibroglandular tissue299–301 ). Note: data in Table 8.5 are taken at
multiple non-zero ‘pre-compression’ strains and are thus properly refered to as the ‘tangent’ moduli, instead
of Young’s moduli. However, I will follow the literature in referring to these quantities as Young’s moduli
for the remainder of this section.
The data in Figure 8.21 emphasizes the similarity between these measurements and typical stress versus
strain curves (i.e., applied force per area versus fractional change in sample length). We expect the pressure
on the surface of the breast to be heterogeneous and for the area of contact between breast tissue and the
compression plate to change during compression, but load and surface pressure may nonetheless provide
a proxy for stress measurements and ∆d/d0 for strain. If we ignore complicating factors, the slope of
a linear fit to the pressure versus ∆d/d0 data in Figure 8.21 can be thought of as an equivalent Young’s
modulus (Equation 8.1, Y = 64 kPa, 95% confidence interval, [46, 81] kPa). Note, for consistency with
data presented in the proceeding sections, ∆d/d0 is reported as a percentage and the slope is therefore
scaled by a factor of 100 to obtain Y . This falls within the wide-ranging values reported for normal breast
tissue299–301 (Table 8.5) at similar strains, despite the highly idealized analysis ignoring the internal breast
structure.
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Figure 8.20: Comparison between Load, Pressure, and change in plate separation (∆d/d0 ) in 6 measurement
series (see Figure 8.14) on 5 subjects. Pressure reported is the average between the five sensors with highest
pressure readings for a particular subject. Data from the first compression (green), second compression
(blue), and baseline (red) periods are plotted separately, with corresponding individual and joint (black) fits,
along with a linear fit to the low-compression region (∆d/d0 < 20%, red). Dashed lines indicate 95%
confidence intervals of the fit parameters. Normal systolic (magenta) and diastolic (cyan) blood pressures66
are included for comparison.
Table 8.5 shows the measured Young’s moduli to increase with strain. We expect stretching of the skin
and Cooper’s ligaments (connecting skin to glandular tissue) provide most of the mechanical resistance to
deformation. Fung308, 309 describes an exponential dependence of stress on strain in uniaxial extension of
biomaterials:
Y =

∂σ
∂F/A0
=
= bem ,
∂
∂∆d/d0

(8.2)

b m
(e − 1)
m

(8.3)

which gives
σ=

for constants b and m. Others301, 303 have previously used this form of a strain-dependent Young’s modulus
(tangent modulus) in FEM modeling of breast tissue. Results of fitting Equation 8.2 to data from Krouskop
and Wellman are in Table 8.6. The exponential increase in pressure and load due to increased ∆d/d0
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(Figure 8.21) is in the range of the values for fatty and fibroglandular tissue reported in Table 8.6.
These data are preliminary and there are multiple possible refinements to our simplifying models. Of
special concern to the assumption of homogeneity are the Cooper’s ligaments connecting the skin to glandular tissues. Furthermore, Azar et al.303 has suggested that fibroglandular and fatty tissues in the breast
become compartmentalized and therefore differ in mechanical properties from isolated excised samples.
Additionally, work by Lorenzen et al.297 with MR elastography suggests large (∼±30%) changes in fibroglandular elasticity occur during the course of a woman’s menstrual cycle. Despite these limitations, we are
encouraged by the consistency of our initial data with published results.
The measured blood flow fell to less than 20% of baseline at an average load of ∼40 N (Figure 8.19),
significantly less than the load typically used for X-ray mammography, although measured surface pressures
were well above normal systolic (16 kPa) and diastolic (10.7 kPa)66 blood pressures. This large change in
blood flow may have significant impact on the choice of protocols for contrast agent injection in compressed
imaging.

Samani et al.299

Wellman et al.301

Krouskop et al.300
∆ Pressure vs. ∆d/d0

Strain
5%
5%
5%
5%
15%
15%
5%
5%
20%
20%
< 20%

Tissue Type
Fat
FG
Fat
FG
Fat
FG
Fat
FG
Fat
FG
Whole Breast

Young’s Modulus [kPa]
3.25 ± 0.91
3.24 ± 0.61
6.6 ± 7
33 ± 12
174 ± 8.4
271.8 ± 167.7
18 ± 7
28 ± 14
20 ± 8
48 ± 15
64

Table 8.5: Tabulation of Young’s Moduli of Breast Tissue, from the literature. All of the literature data were
collected by compressing excised samples; ‘whole breast’ fit is derived from data shown in Figure 8.20.
Note, ∆d/d0 is expressed as a percentage in Figure 8.21 and the calculated slope is therefore multiplied by
a factor of 100. FG: Fibroglandular.

Krouskop et al.
Wellman et al.
Krouskop et al.
Wellman et al.
∆ Pressure vs. ∆d/d0

Fat
Fat
FG
FG
Whole Breast

b/m
18.50
4.46
27.5
15.1
4.5

m
0
7.4
3.64
1.23
5.8

Table 8.6: Non-linear stress-strain models of breast tissue. Data from Krouskop et al.300 and Wellman et
al.301 fit to Y = bem by Tanner et al.305 and results from fits of data shown in Figure 8.21. Note, ∆d/d0
is expressed as a percentage in Figure 8.21 and the value calculated for m is therefore multiplied by a factor
of 100. FG: Fibroglandular.
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Figure 8.21: Comparison of applied Load and Pressure to fractional change in plate separation (strain)
using the Version 3 compression system. (∆d/d0 ) in 6 measurement series (see Figure 8.14) on 5 subjects.
Pressure reported is the average between the five sensors with highest pressure readings for a particular
subject. (top row) Data from the first compression (green), second compression (blue), and baseline (red)
periods are plotted separately, with corresponding individual and joint fits. (bottom row) Combined data set
with joint (black) fits, along with linear fits to the low-compression region (∆d/d0 < 20%, red). Data in
these plots is also shown in Figure 8.20 with the abscissae and ordinates exchanged. Dashed lines indicate
95% confidence intervals of the fit parameters.
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8.5

Ongoing Work

Future work on this project will be focused on additional healthy subject recruitment and translation into
the clinical environment for measurement of cancer patients. We anticipate results from this work assisting
clinicians in designing individualized treatment plans for patients.

8.5.1

Instrumentation Improvements

In conversation with our clinical collaborators, we determined that instruments needed for the oncology
clinic should be small, quiet, unobtrusive, and convenient. As this study is intended to eventually measure
hemodynamics in cancer patients, physician and patient acceptance will be critically important in determining subject recruitment. We therefore and built a combined TD-DOS and DCS system designed to function
in this environment310v . A photo of this more clinician- and patient-friendly system is shown in Figure 8.22.
In addition to the obvious reduction in size compared to the GenIII system (see Figure 6.14), this portable
system has its own battery power supply, permitting ∼30 minutes of measurements untethered to a power
source. This feature permits a system to be prepared in a back room, then wheeled out to whichever exam
room is currently being used, and finally returned to storage.
This system is based around 2 TCSPC detector channels (SPC-130, with PMC-100 PMTs, Becker and
Hickl) and 3 lasers at 650, 785, and 830 nm, pulsed at 50 MHz (BHLP-700, Becker and Hickl). These
components achieve stability more quickly (∼15 min.) and are much smaller then our 6 wavelength system,
described in Section 6.1. Furthermore, using independent TCSPC channels (i.e., no routers) enables higher
photon counting rates and thus more rapid data collection. The data collection rate is not critical for the static
TD measurements in the Opt/MRI GenIII DOT system (Section 6), but the rate is critical for the dynamic
measurements in this breast compression study. Additionally, the PMC-100 PMTs can be switched on and
off rapidly to prevent damage from the DCS laser, reducing the need for optical shutters.

8.5.2

Portable Compression Platform for Clinical Research

As a practical matter, measurements of cancer patients must take place in the hospital, preferably in the
oncologist’s office, not in a physics lab. We have therefore constructed a mobile compression system (Figure 8.13) which can be easily moved into clinical spaces for a series of measurements.
v David L. Minkoff performed most of the detailed mechanical design and construction necessary to miniaturize the opto-electronic
enclosure.
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Figure 8.22: Portable TD and DCS system. DCS Sources: Crysta Laser (785 nm); DCS Detectors: Pacer
SPCM-AQ4C APD; TD Source: Becker and Hickl BHLP-700 (685, 785, and 830 nm); TD Detector: Becker
and Hickl PMC-100 with SPC-140 TCSPC card. UPS: Un-interruptible Power Supply

8.5.3

Future Research

The third version of our compression system will permit us to investigate scattering changes during compression and increase our data collection rate, through a higher SNR in our DCS system. We plan to continuously
measure blood pressure during our studies. This will allow us to normalize our pressure measurements to
each subject’s current internal blood pressure and perhaps provide improved insight into individual hemodynamic responses. Furthermore, we are in discussions with colleagues in the Radiology Department on
combining our compression system with their X-Ray Tomosynthesis device. Eventually, we will use the
techniques and instrumentation developed here to advance our work on Diffuse Correlation Tomography
(DCT), permitting us to make 3D differential images of blood flow in the breast using optical measurements.

8.6

Conclusion

Full volume-tomographic reconstructions of the breast require transmission measurements: the results of
this study are the first transmission DCS measurements of the human breast. These data suggest that Diffuse
Correlation Tomography (DCT) in the breast may be possible with current technologies. In Section 6.3, I
described how the GenIII Opt/MRI system has been designed to permit DCS measurements and potentially
permit DCT using spatial prior information from MRI. Such combined imaging also would permit us to
compare blood flow measured by Arterial Spin Labeling236 (ASL) and DCT in the breast.
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Chapter 9

Conclusion
This thesis brings together three themes: the development and application of instrumentation for simultaneous DOT and MR Imaging (Chapter 4-6), introduction and application of a statistical analysis scheme for
DOT images (Chapter 7), and reported instrumentation and the first results from transmission measurements
of microvascular blood flow in the breast during mammographic compression (Chapter 8). The first theme
has resulted in both co-registered contrast enhanced DOT-MR imaging and a flexible modular imaging platform to continue this work with 3 T MRI. The second theme provides proof of concept multi-parameter
cancer detection and localization with DOT data; future work will bring the first and second themes together by including MR data in the statistical tools to identify and diagnose breast cancer. The third theme
provides initial data for DCT in breast cancer; the GenIII Opt/MR imaging system will add optical flow
measurements, allowing linkage of all three themes. The ultimate focus of this work is to extract maximally
useful information for the identification, classification, and treatment of breast cancer.
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Appendix A
ICG Pharmacokinetics in Breast Cancer

As noted in Section 3.1.3, Indocyanine Green (ICG) is an FDA approved optical contrast agent which
may have diagnostic utility through imaging of both uptake and washout kinetics. Cuccia173 described a twocompartment model (schematic in Figure A.1) for ICG in tissue, under a set of simplifying assumptions.
Diffuse optical measurements sample many cubic centimeters of tissue, averaging over both microvasculature, extracellular space, and the various cells which make up a particular tissue. Therefore, the total
concentration (CT ) of ICG derived from in vivo diffuse optical measurements is the volume weighted combination of the plasma (Vp ,Cp ) and extravascular, extracellular space (EES) (Ve ,Ce ) concentrations, assuming
no ICG penetrates cell membranes.
CT = Vp Cp + Ve Ce .

(A.1)

Note that we may constrain Vp with the measured total hemoglobin Hbt concentration, provided we assume
the distribution of red blood cells (RBC) throughout the plasma and the hemoglobin content of each RBC is
consistent; see Eqn. A.5.
The change in concentration of ICG in the EES (the majority of volume probed optically) is
Ċe = kin Cp − kout Ce .

(A.2)

Bi-exponential elimination from the plasma by the liver is described as
Cp = A1 e−α1 t + A2 e−α2 t

(A.3)

where α1,2 are rate constants and A1,2 are the amplitudes of the corresponding process.
Following Cuccia’s solution for CT [t = 0], in the case where
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1
α1,2

and

1
kin,out

are much less then the

Figure A.1: Schematic of two-compartment model from Cuccia173 . Compartments are blood plasma (volume, Vp ) and extra-vascular, extracellular space (EES, volume, Ve ). Cuccia assumes a bi-exponential (α1
and α2 ) elimination by the liver and exchange between the plasma and EES (kin , plasma to EES and kout ,
EES to plasma).
recirculation time (i.e. ignore the plasma distribution in the initial bolus) , we can derive:




Ve kin
Ve kin
e−α1 t + A2 Vp +
e−α2 t
CT [t] =A1 Vp +
kout − α1
kout − α2
 



Ve kin
Ve kin
− A1
+ A2
e−kout t
kout − α1
kout − α2

(A.4)

This solution for CT [t] has eight parameters; we can improve the stability of the fit by reducing or constraining them. Note, Ve and kin only appear as a product, permitting us to eliminate one variable by defining
κ = Ve kin . As noted above, Vp is proportional to measuredHbt .


Hbt 100 − Hct
= Hbt ζ ' 2.415 × 10−4 × Hbt
Vp =
HbB
Hct

(A.5)

where HbB ' 5, 421µM is the average concentration of hemoglobin in each blood cell (32-36 g/dL; ∼2733pg66 ) and Hct is the hematocrit; for convenience, these factors are lumped into ζ, a constant for any
particular patient. In healthy adult females, the hematocrit is ∼ 36 − 45%311 . (For other applications, note
that male hematocrit is ∼41-51%.) With these substitutions, Eqn. A.4 reduces to




κ
κ
−α1 t
CT [t] =A1 Hbt ζ +
e
+ A2 Hbt ζ +
e−α2 t
kout − α1
kout − α2
 



κ
κ
− A1
+ A2
e−kout t
kout − α1
kout − α2

(A.6)

We can further simplify this expression by noting that long term ICG elimination is on the order of hours,
so α1 ' 0



κ





κ
CT [t] =A1 Hbt ζ +
+ A2 Hbt ζ +
kout
kout − α2
 



κ
κ
− A1
+ A2
e−kout t
kout
kout − α2
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e−α2 t
(A.7)

(Equation 5.1). ICG absorption data can then be fitted to this function. I thank Dr. Ulas Sunar for providing
the original codes I used for this analysis. Note that Hagen190 has recently reported fluorescence imaging of
ICG in breast cancers up to 24 hours after a consistent (not bolus) infusion.
The two compartment fit described in Equation 5.1 above has six parameters after simplification. We
also utilized a heuristic double exponential fit:


C[t] = A −e−k1 (t−t0 ) + e−k2 (t−t0 )

(A.8)

(Equation 5.2). We found that the double exponential fit was more stable for low time resolution data, but it
does not have the obvious physiological interpretation of Equation 5.1. Examples of data fit to both models
is shown in Figure 5.4. Note that the double exponential model has difficulty fitting the lope of the curve;
especially on peaked data such as shown here, the downslope tends to be over estimated.

194

Appendix B
Additional Plots for Compression Version 3 Results

This section expands on the data shown in Section 8.4.3 by showing separate fits (Figure B.1-B.4) to
data from first and second breast compressions described in Section 8.4.2. We do not observe significantly
different responses to sequential compression in the present data.
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Figure B.1: Observed changes in blood oxygenation (StO2 ) versus Load, Pressure, and change in plate
separation (∆d/d0 ) in 6 measurement series (see Figure 8.14) on 5 subjects. Pressure reported is the average between the five sensors with highest pressure readings for a particular subject. Data from the first
compression (green), second compression (blue), and baseline (red) periods are plotted separately, with corresponding individual and joint (black) fits. Dashed lines indicate 95% confidence intervals. Note, the same
data is shown in fig:compV3:res:deltaSat. Normal systolic (magenta) and diastolic (cyan) blood pressures66
are included for comparison.
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Figure B.2: Observed changes in total hemoglobin concentration (Hbt ) versus Load, Pressure, and change
in plate separation (∆d/d0 ) in 6 measurement series (see Figure 8.14) on 5 subjects. Pressure reported
is the average between the five sensors with highest pressure readings for a particular subject. Data from
the first compression (green), second compression (blue), and baseline (red) periods are plotted separately,
with corresponding individual and joint (black) fits. Dashed lines indicate 95% confidence intervals. Note,
the same data is shown in fig:compV3:res:deltaHb. Normal systolic (magenta) and diastolic (cyan) blood
pressures66 are included for comparison.
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Figure B.3: Observed changes in relative blood flow (rBF) versus Load, Pressure, and change in plate separation (∆d/d0 ) in 6 measurement series (see Figure 8.14) on 5 subjects. Pressure reported is the average
between the five sensors with highest pressure readings for a particular subject. Data from the first compression (green), second compression (blue), and baseline (red) periods are plotted separately, with corresponding individual and joint (black) fits. Dashed lines indicate 95% confidence intervals. Note, the same data is
shown in fig:compV3:res:deltaRBF. Normal systolic (magenta) and diastolic (cyan) blood pressures66 are
included for comparison.
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Figure B.4: Comparison between Load, Pressure, and change in plate separation (∆d/d0 ) in 6 measurement
series (see Figure 8.14) on 5 subjects. Pressure reported is the average between the five sensors with highest
pressure readings for a particular subject. Data from the first compression (green), second compression
(blue), and baseline (red) periods are plotted separately, with corresponding individual and joint (black)
fits, along with a linear fit to the low-compression region (∆d/d0 < 20%, red). Dashed lines indicate
95% confidence intervals. Note, the same data is shown in fig:compV3:res:loadDistPres. Normal systolic
(magenta) and diastolic (cyan) blood pressures66 are included for comparison.
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Figure B.5: Comparison of applied Load and Pressure to fractional change in plate separation (strain) using
the Version 3 compression system. (∆d/d0 ) in 6 measurement series (see Figure 8.14) on 5 subjects. Pressure reported is the average between the five sensors with highest pressure readings for a particular subject.
(top row) Data from the first compression (green), second compression (blue), and baseline (red) periods
are plotted separately, with corresponding individual and joint fits. (bottom row) Combined data set with
joint (black) fits, along with linear fits to the low-compression region (∆d/d0 < 20%, red). Data in these
plots is also shown in Figure 8.20 with the abscissae and ordinates exchanged. Dashed lines indicate 95%
confidence intervals of the fit parameters.

200

Appendix C
Phantoms

C.1

Liquid and Gelatin Phantoms

This is a brief description of some of the phantoms I’ve used in my work with DOT/DOS. For a more
complete explanation, I highly recommend Dr. Regine Choe’s careful explanation of the recipes for various
phantoms in her thesis312 . This work has excellent step-by-step instructions for solid and liquid phantoms,
including oxygenation phantoms using blood.
I have primarily utilized liquid phantoms in this work. This allowed me to adjust the absorption, scattering, and geometry to my experiment. Gelatin phantoms utilize the same ingredients as liquid phantoms,
added to cooked gelatin during cooling. If one requires a phantom to function at only a single wavelength
or one is not planning on using spectral priors in one’s computations, a phantom with little or no wavelength
dependence is both sufficient and simpler to construct. India ink provides an inexpensive and convenient
choice of absorber, but tends to sediment out and the absorbence should be measured the day of the phantom
construction. Absorption measured with a spectrophotometer at a specific wavelength allows calculation of
the necessary concentration of ink in the final phantom volume. Note the difference in bases between typical
spectrophotometer measurements (base 10) and µa (base e).
Given that much of the work in DOT and DOS focuses on measurement of blood concentration and
oxygenation, it is natural to use for in vitro phantoms. One can control the oxygenation through the addition
of yeast or carefully controlling the oxygen levels in the gas available for exchange with the phantom.
However, blood phantoms are biohazards, cannot be used for more then a few hours, and, given variations
in the blood supply, are somewhat difficult to reproduce accurately. Note that it is necessary to lyse red
blood cells (as they are significant scatterers), remove the cell membranes, and measure the hemoglobin of
each blood sample as the hematocrite can vary significantly between blood donors. As such, it is sometimes
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convenient to use various colored inks to produce a more durable wavelength dependent phantom. Inks with
features in the measured spectral window are useful for multi-spectral reconstructions or measurements.
Spectra of several useful inks are shown in Figure C.1 (Nigrosini , Higgins drawing inksii , ICGiii , and
Epolight 2717iv ).
With the exception of the ink, the spectra for the chromophores mentioned above are available at the
wonderfully helpful website of the Oregon Medical Laser Centerv . Multi-dye phantoms (e.g. Nigrosin and
Epolight 2717 in Figure C.1) allow independent titration and simulation of Hb and HbO2 (e.g. Figure 3.3),
permitting more convenient instrument testing than adjusting the saturation in blood phantoms.
1

Normalized Absorbance

0.8
Nigrosin
Higgens Black
Higgens Green
ICG, 6.5 µM
ICG, 65 µM
ICG, 650 µM
ICG, 1.29 mM
Epolight 2717

0.6

0.4

0.2

0
600

700

800
Wavelength [nm]

900

1000

Figure C.1: Spectra of several inks used in DOS/DOT phantoms. Spectra are normalized for display purposes. Note that ICG spectra are concentration dependent. ICG spectra were obtained from
http://omlc.ogi.edu/spectra/ ; the remaining spectra were measured in our lab.
Several different scattering agents are used in diffuse optics, including those listed in Table C.1. The soy
emulsions are intended for therapeutic injection and are packaged in sterile vessels; this can be advantageous
in phantoms or matching fluids which will come into contact with human subjects.

Mono-dispersed

microspheres allow calculation of scattering properties with Mie theory, but are generally too expensive for
large volumes. The hollow latex spheres in Ropaque R Ultra E are much less expensive, but also much less
well characterized. As much of the breast DOT work in our lab uses a scattering bath as a matching fluid,
we made almost all of our liquid and gelatin phantoms with soy emulsions.
i Sigma-Aldrich,

www.sigmaaldrich.com
www.higginsinks.com/
iii Akorn, www.akorn.com
iv Epolin, www.epolin.com
v http://omlc.ogi.edu/spectra, accessed June 2007.
ii Higgins
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Soy Emulsions

Polymer Spheres

Liposyn II

Pharmacia and Upjohn, Erlangen, Germany, invented by
Wretlind313
Hospira Inc, Lake Forest IL.

Ropaque R Ultra E
Microspheres

Rohm and Hass, Philadelphia PA
Various suppliers

Milk

Homogenized

Intralipid

Table C.1: Scattering agents used in DOS/DOT phantoms. Soy Emulsions were introduced into diffuse
optics by Driver314 .
As my measurements included TRS data, I measured the absolute properties of each phantom at the time
of use (with the exception of the high absorption of some targets produced by adding additional ink to the
background fluid; these absorptions were calculated from spectroscopic measurements of serial dilutions
of the ink added). However, I required a formula to calculate the approximate parameters of the phantom
based on the ratio of ingredients so as to match the phantom to the particular task at hand. Determining the
quantity of ink to add to the phantom simply requires a measurement with a spectrophotometer and then
calculation of the dilution required to bring the phantom to the desired µa . I obtained a calibration curve to
relate the quantity of 30% Liposyn III to the resulting scattering and found the relationship to be quite close
to linear over the tested range of 5-15 cm−1 at 785 nm.
µ0s = 260x + 2.3

(C.1)

where x is the fractional volume of Intralipid (i.e. for 60 ml in 2 L x=60/2000=0.03). The resulting values
are in fairly close agreement with Choe312 and van Staveren et al.315 .
We utilize gelatin phantoms for several studies where liquid phantoms are inconvenient. Our basic
recipe, listed in Table C.2, is based of that from Soren D. Konecky and has contributions from Ellen Foster
and Tiffany Alverna.
De-Gassed Water
Gelatin
NaCl
Sodium Azide
20% Intralipid

4250 ml
300 g
7.5 g
21 g
350 ml

Table C.2: Basic gelatin phantom recipe for phantoms totaling 4.25 L. Sodium Azide is a mitochondrial
poison used to increase the phantom life and NaCl to make the phantom visible in MR images. Gelatin
(from porcine skin, Sigma-Aldrich) is included at 70 g per liter.
We typically make gelatin phantoms with inclusions of contrasting absorption or scattering to serve as
targets. These inclusions are best introduced to the gelatin phantom after the background has solidified
overnight and just before the target solution solidifies.
The sequence of events for a typical phantom used with our imaging systems is as follows:
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1 Mix 182 g gelatin to 2,600 ml cold stock solution.
2 Heat and stir solution (∼5 minutes in microwave) until gelatin is completely dissolved.
3 Pour solution into mold.
4 Add 1,200 ml (cold) stock solution.
5 Stir thoroughly.
6 Wait until solution reaches room temperature, do not allow to solidify.
7 Add 160 ml Intralipid and ink as appropriate for desired absorption.
8 Stir thoroughly.
9 Cover and place in refrigerator to solidify. If mold is sealed, rotating the mold during the solidification
process improves homogeneity.
10 If inclusions are to be added, follow above procedure until target gelatin solution is almost solidified,
cut an inclusion in background phantom, and add target solution.
We have noted that air bubble formation can be reduced by degassing any liquids used and by stirring the
viscous gelatin solution slowly. We have found the optimal cooling technique to be placing the hot gelatin
solution in a cold room on a stir plate with a large magnetic stir bar. This keeps the solution mixed until it
solidifies.

C.2

Compression Phantoms

The compression systems required separate phantoms to test the optics and the load and pressure sensors.
The optical phantoms were liquid-filled balloons, allowing adjustment of the plate separation. Production
of liquid phantoms is described in Section C.1. Note: the use of large balloons (to minimize stretching),
preferably one inside another, will reduce the rupture rate of this particular phantom.
The load sensor were calibrated using a digital scale and foam rubber to protect the pressure sensors.
This calibration varied less than 5% over the course of a week.
Pressure sensors were calibrated using a rubber bladder and calibrated gas pressure gauge. We utilized
a bladder from a thigh blood pressure cuff to apply equal pressure across the entire compression plate.
We were somewhat concerned with the possibility of skin-sensor coupling, especially due to sheer forces.
Differences between measurements with rubber bladders and volunteer’s tissue was clearly observed for the
‘piston’ pressure sensor described in Section 8.2.2; we had much less difficulty using flat resistive sensors
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described in the same section. We attempted to model the tissue-plate coupling during calibration by using
∼1.5 cm slices of meat and liver obtained from a local butcher. These phantoms displayed similar reductions
in load after compression as tissue. At least part of this effect was due to the internal pressure forcing out
remnant blood out of the meat and liver. Allowing for this falloff in pressure under compression, the resistive
sensors showed little difference in results between plate to rubber bladder or plate to meat coupling.
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Glossary
—— ——
λ

Wavelength in nm.

µ0s

Reduced Scattering coefficient.

µa

Absorption Coefficient.

ω

Angular Frequency.

Ψ

Photon Fluence Rate.

z0

z0 = µ0s

−1

. A diffuse optics source is often modeled as a point source displaced z0 into

the medum, instead of a source with a specified numerical aperature placed on the medium
boundary.

—— A ——
ABI

Advanced Breast Imaging Study, PI: Dr. Mitchell Schnall.

ACRIN

American College of Radiology Imaging Network.

angiogenesis The development of new blood-vessels, often refering to vascular growth around a cancerous lesion.
ANSI

American National Standards Institute.

APD

Avalanche Photo Diode.

ASL

Arterial Spin Labeling.

AUC

Area Under the Receiver Operating Characteristic (ROC) Curve.
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—— B ——
BH

Becker and Hickl Gmbh.

Body Mass Index Body Mass Index, the ratio of a person’s mass in kg to the square of his height in m.
BOLD

Blood Oxygenation Level Dependent (fMRI signal).

—— C ——
c

Speed of light in the relevant medium.

CCD

Charge Coupled Device.

CE-MRI

Contrast Enhanced Magnetic Resonance Imaging, typically with a gadolinium chelate such as
Gd-DTPA.

CFD

Constant Fraction Discriminator.

CMROI

Center for Magnetic Resonance and Optical Imaging, an NIH-funded Research Resource at
the University of Pennsylvania.

CAD

Computer Aided Diagnosis; Use of computerized algorithms to assist in the identification of
disease states.

CT

X-Ray Computerized Tomography.

CW

Continuous Wave (i.e. FD with ω =0).

—— D ——
D0

Homogeneous Photon Diffusion Coefficient.

Da

Dalton, a unit of mass equal to one twelfth of the rest mass of an unbound atom of carbon-12
in its nuclear and electronic ground state.

Dartmouth

Dartmouth College.

DCS

Diffuse Correlation Spectroscopy.

DCT

Diffuse Correlation Tomography.

DOBI

DOBI Medical International Inc, Mahwah, NJ. ComfortScan c http://dobiglobal.com/dobisys1.html,
now available from www.xinaomdt.com/en/.
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DOS

Diffuse Optical Spectroscopy.

DOT

Diffuse Optical Tomography.

DP

Differential Path length (see DPF).

DPDW

Diffuse Photon Density Wave.

DPF

Differential Path length Factor.

DWS

Diffusing Wave Spectroscopy.

—— E ——
EES

Extravascular, Extracellular Space.

—— F ——
False Positive Rate Fraction of incorrectly classified ‘positive’ subjects in a binary classification test.
FD

Frequency Domain.

FDA

United States Food and Drug Administration.

FDG

Fluoro-deoxyglucose, an F18 PET agent.

fDOS

Functional DOS.

FDOT

Fluorescent Diffuse Optical Tomography.

FEM

Finite Element Method.

fiducial

A fiducial marker allows registration of coordinate systems; here, the markers are rigidly fixed
in the breast compression plates and are visible in the MR images.

fluence

Flux of particles through a specified area.

fM

Femto-Molar (10−12 ).

fMRI

Functional MRI.

fNIRS

Functional NIRS.

FOV

Field of View.

FWHM

Full Width at Half Maximum value.
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—— G ——
Gd

Gadolinium, MRI contrast agent.

Gd-DTPA

Gadolinium Diethylenetriamine Penta-acetic Acid; commonly used Gd chelate for MRI contrast.

Generation I, GenI

First Generation University of Pennsylvania simultaneous time-resolved optical

and magnetic resonance imaging system, built by V. Ntziachristos and X. Ma.
Generation II, GenII

Second Generation University of Pennsylvania simultaneous time-resolved opti-

cal and magnetic resonance imaging system, built by X. Intes and J. Yu, used for clinical
experiments by D. Busch and Z. Zhao.
Generation III, GenIII

Third Generation University of Pennsylvania simultaneous time-resolved optical

and magnetic resonance imaging system, built by D. Busch.
Gold-Standard A benchmark test, assumed to be perfectly accurate, to which other classification techniques are compared.

—— H ——
hematocrit Percentage of whole blood occupied by red blood cells.
Hb

Hemoglobin.

HbO2

Oxy-hemoglobin.

Hbt

Total hemoglobin concentration, Hbt =Hb+HbO2 .

H2 O

Water.

HUP

Hospital of the University of Pennsylvania.

—— I ——
ICG

Indocyanine Green.

IRB

Institutional Safety Review Board.

IRF

Instrument Response Function, in TD measurements, the convolution of the pulse width of
the laser, the broadening introduced by the source and detector fibers, and the broadening
introduced by the response time of the detector.

IV

Intravenous, usually referring to a line for injection of drugs.
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—— K ——
k0

Complex wavenumber of DPDW.

—— L ——
la

Mean free path between absorption events.

LD

Laser Diode.

ls

Mean free path between scattering events.

—— M ——
MFP

Mean free path, the average distance traveled prior to a certain type of interaction, for example
scattering.

MGH

Massachusetts General Hospital.

MHz

MegaHertz=106 Hz.

MPE

Maximum Permissible Exposure; regulatory limit on the optical power which may be applied
to human tissue.

MR

Magnetic Resonance.

MRI

Magnetic Resonance Imaging.

—— N ——
NA

Numerical Aperature; sine of the half acceptance angle to an optical system, multiplied by the
index of rrefraction N A = nSin[θ].

NIR

Near Infrared (∼650-950nm).

NIRS

Near Infrared Spectroscopy; synonym for DOS.

—— O ——
OI

Optical Index. Composite parameter to increase breast cancer contrast developed at the University of Pennsylvania.

optodes

Collectively, source and detector optical fibers, in analogy with ‘electrodes’.
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—— P ——
PD

Photodiode.

PDT

Photo-dynamic Therapy.

Penn

Pennsylvania, University of.

PET

Positron Emission Tomography.

—— D ——
D

Photon Diffusion Coefficient, D =

v
3µ0s

[cm2 s−1 ].

—— P ——
PMT

Photomultiplier tube.

ps

Pico second, 10− 12s.

PTB

Physikalisch-Technische Bundesanstalt, German national metrology institute.

—— R ——
RBC

Red Blood Cell.

rBF

Relative Blood Flow.

RF

Radio Frequency.

ROC

Receiver Operating Characteristic (ROC). Often, ROC curve; plot of the true positive vs. false
positive rates of a particular test, e.g., of malignancy.

RTE

Radiative Transport Equation.

—— S ——
saturation

Blood Oxygen Saturation, StO2 =HbO2 /Hbt .

sensitivity Sensitivity of a test to a condition; the true positive rate.
SNL

Sentinel Lymph Node.

SNR

Signal to Noise Ratio.
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specificity Specificity of a test; the true negative rate (1 minus the false positive rate).
SVD

Singular Value Decomposition.

—— T ——
T1

Population Decay Time, can be utilized to distinguish between fatty and glandular (more water
bearing) tissue to provide information on tissue structure from MRI exams.

T2

Phase Decay Time, from MRI.

TCSPC

Time Correlated Single Photon Counting.

TD

Time Domain.

TD-DOS

Time Domain Diffuse Optical Spectroscopy.

TIBS

Transit Time Spread.

TOAST

Time-resolved Optical Absorption and Scattering Tomography software package, developed
by Dr. Simon Arridge and Dr. Martin Schweiger at University College London85, 86 .

TOI

Tissue Optical Index. Composite parameter to increase breast cancer contrast developed at
University of California at Irvine.

transillumination Transillumination: illuminating a quasi-slab shaped sample on one face and detecting
the transmitted light on the other.
TRS

Time Resolved Spectroscopy, often used as a synonym for TD-DOS.

True Negative Rate Fraction of correctly classified ‘negative’ subjects in a binary classification test.
True Positive Rate Fraction of correctly classified ‘positive’ subjects in a binary classification test.
True Positive Rate Fraction of correctly classified ‘positive’ subjects in a binary classification test.
tSVD

Truncated Singular Value Decomposition, in which singular values less than some cutoff value
are set to zero.

TTS

Transit Time Spread.

—— U ——
UCI

University of California, Irvine.
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—— V ——
ViOptix

Commercial optical instrument maker, constructed handheld breast compression device167 ;
www.vioptix.com.

—— X ——
X-Ray Tomography CT reconstruction of tomographic images from a limited selection of angular projections.

—— Z ——
Z-Score

A normalization procedure, in which a data vector is transformed by subtracting the mean and
dividing the result by the standard deviation.
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